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T-cells engineered to target tumour antigens through surface-expressed chimeric 
antigen receptors (CARs) are highly effective in treating some leukaemias. The 
challenge is to extend this success to solid tumours. Tumour endothelial marker 8 
(TEM8) is a conserved transmembrane protein overexpressed on the vasculature of 
many solid tumours but low or undetectable on healthy tissues, making it a potential 
CAR T-cell target. This thesis explores the safety and therapeutic efficacy of this 
approach by generating five human TEM8-specific CARs, expressing them in T-
lymphocytes, and characterising their functional responses to TEM8 in vitro. Four of 
the five CARs showed unexpected reactivity to control cells, and in mouse studies 
some of these proved toxic while most were selectively lost from the circulation, an 
effect that was TEM8-dependent. Only one CAR selectively responded to target cells 
overexpressing human TEM8 in vitro but was unable to recognise mouse TEM8, so 
further in vivo studies were not possible. These results highlight the sensitivity and 
potency of CAR-engineered T-cells and demonstrate the need for additional safety 
measures if targeting TEM8. The thesis also demonstrates that another TEM, 
CLEC14A, is overexpressed in some inflammatory liver diseases, and identifies a 
suitable mouse model for exploring the therapeutic potential of CLEC14A-specific 
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The innate and adaptive immune system function in concert to protect the host from 
invading microorganisms, potentially damaging toxins and other foreign substances 
encountered on a regular basis. The adaptive immune system also has a crucial role 
in identifying mutated self-antigens expressed by many tumours, with T-lymphocytes 
– the principal drivers of cell-mediated immunity – playing a central part in the 
antitumour immune response. While immune attack can lead to tumour elimination, T-
cells and other immune effectors also select for less immunogenic malignant cells, 
which are able to escape destruction and instead contribute to cancer progression and 
metastasis. This dual role of the immune system in tumour elimination and sculpting is 
termed ‘immunoediting’. Harnessing the potential of the antitumour immune response 
while finding ways to circumvent tumour resistance has been the principal goal of 
cancer immunotherapy, which has emerged as a very promising approach to treating 
cancer. Several immunotherapy treatment modalities have been implemented to date, 
including cancer vaccines, immune checkpoint blockade and transfer of autologous 
tumour-specific lymphocytes, to name just a few of the most common ones. 
 
Technological advances led to the emergence of T-cells genetically engineered to 
express high-affinity T-cell receptors (TCRs) or, more recently, chimeric antigen 
receptors (CARs), capable of recognising the desired tumour antigen with high 
specificity and eliciting a potent cytotoxic response. With this as with other 
immunotherapies, selectivity for tumour tissue is crucial in order to avoid potentially 




tumour microenvironment and the fact that truly selective tumour antigens are very 
difficult to identify. Tumour-associated vasculature is more easily accessible to immune 
effectors and may be sufficiently different to normal vasculature to permit 
discrimination in targeting. Tumour endothelial markers (TEMs) markedly 
overexpressed on tumour-associated vessels but absent from normal blood vessels, 
in particular TEM8, may represent a novel, highly selective target for cancer 
immunotherapies including CAR-engineered T-cells. Therefore, the exploration of this 
particular targeted approach is the major focus of this thesis.  
 
CAR engineering is not limited solely to conventional T-cells; regulatory T-cells (Tregs) 
can be modified in the same way, and their natural immunosuppressive capacity, so 
often detrimental in cancer, can be applied to treating inflammatory conditions instead. 
One such approach, where CAR Tregs are directed against an endothelial marker 
overexpressed in inflammatory liver conditions, CLEC14A, potentially provides a novel 
way to treat debilitating immune-mediated diseases and is also explored herein. 
 
 
1.1 T-cells and their role in the immune response 
 
1.1.1 Innate and adaptive immunity 
To ensure host survival, immune cells need to be capable of successfully 
discriminating between self- and non-self in order to eradicate outside threats while 
avoiding damage to host’s own tissues. This balance between immune destruction of 




through the concerted efforts of two complementary arms of the immune system – 
innate and adaptive1,2. Innate responses are encoded by germ line genes and rely on 
recognition of broad molecular patterns shared by many different pathogens and toxins 
which differentiate them from the mammalian host. This means that the innate immune 
system is antigen-nonspecific but able to react quickly to pathogenic attack, usually 
within minutes or hours, thus forming the first line of host defence3. Components of 
innate immunity include physical barriers such as the skin and mucosa, soluble factors 
such as cytokines and chemokines which modulate leukocyte function and migration 
respectively, and leukocytes of the myeloid lineage as well as natural killer (NK) 
lymphocytes1. All of these have a crucial role in both defending the host and 
communicating with the adaptive arm of the immune system to prime it for response. 
 
Adaptive immune responses are encoded in gene elements which undergo somatic 
rearrangement to form highly specific antigen-binding structures capable of 
recognising virtually any individual foreign invader2. This unique feature pertains to the 
main drivers of adaptive immunity, T- and B-lymphocytes, which are initially present in 
small numbers but undergo clonal expansion when presented with their cognate 
antigen in order to effect a temporally delayed but very powerful and antigen-specific 
immune attack. Another key characteristic of adaptive immunity is the formation of 
immunological memory, whereby a portion of T- and B-lymphocytes persists in the 
body after the initial antigen encounter and mounts a very rapid and potent immune 
response if the same antigen is ever encountered again1,2. Even though both types of 
lymphocytes drive adaptive responses, there are fundamental differences between 




(Ig), which binds cognate antigen without any need for previous antigen processing 
and presentation. On the other hand, T-cells express the membrane-bound T-cell 
receptor (TCR), which is only able to bind antigen when it is correctly processed and 
presented on the surface of a cell (see section 1.1.2). In addition, unlike B-cells which 
develop fully in the bone marrow, T-cells migrate out of it to undergo their maturation 
in the lymphoid organ known as the thymus1,2. 
 
1.1.2 TCR generation and T-cell development 
Self-tolerance as a hallmark of the whole immune system is particularly important for 
T-cells, which recognise foreign or mutated peptide antigens only in association with 
self major histocompatibility complex (MHC) (also known in humans as human 
leukocyte antigen – HLA) molecules4. In fact, the TCR on the surface of T-lymphocytes, 
which binds the MHC-antigen molecular complex, has very low affinity for antigen 
alone or for MHC molecules presenting other peptides. It is instead constrained to 
recognising the antigenic peptide-MHC complex as a whole, a characteristic termed 
‘MHC restriction’ and first demonstrated in a series of experiments in mice in the 
1970s5,6. This unique ability of the T-cell is achieved through the sophisticated process 
of thymic selection and maturation which is summarised below and in Figure 1.1. 
 
Haematopoietic stem cells give rise to committed T-cell precursors in the bone marrow, 
which then migrate to the thymus to begin their differentiation into mature T-cells. 
These precursors, or pro-thymocytes, do not express CD3, CD4 or CD8 surface 
markers, and are known as ‘double-negative’ (CD4–CD8–)2. Upon arrival into the 




of their numerous variable (V), diversity (D) and joining (J) gene elements into fully 
formed VaJa and VbDbJb chains of the TCR. This process of apparently random 
combinatorial assembly results in a hugely diverse array of functional antigen-specific 
TCRs4. The b chain of the TCR is the first to undergo rearrangement while the double-
negative T-cell precursors are still in the subcapsular zone of the thymus. Provided the 
rearrangement is productive and results in a functional b chain, the cells progress into 
the thymic cortex where the same process happens for the a chain; upon formation of 
a fully functional ab TCR, the expression of CD3, CD4 and CD8 is also induced on the 
cell surface and marks their transition to ‘double-positive’ T-cells (CD4+CD8+)2,4. 
 
While still in the thymic cortex, the developing lymphocytes interact with self MHC 
molecules found on the surface of the cortical epithelial cells. If they do so with 
sufficient affinity, they progress into the thymic medulla, while the T-cells that do not 
bind self MHC molecules are eliminated by apoptosis – this constitutes positive 
selection7. It is at this juncture that double-positive lymphocytes which interact with 
class I MHC molecules become single positive for CD8, and those that bind class II 
MHC molecules become CD4 positive only4. Finally, the positively selected CD8 and 
CD4 T-cells that have entered the thymic medulla interact with a vast variety of tissue-
specific self-peptides presented in the context of MHC molecules on the surface of 
medullary epithelial cells. The T-cells that bind self-peptides too strongly are 
considered autoreactive and are therefore apoptosed (negative selection), while the 
remainder – approximately 5% of the starting double-negative thymocyte population – 
are exported into the peripheral circulation7. The vast majority of circulating T-cells use 




an alternate version of the TCR, gd, do not express surface CD4 or CD8 and are 







Figure 1.1 – T-cell development in the thymus 
Haematopoietic precursors committed to the T-cell lineage leave the bone marrow for 
the subcapsular zone of the thymus. They then proceed through the thymic cortex and 
medulla, rearranging their T-cell receptor (TCR) a and b chain gene elements and 
undergoing positive and negative selection to eliminate those T-cells that respectively 
show inadequate affinity for self human leukocyte antigen (HLA) molecules or 
excessive binding to self-peptides expressed in the context of host HLA. During the 
selection process the lymphocytes become single positive for either CD4 or CD8, 
finally leaving the thymus as mature CD4 or CD8 T-cells with a fully functional ab TCR. 
A small proportion of T-cells rearrange their g and d TCR chains instead, do not express 
surface CD4 or CD8 and undergo most of their maturation in the extrathymic 
compartment. Adapted from The Journal of Allergy and Clinical Immunology, 125(2 
Suppl 2), David D. Chaplin, Overview of the immune response, S3-23, Copyright 





1.1.3 Antigen recognition and T-cell activation 
Mature ab T-cells, characterised as either CD4+ or CD8+, are antigen-naïve after 
leaving the thymus. They concentrate in secondary lymphoid organs such as the 
spleen and lymph nodes where they eventually encounter antigenic peptide-MHC 
complexes2. Depending on the nature of antigenic challenge, two major classes of 
MHC molecules present the peptide to the T-cells to trigger different kinds of T-cell 
responses. MHC class I proteins are constitutively expressed on all nucleated cells, 
and generally present endogenous peptides derived from host cell proteins (including 
tumour-specific proteins if the cell is cancerous) or from intracellular pathogens such 
as viruses4. MHC class I-peptide antigen complexes are recognised by CD8 T-cells, 
with the CD8 co-receptor interacting directly with the class I molecule to stabilise the 
complex and ensure full T-cell activation8. Upon engagement of their TCR by peptide-
MHC class I, CD8 T-cells become cytotoxic T-lymphocytes (CTLs) which induce target 
cell apoptosis by direct cell-to-cell contact and release of various pro-apoptotic factors 
including granzymes and perforin4. 
 
In contrast to class I, MHC class II molecules are present mainly on the surface of 
“professional” antigen-presenting cells (APCs), which include dendritic cells (DCs), 
monocytes, macrophages and B-lymphocytes. APCs are found in large numbers in the 
skin and mucosa, where they are most likely to encounter pathogens; they specialise 
in taking up exogenous antigens, such as those derived from bacteria and parasites, 
by endocytosis or phagocytosis and processing them for presentation in association 
with MHC class II molecules on the cell surface9. APCs are then able to travel from the 




complexes interact with the TCR of CD4 T-cells. CD4 ab T-cells are the most 
numerous T-cell subset in the body and perform a variety of functions upon activation. 
Most of them are designated as T-helper cells and enhance T- and B-cell responses 
through cognate signalling or the secretion of various cytokines, but an important group 
of CD4 T-cells have a regulatory role and prevent autoimmunity and immune-mediated 
tissue damage4 – these regulatory T-cells (Tregs) will be discussed in section 1.7. 
 
1.1.4 TCR signalling, co-stimulation and co-inhibition 
In order to achieve full T-cell activation, signalling through the TCR alone is not enough. 
A host of co-stimulatory molecules is also required – without additional signals, 
stimulation of TCR in isolation leads to a state of functional unresponsiveness, or 
‘anergy’10. The ab TCR is associated with the CD3 complex of accessory chains, 
consisting of transmembrane g, d and e chains and a predominantly intracytoplasmic 
CD3z homodimer (Figure 1.2). Each chain contains an immunoreceptor tyrosine-
based activation motif (ITAM) on its cytoplasmic portion, with CD3z chains containing 
three ITAMs each. When phosphorylated as a consequence of peptide-MHC binding 
to the TCR, ITAMs in turn initiate a string of phosphorylation reactions leading to the 
ultimate activation of genes responsible for T-lymphocyte proliferation and 
differentiation2,4. 
 
Perhaps the most well-described co-stimulatory receptor expressed on the surface of 
T-lymphocytes is CD28, which was found to induce T-cell proliferation, augment 
lymphocyte interleukin-2 (IL-2) production and cause overall amplification of the 




importance of CD28 co-stimulation was further shown in studies of CD28-/- mice, which 
mounted a weak immune response and had impaired T-cell proliferation12,13. CD28 
binds B7-1 (CD80) on the surface of the APC, as evidenced by B7-specific monoclonal 
antibodies (mAbs) inhibiting this interaction14, and by CD28-deficient T-cells exhibiting 
no B7-dependent co-stimulation12.  A second ligand for CD28 on the APC was 
subsequently identified as B7-2 (CD86)15. The structural homologue of CD28 – 
cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) – is also found on the T-cell 
surface and binds CD80 and CD86, but with the opposite effect of T-cell inhibition 
rather than stimulation16. CD28 and CTLA-4 are therefore mutually antagonistic, with 
CD28 expressed constitutively on T-cells while CTLA-4 is induced upon activation, and 
its upregulation in turn downregulates CD28 expression17.  
 
This already complex picture is further compounded by the presence of numerous 
other co-stimulatory and co-inhibitory molecules on the surface of T-lymphocytes. 
These include co-stimulatory molecules 4-1BB (CD137) and OX40 (CD134), which 
bind their respective ligands 4-1BBL and OX40L on the APC and promote cytokine 
production and T-cell survival via upregulaton of various anti-apoptotic factors18. 
Conversely, the programmed cell death protein-1 (PD-1) is, like CTLA-4, co-inhibitory, 
and alongside other surface-expressed inhibitory molecules like lymphocyte-activation 
gene-3 (LAG-3) and T-cell immunoglobulin mucin-3 (TIM-3) serves as an indicator of 
T-cell exhaustion19. In all cases, upon TCR/CD3 activation, significant rearrangement 
of the receptors and the various co-stimulatory molecules takes place to form a so-
called ‘immunological synapse’20 (Figure 1.3). Successful synapse formation is what 











Figure 1.2 – The structure of the ab T-cell receptor 
The ab T-cell receptor (TCR) consists of the ab heterodimer together with the CD3 
complex of accessory chains: one g, one e, two d (all transmembrane) and a 
predominantly intracellular CD3z homodimer, which signals into the cell once the TCR 
binds to a peptide-MHC complex. Reprinted by permission from Macmillan Publishers 
Ltd: NATURE (Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. 







Figure 1.3 – The immunological synapse 
The structure of the binding interface between a T-cell and an antigen-presenting cell 
(APC), termed immunological synapse, showing the interaction between the TCR/CD3 
complex on the surface of the T-cell and the peptide-MHC ligand on the APC surface, 
together with a host of co-stimulatory (blue) and co-inhibitory molecules (yellow) as 
well as surface markers that do not participate in the signalling (grey). Upon TCR/CD3 
binding of the peptide-MHC, the cytoplasmic portions of the CD3 chains are 
phosphorylated by tyrosine kinases including LCK, which in turn recruit signalling 
molecules such as z-chain associated protein 70 (ZAP70) – this starts a signalling 
cascade which ultimately leads to T-cell activation. PI3K, phosphatidylinositol 3-kinase; 
CTLA4, cytotoxic T-lymphocyte associated antigen 4; SHP2, Src homology region 2-
containing protein tyrosine phosphatase 2; LFA1, leukocyte function-associated 
antigen 1; ICAM1, intercellular adhesion molecule 1. Reprinted by permission from 
Macmillan Publishers Ltd: NATURE REVIEWS IMMUNOLOGY (Huppa JB, Davis MM. 






1.2  Cancer immunoediting 
It is now widely recognised that the host immune system is heavily involved in tumour 
regulation. Cells that have escaped intrinsic control mechanisms and started to 
proliferate without key environmental stimuli, thus acquiring potential to become 
cancerous, can be recognised through their expression of mutated antigens, or ‘neo-
antigens’, and eliminated by immune effector cells including T-lymphocytes23. This 
elimination of pre-malignant and malignant cells is known as cancer 
immunosurveillance, and evidence of it in both mice and humans has steadily 
accumulated over the years (discussed in more detail in section 1.2.1). 
 
More recently it has become apparent that, rather than only being host-protective, the 
immune system also has the capacity to shape tumour development. Evidence for this 
was first found in a study of immunodeficient mice that lacked either responsiveness 
to interferon gamma (IFNg) or all of their lymphocytes, including T-lymphocytes24. 
These mice were more susceptible to methylcholanthrene (MCA)-induced sarcomas 
as well as spontaneous development of epithelial carcinomas compared to their wild-
type counterparts. Importantly, however, when MCA sarcomas from immunodeficient 
hosts were transplanted into wild-type mice, 40% were spontaneously rejected, while 
MCA sarcomas from immunocompetent hosts all exhibited growth and progression in 
wild-type mice after the same transplantation procedure24. This showed the capacity 
of the immune system to alter tumour immunogenicity, with tumours generated in the 
presence of an intact immune system being much less immunogenic and therefore 
exhibiting higher potential for progression and metastasis. Evidence from this study led 




system’s dual role in immunosurveillance and tumour-sculpting. Cancer immunoediting 
is divided into three stages, each of which is discussed in more detail below – 
elimination, equilibrium and escape26 (Figure 1.4). 
 
1.2.1 Tumour elimination 
The elimination phase, previously referred to as cancer immunosurveillance, is 
characterised by cells of both innate and adaptive immunity recognising and killing 
transformed cells in the host before they become clinically apparent, thus restoring 
physiological balance23. Even though this process has never been visualised, it has 
been shown in vivo in numerous mouse models where parts of the immune system 
have been abolished by gene knockout or neutralising antibodies, as well as in the 
more complex and varied settings of human clinical trials. In addition to the study 
discussed above24, the heavy implication of T-cells in tumour regulation has been 
demonstrated in several others, with mice lacking ab T-cells27, the less common gd T-
cells27, or T-lymphocytes in general28 all being more susceptible to chemical 
carcinogen-induced sarcomas. Furthermore, mice deficient in IFNg and perforin, two 
key effector molecules secreted by cytotoxic T-lymphocytes, showed significantly 
reduced capacity for preventing prostate and mammary tumour metastases to the lung 
compared to mice lacking only one of the two, with IFNg also controlling mouse 
sarcoma growth rate29. In fact, IFNg is an important mediator of immunosurveillance 
with the capability to enhance tumour cell immunogenicity30, partly through 
upregulation of MHC class I expression on tumour cells and consequent better tumour 
targeting by CD8 T-lymphocytes24,31. The role of perforin is also crucial – perforin-




their wild-type counterparts32, which increased further when mice also lacked b2-
microglobulin (b2m) necessary for MHC class I molecule function33. The above studies 
all demonstrated the importance of CTLs in tumour initiation and progression. 
Interestingly, defects in perforin cytotoxicity were also shown to increase susceptibility 
to haematological malignancies in humans34, providing further evidence for the role of 
adaptive immunity in tumour elimination. 
 
Advances in human T-cell culture methods, the ability to mimic the immune response 
in vitro with the help of dendritic cells, and screening of serum samples from neoplastic 
patients for immune reactivity to specific tumour proteins led to the discovery of a 
multitude of tumour antigens which the human immune system can recognise35. 
Examples include the cancer-testis antigens melanoma-associated antigen-1 (MAGE-
A1)36 and New York esophageal squamous cell carcinoma-1 (NY-ESO-1), the latter of 
which is found in a wide variety of cancers including those of the breast, prostate, 
bladder and liver as well as in healthy testes and ovaries37. Both MAGE-A and NY-
ESO-1 are also expressed in conjunction in metastatic melanoma lesions38. Another 
tumour antigen, cyclin B1, is aberrantly expressed in the cytoplasm of many human 
tumour cells including those from breast and head and neck cancers while being barely 
detectable in normal cells39. In these and many other cases, the tumour antigens were 
found to trigger CTL responses in vitro. Clinical evidence of cancer 
immunosurveillance in humans is harder to come by due to the complex nature of the 
human body compared to mouse models and the requirement for large clinical trials 
with long-term follow-up. Nonetheless, immunosuppression has been linked to 




higher risk of virus-associated cancers40 and smoking-independent lung 
adenocarcinomas41,42 than the wider population. A study of heart and lung transplant 
patients in a 15-year period, all of whom received immunosuppressive treatment to 
prevent graft rejection, found that their risk of cancer diagnosis was increased 
sevenfold compared to the general population, with leukaemias and lymphomas being 
the predominant cancer types diagnosed in this group43. In addition, CD8 tumour-
infiltrating lymphocytes (TILs), when present in high numbers within the tumour, 
strongly correlate with favourable clinical outcomes in various cancers. The fact that 
TILs are good predictors of survival was first observed in melanoma patients44,45, 
followed by the finding that nearly 40% of patients with ovarian cancer who had high 
TIL numbers survived longer than five years post-diagnosis compared to only 4.5% of 
patients with low TIL numbers46. A multi-centre study of patients with colon cancer 
determined that the presence of tumour-infiltrating cells, including TILs, was a more 
accurate predictor of clinical outcome than histopathological staining methods47. These 
and other studies highlighted the importance of TILs as a prognostic indicator and 
influenced their subsequent use in tumour immunotherapy, which is discussed further 
in section 1.3.3. 
 
1.2.2 Immunity-induced tumour equilibrium 
Certain tumour cells are able to evade destruction by the immune system yet remain 
partially controlled, resulting in incomplete tumour elimination and entry into a state of 
dynamic balance with host immunity instead. In this equilibrium phase, the antitumour 
immune response keeps the cancer in a ‘dormant’ state and prevents its outgrowth, 




a study of wild-type mice injected with low-dose MCA48, which led to tumour 
establishment in a small number of treated animals. However, when the remaining 
mice with no overt tumours were depleted of CD4 and CD8 T-cells, or when cytokines 
mediating adaptive immunity such as IFNg or interleukin-12 (IL-12) were blocked using 
mAbs, approximately half the mice displayed progressive sarcoma. Furthermore, this 
was only found when mAbs were directed against CD4, CD8 or the above cytokines, 
with anti-NK cell mAbs showing no effect on tumour progression48, thus providing 
evidence for the crucial role of T-lymphocytes in keeping the tumour in check. The fact 
that T-cells are essential for inducing tumour equilibrium was shown in a further study 
in a murine model of a p53-mutant tumour, where T-cell cytokines IFNg and tumour 
necrosis factor a (TNFa) induced cancer growth arrest and senescence49. Another 
study in a mouse model of metastatic melanoma showed that CD8 T-cell depletion led 
to significantly faster progression to metastases, and suggested that keeping the 
disseminated tumour in a dormant state that does not lead to macroscopic metastases 
is a viable therapeutic strategy in cancer patients50. 
 
It has been shown that tumours can stay dormant in human hosts for years or even 
decades before any clinical manifestation, a phenomenon known as minimal residual 
disease23. For example, circulating tumour cells have been detected in former breast 
cancer patients up to 22 years after mastectomy with no evidence of clinical disease, 
thus supporting the hypothesis of cancer equilibrium in humans51. Evidence implicating 
the immune system in this process can be found in the rare, but significant cases where 
an occult tumour was unintentionally transplanted from donor to immunosuppressed 




donor-related tumours have been detected in the past, some of which never 
manifested in the donors themselves and only developed many months or years later 
in the immunosuppressed individual receiving the organ52. Several cases have also 
been reported of patients developing melanoma from transplanted organs originating 
from donors who underwent successful melanoma surgery and been cleared of cancer 
years earlier; some of the recipients progressed to metastatic melanoma with fatal 
outcomes53. These reports highlight the existence of a balance between cancer and 
the human immune system, which is nonetheless broken down once the immune 
system is compromised. However, long periods of tumour dormancy and apparent lack 
of clinical disease in many patients suggest that tumour equilibrium is a valid 
therapeutic endpoint in the cases where cancer elimination cannot be achieved. 
 
1.2.3 Immunosuppression and tumour escape 
It has been shown that, in a mouse model of tumour dormancy in acute myeloid 
leukaemia, residual tumour cells become increasingly resistant to CTL-mediated killing 
with increased time they spend dormant in the host54. In this study, leukaemic cells 
that persisted upregulated their surface expression of PD-1 ligand-1 (PD-L1) and the 
CTLA-4 ligand CD80, thus leading to downregulation of the T-cell response. Blocking 
CTLA-4, CD80 or PD-L1 enhanced T-cell cytotoxicity and led to prolonged mouse 
survival54. It has also been shown that cancer recognition by T-cells is reduced by the 
promotion of outgrowth of tumour cells lacking strongly immunogenic mutant 
peptides55. These studies provide evidence for the tendency of tumour cells to become 
less immunogenic under selective pressure by the immune system, ultimately leading 




spreading in the host. This last phase of cancer immunoediting, in which the immune 
system fails to control the tumour, is termed tumour escape23, and cancer cells are 
able to employ a variety of mechanisms to achieve it. 
 
Experiments in mice suggest that, over time, tumours are able to promote their own 
growth by further inducing the naturally occurring process of tolerance, whereby T-
cells responsive to self-antigen – and consequently to antigens expressed by tumours 
– are eliminated (much like during the process of thymic selection)23,56,57. Furthermore, 
loss of antigen presentation on the surface of tumour cells renders them ‘invisible’ to 
immune effectors. For example, downregulation of b2m in several patient-derived 
metastatic melanoma cell lines led to loss of MHC class I surface expression and the 
ability to present endogenous antigen, which in turn resulted in poor recognition by 
CD8 T-cells58. Another study showed that, in the presence of CTLs, the absence of 
melanocyte differentiation antigens from the surface of patient-derived melanoma cells 
led to progressive metastases, while one metastasis that persistently expressed 
antigen underwent regression59. Apart from peptide-MHC class I downregulation 
common to many tumours, other mechanisms of tumour immune evasion include 
upregulation of anti-apoptotic factors such as BCL-xL60, deregulation of the Fas-
mediated cell death pathway61, and direct tumour cell contact with, and inhibition of, 
CTLs via PD-1/PD-L1 and/or CTLA-4 interactions as discussed above54. 
 
In addition to the described changes in cancer cells themselves, tumours generate an 
immunosuppressive microenvironment in order to further subvert the host immune 




of products of sterol metabolism that inhibit the expression of CC chemokine receptor-
7 on the surface of dendritic cells; this in turn renders DCs incapable of migrating to 
secondary lymphoid organs to present tumour antigens to cells of adaptive immunity62. 
Another important tumour-secreted molecule is vascular endothelial growth factor 
(VEGF) which plays a crucial role in tumour angiogenesis but also inhibits DC 
maturation, as evidenced by the combination treatment of anti-VEGF antibody and 
peptide-pulsed DCs leading to a potent and prolonged antitumour effect in mice63. 
Immunosuppressive cytokines are also heavily implicated, with transforming growth 
factor beta (TGFb) capable of inhibiting both DC and T-cell function64. A particularly 
potent immunosuppressive enzyme constitutively expressed by most human tumours 
is indoleamine-2,3-dioxygenase (IDO), which metabolises tryptophan and has 
previously been found to suppress T-cell activity in order to prevent maternal rejection 
of the foetus65. In tumours, IDO causes inhibition of CD8 T-cell proliferation and 
stimulation of CD4 T-cell apoptosis, leading to failure of T-lymphocytes to accumulate 
at the tumour site66. 
 
In addition to the above, tumours are able to recruit Tregs, a subset of CD4 T-
lymphocytes which, as mentioned previously, are crucial in mediating tolerance to self-
antigen and eliminating self-reactive effector cells under physiological conditions. 
However, in a tumour setting, these regulatory T-cells act to suppress CTLs through 
various mechanisms, including production of TGFb and IL-10, expression of CTLA-4 
and PD-L1, and consumption of IL-2 which is necessary for continued T-cell 
activation67. There is extensive evidence of increased proportions of Tregs in many 




and late-stage ovarian cancer68, malignant glioma69 and head and neck squamous cell 
carcinoma (HNSCC)70, all of which are found to suppress cytotoxic CD8 T-cell 
responses. The presence of Tregs in the tumour also leads to reduced survival in 
patients with ovarian cancer71 and represents a marker of poor prognosis in pancreatic 
ductal carcinoma72. More recently, it has been shown that eliminating certain Treg 
subsets rather than all intratumoural Tregs could provide an effective approach to 
tumour therapy. Colorectal carcinomas (CRCs) had a much better prognosis if they 
were predominantly infiltrated by Tregs expressing low levels of the transcription factor 
forkhead box P3 (Foxp3), termed Foxp3lo Tregs, rather than their Foxp3hi counterparts, 
suggesting that selective elimination of the Foxp3hi population could boost antitumour 
responses73. Similarly, melanomas and HNSCCs with a high proportion of Tregs 
expressing neuropilin-1 (NRP-1) also exhibited poor prognosis, and deletion of NRP-1 
in a Treg-restricted fashion induced secretion of IFNg, led to fragility of cancer-
promoting wild-type Tregs and increased tumour clearance in a melanoma mouse 
model74. 
 
All of the above suggests that targeting the mechanisms of tumour 
immunosuppression and escape, along with potentiating the antitumour immune 
response, should be the main approach to developing successful cancer 
immunotherapy. Many strategies have already been tried, with various degrees of 






Figure 1.4 – The process of cancer immunoediting 
Cancer immunoediting can be divided into three stages: elimination, equilibrium and 
escape. When normal cells first become cancerous, they are successfully recognised 
and eliminated by both innate and adaptive immune cells such as natural killer (NK) 
and effector T-cells (Teff). During this process, however, the immune system targets 
highly immunogenic tumour cells but is much less effective at killing the poorly 
immunogenic ones, leading to selection of immune-resistant tumour variants and their 
establishment in the body. In the equilibrium stage, the immune system keeps the 
growth of the established tumour in check but is unable to fully eliminate it, mostly due 
to the tumour activating a host of defence mechanisms such as secretion of 
immunosuppressive molecules and cytokines, recruiting regulatory T-cells (Tregs) and 
myeloid-derived suppressor cells (MDSCs) to resist immune attack, and leading to Teff 
exhaustion in the tumour microenvironment. Once these mechanisms completely 
overwhelm the host immune response, and the tumour is able to build a protective 
stroma around itself, it eventually grows and spreads – the phase termed tumour 
escape. PD-L1, programmed cell death protein-1 ligand-1; IDO1, indoleamine-2,3-
dioxygenase 1; IL-10, interleukin-10; TGFb, transforming growth factor-b; CCR2, C-C 
motif chemokine receptor 2. Reprinted by permission from Springer Nature: NATURE 
REVIEWS CANCER (Yarchoan M, Johnson BA, Lutz ER, Laheru DA, Jaffee EM. 






1.3 Tumour immunotherapy 
Tumour immunotherapy refers to the manipulation of the immune system to treat 
cancer. The various approaches tried over the years, with increasing promise, rely 
heavily on rendering established tumours susceptible to immune attack once again 
and/or boosting the pre-existing or exogenously introduced antitumour immunity. The 
main approaches to immunotherapy are described below. 
 
1.3.1 Cancer vaccines 
One strategy is the use of ‘active’ immunotherapy, or cancer vaccines, whereby 
tumour-associated antigens are introduced into patients in order to trigger an immune 
response from host T-cells and antibodies35,76. This has been trialled, for example, in 
patients with stage III or IV NSCLC immunised with a liposome vaccine derived from 
the mucin-1 antigen, which is abnormally expressed and glycosylated in NSCLC77. In 
this and a follow-up study of patient survival78, the 3-year survival rates of patients 
receiving the vaccine and those that did not were 31% and 17% respectively77,78. Even 
so, a subsequent phase III trial found no significant difference in overall survival when 
patients with unresectable stage III NSCLC were given the vaccine following 
chemoradiotherapy compared to those that received placebo instead79. Similarly, 
small-scale evidence of durable clinical response was found in patients with non-
Hodgkin’s lymphoma vaccinated with recombinant lymphoma-specific idiotype80, and 
improved effector T-cell function was observed in trials of DC-based vaccines pulsed 
with human epidermal growth factor receptor-2 (HER2) peptides and injected into 
patients with HER2-positive breast cancer81. However, all of these would need to be 




sipuleucel-T became the first cancer vaccine to be approved by the US Food and Drug 
Administration (FDA) for the treatment of prostate cancer. Sipuleucel-T is obtained by 
ex vivo culturing of autologous peripheral blood mononuclear cells (PBMCs), which 
include T-cells and APCs, with a fusion protein containing prostatic acid phosphatase 
– a tumour antigen expressed in prostate adenocarcinoma – before injecting the 
PBMCs back into the patient82. Even though this approach induces long-lived immunity 
in vivo82 and improves overall survival in men with metastatic castration-resistant 
prostate cancer, it is very expensive – $93,000 for one course of treatment83 – and 
does not in fact increase time to disease progression in comparison with placebo84–86. 
 
The above and the results of many more cancer vaccine trials suggest that, while some 
therapeutic benefit can certainly be seen, it is generally modest and still far from 
making a substantial difference in the case of metastatic disease87. Combinations of 
cancer vaccines with classical chemotherapy and other forms of immunotherapy hold 
some promise for the future. For example, favourable responses to second-line 
chemotherapy have been observed in patients with advanced small cell lung cancer 
previously immunised with tumour suppressor protein p53-based cancer vaccine88. 
Furthermore, depletion of Tregs by targeting CD25 on Treg surface, followed by 
vaccination with melanoma-specific tumour antigens, resulted in induction of tumour-
specific CD8 T-cells in 90% of melanoma patients tested89. Selecting the most 
promising antigens for the vaccines to target, which may include those expressed by 
tumour stromal cells90, induced neo-antigens on disseminated tumour lesions that are 




specific mutations92, is becoming crucial for the success of this immunotherapeutic 
modality. 
 
1.3.2 Immune checkpoint blockade 
The term ‘immune checkpoints’ refers to the variety of inhibitory molecules responsible 
for maintaining the immune system’s self-tolerance and avoiding autoimmunity under 
physiological conditions, and for preventing tissue damage during immune response 
to infection. However, this essential mechanism is co-opted by many tumours as a way 
of mediating immune resistance, in particular against tumour-specific T-cells93. The 
vast array of co-inhibitory molecules on the surface of T-lymphocytes all represent 
immune checkpoint proteins, the inhibition of which has the potential to significantly 
boost the antitumour immune response; therefore, blocking these using mAbs or 
otherwise targeting them has become a major focus of cancer immunotherapy. Two 
immune checkpoint proteins that have been most extensively studied to date are the 
co-inhibitory receptors CTLA-4 and PD-193. 
 
1.3.2.1 Anti-CTLA-4 therapy 
CTLA-4 is immensely important physiologically – its role in downregulating the 
amplitude of T-cell activation is essential for preventing uncontrollable immune 
responses, as evidenced by Ctla4-/- mice all developing lymphoproliferative disease 
and dying of multiorgan failure caused by lymphocytic infiltration by 3-4 weeks of 
age94,95. However, while CTLA-4 downmodulates the responses of both CD8 CTLs and 
CD4 T-helper cells, it conversely enhances the immunosuppressive actions of Tregs, 




effector and regulatory T-cells, which enhances the actions of the former and inhibits 
the suppressive functions of the latter, has been shown to lead to synergistic 
antitumour activity in mouse melanoma96. CTLA-4 inhibition was first shown to lead to 
tumour regression, and even to immunity to secondary tumour attack, when the 
administration of anti-CTLA-4 antibodies to syngeneic mice led to rejection of 
previously implanted colorectal and fibrosarcoma tumours97. Even though there was 
potential for severe immune toxicity, as previously observed in Ctla4-/- mice, this study 
showed that partial CTLA-4 antibody blockade was able to achieve a therapeutic 
window97. In a further study, mice chronically exposed to ultraviolet (UV)-B radiation 
developed fewer UV-induced tumours if treated with an anti-CTLA-4 antibody 
compared to their untreated counterparts, with evidence that the treatment also 
establishes long-term immune protection against photocarcinogenesis98. Moreover, it 
has been demonstrated that poorly immunogenic tumours do not always respond to 
CTLA-4 inhibition alone, but become responsive when anti-CTLA-4 therapy is 
combined with a cancer vaccine, suggesting that, in the absence of significant 
endogenous immunity, combination treatments that boost immune responses may 
work better than immune checkpoint inhibition by itself99. 
 
The accumulated evidence from mice, and the fact that CTLA-4 exhibits 76% overall 
amino acid homology between mice and humans100, led to its incorporation into human 
clinical trials. It was first shown that CTLA-4 antibody blockade could mediate tumour 
regression in certain metastatic melanoma and ovarian carcinoma patients previously 
treated with a cancer vaccine101. However, serious autoimmune adverse effects, which 




metastatic melanoma patients102. The evidence that led to FDA approval of a fully 
humanised anti-CTLA-4 antibody, ipilimumab, in the treatment of metastatic melanoma 
came from a phase III trial which showed a survival benefit of 3.5 months in metastatic 
melanoma patients receiving ipilimumab alone or in combination with a melanoma-
specific gp100 peptide vaccine compared to those who received the vaccine on its 
own103. What was more prominent was the long-term survival rate, with 18% of 
ipilimumab patients surviving for more than two years compared with only 5% of those 
receiving the gp100 vaccine alone103. Ipilimumab has since also been approved for 
adjuvant (i.e. post-surgery) treatment of resected stage III melanoma after a 
multinational phase III trial showed significantly increased recurrence-free survival in 
patients treated with adjuvant ipilimumab versus placebo in this setting104. 
Nevertheless, it was noted that more than 50% of patients on ipilimumab discontinued 
treatment, and five patients (1%) died, due to cutaneous, gastrointestinal, hepatic or 
endocrine adverse events104. Even though this did not translate to a clinically relevant 
difference in health-related quality of life between ipilimumab- and placebo-treated 
patients during the 3-year follow-up105, it is important to bear the potentially life-
threatening toxicities of this antibody in mind as it is being tested in other tumour types, 
including renal cell carcinoma (RCC), ovarian cancer, prostate cancer and urothelial 
carcinoma106. 
 
1.3.2.2 Anti-PD-1/PD-L1 therapy 
PD-1, like CTLA-4, is a suppressor of T-cell activity, but unlike CTLA-4, it exerts its 
action through interference with TCR signalling rather than competing with CD28 for 




anergy, brought about by persistent antigen stimulation, is at least partially mediated 
by upregulation of PD-1 expression on T-lymphocyte surface, and that blocking the 
PD-1 signalling pathway leads to restoration of T-cell functional responsiveness107. 
High PD-1 expression has been noted on TILs originating from various tumours, 
including prostate cancer108 and melanoma109, and PD-1 ligands PD-L1 and PD-L2 are 
commonly overexpressed on the surface of tumour cells. For example, PD-L1 is 
abundant in samples from human lung, ovary and colon cancers as well as melanoma, 
and its forced expression on mouse tumour cells mediates tumour-reactive T-cell 
apoptosis110. PD-L2 was found to be upregulated in NSCLC in addition to PD-L1111, 
and mAb blockade of both ligands had synergistic effects on the enhancement of T-
cell proliferation and effector functions112. More recently, it has been shown in a mouse 
model of progressive sarcoma that T-cells targeting mutant tumour antigens are 
reactivated inside growing tumours following anti PD-1 and/or anti-CTLA-4 therapy, 
thus mediating tumour rejection113. These and other studies in mouse models of cancer 
where inhibition of PD-1 and its ligands led to improved antitumour immunity, as well 
as the much less toxic phenotypes of Pd1-/-, Pdl1-/- and Pdl2-/- mice compared to those 
deficient in CTLA-4, paved the way for human clinical trials93. 
 
In a phase I study of the anti-PD-1 antibody nivolumab in 39 patients with advanced 
melanoma, prostate cancer, CRC, RCC or NSCLC, one complete and two partial 
responses were observed, as well as significant tumour regression in two additional 
patients; importantly, only one patient suffered a serious adverse event diagnosed as 
inflammatory colitis114. This led to a larger trial of the same antibody in 296 patients 




with melanoma (28%), RCC (27%) and NSCLC (18%); almost two thirds of responses 
in patients who were followed up lasted a year or more after therapy was stopped115. 
Even though serious adverse events were noted in 14% of treated patients, with three 
deaths due to pulmonary toxicity, the safety profile was deemed acceptable115. 
Following a series of phase III clinical trials which all showed the significant survival 
benefit and better safety profile of nivolumab compared to standard chemotherapy in 
patients with advanced melanoma116,117, RCC118 and both squamous and non-
squamous NSCLC119–121, nivolumab was approved by the FDA for these conditions106. 
Another anti-PD-1 antibody, pembrolizumab, was also trialled in advanced ipilimumab-
refractory melanoma122, NSCLC123 and various mismatch repair-deficient 
tumours124,125, among others. The consistently observed increase in overall and 
progression-free survival of pembrolizumab-treated patients in all of these led to FDA 
approval of this antibody for several different cancers, including for any solid tumours 
characterised by mismatch repair deficiency or high microsatellite instability – the first 
time a cancer therapy was approved based on a tumour biomarker rather than the 
location of the tissue involved126. 
 
Biomarkers are in fact becoming increasingly important in immune checkpoint 
inhibition, as exemplified by PD-L1 expression on tumour tissue being examined as a 
prognostic indicator of patient response to immunotherapy in the studies mentioned 
above. As PD-L1 blockade has the potential to inhibit the interaction of this ligand with 
both PD-1 and CD80, both of which normally lead to downregulation of antitumour T-
cell responses127, this therapeutic approach has become a very attractive avenue of 




patients with metastatic bladder cancer, demonstrating objective responses in 
approximately half of the patients who exhibited increased PD-L1 expression in the 
tumour128, and in metastatic RCC with promising results129. Durvalumab, a second 
anti-PD-L1 antibody, also led to significantly increased progression-free survival in 
patients with stage III NSCLC previously treated with chemotherapy in a recent phase 
III study130. Overall, immune checkpoint inhibition of both PD-1 and PD-L1 looks very 
promising, with many trials ongoing to gauge the full extent of therapeutic benefit to 
patients. In addition, synergistic blockade of multiple immune checkpoints, of which 
CTLA-4 and PD-1 are only a small fraction, as well as development of combinatorial 
approaches incorporating immune checkpoint blockade and cancer vaccines, are all 
becoming important therapeutic strategies going forward. 
 
1.3.3 TIL therapy 
An approach that has shown great promise and even curative potential in recent years 
is adoptive cell transfer (ACT). ACT involves the ex vivo expansion of autologous or 
HLA-matched tumour-reactive T-cells and their re-infusion back into the patient, where 
the lymphocytes can subsequently reach the tumour and eliminate it87. Usually, ACT 
is preceded by lymphodepletive chemotherapy with or without total body irradiation 
(TBI) in order to deplete Tregs from the patient and create “space” in the 
haematopoietic system, thereby increasing the persistence of transferred T-cells87 
(Figure 1.5). ACT therefore has the ability to overcome the major drawback of 
vaccines, which require de novo induction or boosting of immunity in cancer patients 




lack of a potent T-cell response to tumour self-antigens resulting from central 
tolerance132. 
 
The first clinical report of specifically targeted ACT in humans involved 
cytomegalovirus (CMV)-specific T-cells being expanded ex vivo and administered to 
bone marrow transplant recipients who are generally at high risk of CMV infection, 
resulting in the establishment of protective immunity against CMV133. This led to efforts 
to apply ACT to cancer treatment, where a pioneering study demonstrated that 
adoptive transfer of TILs could be used to successfully treat patients with metastatic 
melanoma – infusions of autologous TILs and high-dose IL-2 resulted in objective 
clinical responses in approximately a third of the patients treated134. To improve T-cell 
persistence and increase response rates, a further study by the same group employed 
an immunodepleting conditioning regimen before adoptive transfer of TILs along with 
high-dose IL-2 into 13 patients with metastatic melanoma135. Six of the 13 patients 
showed marked tumour regression, and another four had mixed responses; five 
patients that exhibited regression also developed autoimmune destruction of 
melanocytes but recovered. The transferred T-cells were specific for the melanoma 
antigen recognised by T-cells 1 (MART-1) and, apart from mediating the destruction of 
metastases, also targeted normal tissue expressing the antigen, thus causing 
autoimmunity135. This study showed that targeting self-antigens to destroy tumours 
was therapeutically feasible as long as autoimmune side effects were minimal or 
controllable. The same study design was implemented in a larger cohort of 35 patients 
who demonstrated a similar response rate of 51% (comprising both complete and 




TBI was added to lymphodepletive chemotherapy137. This last cohort was followed up 
to reveal that 20 patients (22%) exhibited complete tumour regression, and all but one 
of these were still in remission after five or more years138,139. More recently, it was 
shown by the same group that this addition of TBI to lymphodepleting regimens may 
not actually be necessary, with 24% of patients with metastatic melanoma exhibiting 
complete regression following TIL infusion, and median survival of over 3 years, 
regardless of whether they received prior TBI or not140. 
 
The above series of trials, carried out by the Rosenberg group at the National Cancer 
Institute (NCI), as well as trials in at least three other centres which were able to 
reproduce high patient response rates139, showed that TILs could successfully mediate 
durable complete responses in metastatic melanoma patients regardless of previous 
cancer treatment received138. They also highlighted several drawbacks of this 
approach and factors to take into account when developing further T-cell-based 
immunotherapies. Ex vivo TIL expansion protocols and tumour-specificity screens prior 
to re-infusion into patients were initially very labour-intensive, and it soon became 
obvious that less time-consuming approaches were needed132. This was somewhat 
improved by developing a more rapid TIL generation method that enriches for CD8 T-
cells and still produces objective responses in melanoma patients141, but the 
therapeutic efficacy of this approach may be inferior to the one seen with standard TIL 
expansion methods139. In addition, a significant positive correlation was observed 
between the likelihood of complete response to treatment and the administration of 
TILs which had longer telomeres, were less differentiated, or were present in higher 




previous studies in mice where less differentiated cells, and those with greater 
proliferative potential, exhibited more potent antitumour activity upon infusion142. Taken 
together, these findings further highlighted the need to minimise the time TILs spent in 
culture prior to adoptive transfer as well as to avoid T-cell senescence and anergy, 
possibly by CD28 co-stimulation to enhance telomere length in vitro, or by uncoupling 
T-cell proliferation from differentiation into effectors131. Finally, naturally occurring TILs 
are only detectable and therapeutically active in a small minority of cancers, mostly 
melanomas, making their isolation from other tumours, even those that do contain T-
cells, impossible or ineffective87,132. This is in part because melanoma biopsies can be 
readily obtained unlike those from most cancers, but the main reason suggested for 
the presence of therapeutic TILs only in melanoma is the immunogenicity of this 
tumour, which carries more mutations than any other tumour type87,131. In order to 
target other, less immunogenic tumours, and eliminate the need for isolation of rare 
TILs, more recent efforts have been directed towards genetic engineering of T-cells 
resulting in their expression of receptors highly specific for any given tumour antigen. 
To this end, T-cells purified from patient blood can be engineered to express either 






Figure 1.5 – Overview of adoptive cell transfer 
Adoptive cell transfer (ACT) can be carried out in several different ways. A patient’s 
own T-cells, or in some instances the T-cells from a healthy donor (either HLA-matched 
or one whose cells have been modified to switch off alloreactivity) can be engineered 
in vitro to express a tumour-specific high-affinity T-cell receptor (TCR) or chimeric 
antigen receptor (CAR) before being infused back into the patient. In case of certain 
solid tumours (e.g. melanoma), the patient’s own tumour-infiltrating lymphocytes (TILs) 
can be harvested from a tumour sample, expanded and re-infused. In the majority of 
cases, the ACT recipient will undergo some form of lymphodepletion prior to T-cell 
infusion in order to increase the chance of their successful engraftment. Reprinted by 
permission from The American Association of Immunologists, Inc.: JOURNAL OF 
IMMUNOLOGY (Barrett DM, Grupp SA, June CH. Chimeric Antigen Receptor- and 
TCR-Modified T Cells Enter Main Street and Wall Street. 195(3):755–61), copyright 





1.3.4 TCR-engineered T-cell therapy 
The genetic transfer of TCR a and b chains from one T-cell population to another was 
shown to lead to successful transfer of antigen specificity both for murine144 and human 
TCRs145. However, the tumour-specific T-cells originally used to obtain TCRs for 
transfer were isolated from either cancer patients with high antitumour responses or 
healthy volunteers, where the main obstacles were low frequency in peripheral blood, 
generally poor affinity for self-antigen due to the effects of central tolerance, and an 
overall paucity of suitable culture methods131. In an effort to increase the potency of 
tumour antigen recognition by ab TCR-engineered T-cells used for ACT, several 
approaches have been tried, including enrichment for highly specific TCRs through 
phage displays146 and introduction of single amino acid modifications into the antigen-
binding region of the receptor147. While these indeed resulted in increased antigen 
affinities, such modifications also have the potential to lead to reductions in specificity 
and a higher propensity towards self-reactivity87,147. An alternative approach involves 
vaccinating human HLA transgenic mice with tumour antigens to induce the clonal 
expansion of T-cells expressing TCRs with high affinity and specificity for the antigens 
in question and restricted through common human HLA alleles. Various tumour-
specific TCRs have been generated using this method, including those recognising 
p53 and several melanoma-specific antigens132. 
 
ACT using TCR-engineered T-cells has shown promising results in several clinical 
trials, but apart from tumour regression, significant toxicity has also been observed 
(discussed in more detail below). The main limitation of this approach lies in TCR MHC 




possible lack of response if the tumour has evolved to include antigen-loss variants. In 
addition, the patients need to possess the restricting MHC allele for that TCR, thus 
significantly reducing the patient population that can be treated with any one 
TCR132,139. However, MHC dependence of this approach can also be advantageous, 
as it enables targeting of HLA-peptide complexes derived from intracellular tumour 
antigens that are otherwise inaccessible to other forms of treatment139. 
 
The first trial to achieve tumour regression using infusion of autologous, TCR-
engineered T-cells targeted the melanoma antigen MART-1. Objective responses were 
observed in two out of 15 metastatic melanoma patients tested and, importantly, no 
autoimmune toxicities were reported148. Higher-affinity TCRs specific for MART-1 were 
subsequently generated by transgenic mouse immunisation and used to transduce 
autologous peripheral blood lymphocytes from 20 metastatic melanoma patients149. 
Here, six patients exhibited partial responses, with three ongoing more than a year 
post-treatment; however, 16 patients (80%) exhibited one or more adverse events 
resulting from T-cell mediated autoimmune attack on normal melanocytes, which 
manifested as damage to the skin (rash followed by vitiligo), eyes (uveitis) or ears 
(hearing loss)149. These trials highlighted the potential of engineered T-cells to mediate 
both cancer regression and significant toxicity if the tumour antigen targeted is 
expressed on both normal and tumour tissue. 
 
Unlike the widely expressed MART-1, the cancer-testis antigen NY-ESO-1 is only 
expressed in healthy testes (where it is protected from T-cell recognition by the lack of 




melanoma and synovial cell sarcoma139. High-affinity TCRs specific for NY-ESO-1 
were trialled in a cohort of 11 patients with metastatic melanoma and six with 
metastatic synovial cell sarcoma, where five patients in the former group, and four in 
the latter, exhibited tumour regression. Two of the five responses in the melanoma 
patient group were complete and ongoing more than one year after treatment, and 
none of the patients in the trial experienced autoimmune side effects150. In a follow-up 
trial to this one, it was found that 11/20 melanoma and 11/18 synovial cell sarcoma 
patients treated with NY-ESO-1 TCR T-cells exhibited objective responses, with 
approximately a third of the patients in each group surviving for at least 3 years151. In 
a different study, NY-ESO-1 targeting T-cells also induced promising clinical responses 
in 16/20 patients with multiple myeloma152.  
 
In contrast to these successes, targeting another cancer-testis antigen, MAGE-A3, led 
to unexpected toxicity reactions with fatal outcomes. In a trial of a HLA-A2-restricted 
MAGE-A3-specific TCR in nine cancer patients153, five experienced clinical regression 
but three showed severe neural toxicities, and two of the three patients died. 
Subsequent analyses revealed TCR cross-reactivity with non-identical HLA-A2-
restricted epitopes in MAGE-A9 and -A12, with previously undiscovered expression of 
MAGE-A12 in brain tissue being responsible for the toxicity reactions153. Two other 
trials evaluated a high-affinity HLA-A1-restricted TCR specific for MAGE-A3 in patients 
with melanoma and myeloma, but the first patient to be treated in each of the trials 
developed fatal cardiac toxicity154,155. High infiltration of engineered T-cells into 
myocardial tissue was reported, which was subsequently discovered to be due to off-




expressed by beating, but not resting, cardiac myocytes154,155. These trials highlighted 
the need for high-sensitivity testing of target antigen expression in vital normal tissues 
in order to predict on-target/off-tumour toxicities. In addition, it is necessary to assess 
the cross-reactivity of TCRs generated in human HLA transgenic mice, as these would 
not have been subjected to thymic selection in humans and therefore may exhibit high 
affinity to certain normally occurring human proteins139. Applying these essential tests 
prior to TCR-based ACT should mitigate for severe adverse reactions in what 
otherwise continues to be a very promising approach. 
 
 
1.4 Chimeric antigen receptor (CAR) therapy 
Instead of highly specific TCRs, T-cells can be genetically engineered to express CARs 
– recombinant receptors which bring together the antigen-binding specificity of an 
antibody or of a natural ligand receptor and the T-cell activating properties of a TCR. 
Unlike TCRs, CARs can recognise native antigens (including proteins, glycolipids and 
carbohydrates) on the tumour cell surface in a MHC-independent fashion156. Even 
though they are limited to the recognition of surface antigens alone, without the means 
to detect intracellular antigens like TCRs, the MHC independence of CAR recognition 
eliminates the need for patient HLA haplotype matching and circumvents the 
downregulation of the MHC-antigen processing pathway employed by many 
tumours156. CARs tested in clinical trials to date have led to very encouraging outcomes 
in patients with haematological malignancies, with increasing potential to expand this 




1.4.1 CAR design 
CARs are modular receptors consisting of an antigen-binding extracellular domain 
linked via a transmembrane region to an intracellular signalling domain, sometimes 
with a ‘hinge’ or ‘spacer region’ between the extracellular domain and the 
transmembrane one156–158 (Figure 1.6, left). The extracellular moiety is most 
commonly a single-chain variable fragment (scFv) incorporating antigen-binding 
sequences of both heavy and light chains of a human or murine antibody, although 
fragment antigen binding (Fab) regions of antibodies as well as natural ligand receptors 
have also been used156,158. The CAR intracellular domain overwhelmingly comprises 
the CD3z chain originating from the TCR/CD3 receptor complex or, less commonly, 
the Ig fragment crystallisable (Fc) receptor g chain156. A crucial consideration is the 
position of the CAR-targeted epitope and its distance from the target cell surface, 
where the CAR spacer region becomes important. The length and flexibility of the CAR, 
altered by changing the length of the spacer, is likely to affect immunological synapse 
formation156,157. For example, introducing a spacer into a CAR specific for the tumour-
associated antigen neural cell adhesion molecule (NCAM) enhances cytokine release 
and cytotoxicity of NCAM-specific CAR-transduced T-cells159, possibly because the 
target epitope is found close to the cell surface and thus requires a more flexible CAR 
to interact with it. Conversely, a CAR specific for carcinoembryonic antigen (CEA), 
which binds to the easily accessible CEA amino terminal, exhibits optimum activity 
without a spacer159. Direct comparative studies to assess the different affinities and 
specificities of CARs binding the same epitope, but that differ in all the above variables, 





Studies in transgenic mice revealed that, while able to support proliferation and effector 
functions of pre-activated T-cells, signalling through the CAR CD3z chain alone was 
not sufficient to activate resting T-lymphocytes, thus rendering them susceptible to 
anergy160; cytokine release in response to target cells was also much more robust in 
the presence of CD80-mediated co-stimulation than with CD3z signalling alone161. 
These observations led to engineering the 1st generation CARs, which contained CD3z 
as the sole intracellular signalling domain, into 2nd generation CARs that also 
incorporated the cytoplasmic domain of a co-stimulatory molecule, such as CD28, 4-
1BB or OX40156 (Figure 1.6). The dual signalling provided by CD3z and CD28 resulted 
in more potent and persistent CAR-transduced T-cells, as evidenced by rapid 
proliferation rates and significant IL-2 production in vitro162 and greater antitumour 
activity in vivo163,164. Furthermore, autologous T-cells transduced with CD28/CD3z 2nd 
generation CARs specific for the B-lymphocyte surface antigen CD19 showed 
significantly enhanced persistence and expansion after infusion into patients with B-
cell lymphomas compared to T-cells expressing 1st generation CD19-specific CARs165. 
4-1BB is another commonly used co-stimulatory domain in CAR constructs instead of 
CD28. There is as yet no clear consensus on which one is optimal, with in vivo studies 
demonstrating that 4-1BB/CD3z CAR T-cells exhibit greater persistence and can, 
given time, eliminate the targeted tumour, but that CD28/CD3z CAR T-cells are able 
to do so more quickly owing to their more potent anti-tumour effect166. 
 
3rd generation CARs, comprising two co-stimulatory domains (most commonly CD28 
and 4-1BB) in addition to the CD3z activation domain (Figure 1.6), seemingly confer 




adoptively transferred into tumour-bearing mice167,168. However, their infusion into 
three B-cell and mantle cell lymphoma patients in a pilot clinical trial only gave one 
partial response in a patient who eventually relapsed169. A 4th generation of CAR-
transduced T-cells, termed T-cells redirected for universal cytokine killing (TRUCKs), 
has also been described170. These ‘armoured CAR’ T-lymphocytes are engineered to 
release a transgenic product, commonly a pro-inflammatory cytokine such as IL-12, 
once their CAR is activated by the target antigen. This in turn results in further 
enhancement of T-cell proliferation and function and, more importantly, in the 
additional recruitment of innate immune effectors specifically to the tumour 
microenvironment, thus inducing superior tumour killing while limiting cytokine-
mediated systemic toxicity156,170. Preclinical studies of IL-12-secreting CAR-
transduced T-cells targeted against CD19171 and VEGF receptor-2 (VEGFR-2)172, and 
further studies of armoured CAR T-cells with alternative genetic payloads such as 4-
1BBL and CD40L173, have all highlighted the increased efficacy and promise of this 






Figure 1.6 – The structure and main properties of 1st, 2nd and 3rd generation CARs 
All CARs consist of an extracellular region – usually an antibody-derived single-chain 
variable fragment (scFv) – linked via a hinge/spacer (if present) to a transmembrane 
and an intracellular region, the latter signalling into the T-cell upon antigen binding. 
The intracellular region always comprises a signalling domain such as CD3z, which is 
present either alone (1st generation) or together with one or two co-stimulatory domains 
(2nd and 3rd generation CARs respectively). The most widely used co-stimulatory 
domains are CD28 and 4-1BB, both of which increase the capacity of the T-cell to 
release cytokines and proliferate, but the presence of 4-1BB may lead to greater CAR 
T-cell persistence in the circulation after infusion. Each co-stimulatory domain also 
results in a different metabolic and phenotypic profile of the engineered T-cell. 
Reprinted from Irving M, Vuillefroy de Silly R, Scholten K, Dilek N and Coukos G (2017) 
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t 




1.4.2 CAR therapy of haematological tumours 
The current paradigm for CAR therapy is the targeting of CD19, which is expressed on 
healthy B-cells but is also overexpressed in the majority of B-cell leukaemias and 
lymphomas156. CD19-specific CAR-engineered T-cells were first shown to successfully 
eliminate B-cell malignancies in several mouse studies163,164,175 before being tested in 
human clinical trials, where they gave highly promising patient outcomes. As of 
January 2018, over 250 CAR T-cell trials have been reported worldwide176, the majority 
of which are directed against haematological tumours; the main CAR target in these 
remains CD19, but alternative ones include CD20, CD30 and Lewis-Y antigen177. 
 
The most striking results with CD19-specific CARs have been observed by the groups 
working at the NCI, the Memorial Sloan-Kettering Cancer Center (MSKCC) and the 
University of Pennsylvania (UPenn). In an initial study by the NCI group, a patient with 
advanced follicular lymphoma experienced dramatic tumour regression following the 
administration of autologous CD28/CD3z CD19-specific CAR T-cells178. The same 
group followed this up with a series of trials in advanced B-cell lymphomas or chronic 
lymphocytic leukaemia (CLL) and observed remissions in the majority of patients in 
each, most recently demonstrating that this CAR achieved long-term responses in 
patients with diffuse large B-cell lymphoma179–181. The MSKCC group focused on 
trialling their CD28/CD3z CD19-specific CAR in patients with CLL and B-cell acute 
lymphoblastic leukaemia (B-ALL), achieving modest responses in CLL182 but highly 
promising response rates of up to 88% in patients with B-ALL, enabling them to 
subsequently undergo allogeneic haematopoietic stem cell transplantation (allo-




small-scale trials in CLL185,186 and pre-B-cell ALL187 with very promising results, 
culminating in a striking 90% complete response rate when 30 children and adults with 
relapsed ALL were treated with the same CAR188. More recently, this group also 
reported a 57% overall response rate in treated patients with relapsed/refractory CLL, 
half of which were complete remissions189.  
 
Taken together, these very promising results from several trials, along with many 
others reported or ongoing177,190–192, highlight the potential of CAR T-cell therapy in 
CD19+ and other haematological malignancies. However, they also point to several 
important issues that need to be addressed. Comparisons between the different trials 
are difficult as each one uses different CAR and T-cell manufacturing methods, 
lymphodepletion regimens and dosing schedules. It is therefore challenging to draw 
definitive conclusions regarding the varying patient outcomes, making future 
standardisation of CAR T-cell therapy a top priority156. Moreover, CAR T-cells caused 
substantial side effects in a significant portion of patients treated in all of the trials 
above, with the two main safety issues being on-target/off-tumour toxicity and cytokine 
release syndrome (CRS). Predictably, targeting CD19 not only led to antitumour 
activity but also to normal B-cell depletion and consequently 
hypogammaglobulinaemia. While this side effect is readily manageable with 
intravenous Ig infusions, other CAR targets expressed on normal as well as tumour 
tissue may result in much less tolerable adverse events, making the target choice a 
highly important consideration193. The other major patient safety concern, “cytokine 
storms” – the release of large amounts of cytokines causing high fever, hypotension, 




above and mostly managed with corticosteroids and the anti-IL-6 antibody 
tocilizumab187,188. However, since this severe side effect cannot be controlled by simply 
reducing treatment dose as T-cells continually proliferate, strategies such as split 
dosing or the introduction of suicide genes may mitigate for this toxicity to some 
extent156. Ultimately, designing highly tumour-specific CARs, the potential toxicity of 
which can be regulated with reasonable ease, represents the definitive aim in the use 
of this treatment modality. 
 
1.4.3 CAR therapy of solid tumours 
One reason why CAR T-cells have proven so successful in haematological 
malignancies is the ease with which they can reach their target antigens on B-cells, 
the blood and lymphatic system being where both T-cells and B-cells naturally reside. 
Solid tumours, however, represent an entirely distinct set of challenges, not least of 
which are the highly immunosuppressive tumour microenvironment and the lack of 
known target antigens expressed on malignant but absent from normal cells156. 
Nevertheless, recent studies in tumour-bearing mice do show some promise. Tumour 
control or eradication has been reported in mice treated with CAR T-cells targeting 
glypican-3 in the treatment of hepatocellular carcinoma (HCC)194 and lung squamous 
cell carcinoma195, mucin-1 in pancreatic cancer196, and both L1 cell adhesion 
molecule197 and the tumour antigen 5T4 in ovarian cancer198. CAR-mediated rejection 
of large established HER2+ tumours199 and control of large pancreatic and lung 
tumours200 in mice have also been described. The promising results of these in vivo 
studies cannot always be safely and effectively translated into the clinic, however, 




specific CAR T-cells administered to a patient with metastatic CRC led to off-tumour 
recognition of low-level HER2 on lung epithelial cells, resulting in a severe cytokine 
storm and the patient’s death201. In another trial, half the examined patients with RCC 
who were administered carboxyanhydrase-IX (CAIX) CAR T-cells had their treatment 
stopped due to CAIX expression on bile duct epithelial cells leading to liver enzyme 
disturbances202, and patients have been reported to develop anaphylaxis203 or 
compartmental CRS204 after being injected with mesothelin-targeted CARs. Despite 
this, promising results from human clinical trials in solid tumours have also been 
reported, such as three of 11 children with active neuroblastoma achieving complete 
remission in response to CAR T-cells targeting the GD2 ganglioside
205, and HER2-
targeted CARs proving safe and showing therapeutic potential in the same 
condition206. 
 
For more successful solid tumour targeting in the future, choosing the correct target 
antigen and improving tumour specificity of transduced T-cells will be crucial. One 
approach to achieving this is using low-affinity scFv regions in CARs such that they 
only respond to their target antigen when it is highly expressed on a given tissue (such 
as a tumour)174. Many novel technologies are also being employed to improve the 
safety of CAR T-cells. One example is combinatorial antigen recognition, whereby T-
cells are engineered to express an antigen-specific CAR and a separate chimeric 
costimulatory receptor (CCR) binding to a second antigen; T-cell activation is then 
rendered ineffective upon CAR binding unless simultaneous CCR recognition of the 
second antigen is also present to provide rescue207. Interestingly, it was also recently 




blood vessels supplying ovarian cancer in mice were able to cause vessel ablation, 
consequent tumour cell depletion and overall reduction in tumour burden208. This, 
along with the previously reported success of 4th generation anti-VEGFR-2 CARs in 
the treatment of established solid tumours in mice172, suggested that tumour 
vasculature could be a very promising and much more easily accessible CAR target. 
 
 
1.5 Tumour angiogenesis 
Angiogenesis is the formation of new blood vessels from pre-existing ones which is 
essential for the physiological processes of development, pregnancy and wound 
healing. However, angiogenesis is also exploited by tumours, where a blood supply is 
crucial for their large-scale growth and metastasis209–211. The process is initiated by 
vasculogenesis, which refers to de novo endothelial cell production. This is followed 
by sprouting angiogenesis involving the activation of endothelial cells on existing blood 
vessels and their subsequent migration, which results in ‘sprouting’ of new blood 
vessels and their remodelling into a functional network209. Tumour angiogenesis is 
driven by pro-angiogenic factors such as VEGF and fibroblast growth factor (FGF), 
which manage to outweigh the effects of endogenous anti-angiogenic factors including 
thrombospondin-1 and endostatin212. In all cases, the resulting tumour vasculature is 
disorganised, tortuous and leaky, frequently exhibiting vascular shunts and sluggish 
blood flow through capillaries. In addition, the microenvironment is profoundly deprived 
of oxygen and nutrients, with hypoxia leading to acidity due to the presence of lactic 
acid from anaerobic metabolism213. Under these conditions, endothelial cells on 




instead proliferating rapidly and actively contributing to the angiogenic process. Their 
differential transcription profile and resulting phenotype therefore make them a very 
attractive candidate for selective tumour targeting209,213. 
 
1.5.1 Tumour vasculature targeting 
The appeal of tumour vasculature as a target of anticancer therapy lies in its many 
favourable characteristics over those of the tumours themselves. Endothelial cells are 
genetically stable, making their targeting unlikely to lead to resistance as well as widely 
applicable to multiple tumour types211. Being directly exposed to blood also makes 
these cells easily accessible to therapeutics and immune effectors, which can 
otherwise have considerable difficulty gaining access to the inhospitable tumour 
microenvironment. In addition, destroying tumour vascular endothelium is very likely to 
lead to a potent bystander effect, as the targeted blood vessel supports the growth of 
many tumour cells211. Proof of principle that large solid tumours can be eradicated by 
targeting their vasculature originally came from a study in which expressing IFNg on a 
neuroblastoma cell line in immunocompromised mice led to MHC class II expression 
on tumour vasculature; injecting the mice with anti-MHC class II antibodies coupled to 
the immunotoxin ricin led to ricin internalisation into the vascular endothelium, 
subsequent vascular collapse and dramatic tumour regression214. While this and other 
early studies were certainly very promising, the main challenge for the application of 
such findings to humans has been the identification of target antigens selectively 





One obvious target is the VEGF family of angiogenesis-promoting proteins, of which 
VEGF-A was the first to be isolated and most extensively studied215. VEGF-A is 
induced by oncogenic genetic mutations and tumour hypoxia, which in turn leads to 
upregulation of its receptors on the tumour endothelium. As such, both VEGF-A and 
its receptors are overexpressed in many different cancers, including breast, lung, 
bladder, ovary, kidney and gastrointestinal tumours, where they correlate with 
increased risk of recurrence and generally poor prognosis215. Some of the principal 
actions of VEGF-A include inhibition of endothelial cell apoptosis and increase in 
vascular permeability, which it effects through interaction with its two receptors, 
VEGFR-1 and VEGFR-2; VEGFR-2 is perceived as crucial for mediating most of these 
pro-angiogenic effects213,215. 
 
Early studies in mice found that mAbs binding the VEGF-A/VEGFR-2 complex 
selectively localised to tumour endothelium216 and inhibited the growth of both newly 
injected and established human tumour xenografts217. These and other studies that 
observed potent antitumour effects and endothelial selectivity of anti-VEGF antibodies 
led to human clinical trials, culminating in FDA approval of the humanised anti-VEGF 
antibody bevacizumab for first-line treatment of metastatic CRC218. Its use has since 
been expanded to include second-line treatment of metastatic CRC, NSCLC, 
metastatic RCC, metastatic breast cancer and glioblastoma, while a number of small-
molecule receptor tyrosine kinase inhibitors targeting VEGFR-2 such as sunitinib have 
also shown clinical efficacy, particularly in renal cancer212,215. These anti-angiogenic 
agents are only a few among a multitude of others available, including aflibercept, the 




and which has been approved for the treatment of metastatic CRC220; trebananib – a 
peptide-Fc fusion protein that prevents the interaction between pro-angiogenic factors 
angiopoietins and their receptors221; and anti-epidermal growth factor receptor (EGFR) 
antibodies such as cetuximab, which indirectly inhibit angiogenesis through their EGFR 
inhibition215. Vascular disrupting agents – compounds that target tumour vasculature 
directly and cause central tumour necrosis – have also been tested in several cancers, 
both as single agents and in combination with conventional chemotherapy, however 
they have so far shown little survival benefit and mostly prohibitive toxicity222. 
 
Despite the reasonable success of current anti-angiogenic therapy, the two main 
issues it faces are still limited efficacy and toxicity. Trial data have pointed to the fact 
that anti-VEGF antibodies mostly show clinical benefit as part of combination therapy 
and not as single agents. Furthermore, inhibiting VEGF proteins or their receptors 
usually only reduces the rate of angiogenesis rather than eliminates it entirely, 
prompting research into alternative tumour angiogenic pathways and novel ways to 
target them212. Side effects such as hypertension and, rarely, thromboembolic events 
are also reported with VEGF-targeted therapies, owing at least in part to their on-
target/off-tumour recognition of VEGF, now well known for its critical role in 
physiological vascular homeostasis independently of any tumour pathology212,223. To 
avoid toxicity issues and increase treatment efficacy, an ideal target of anti-angiogenic 
or vascular-targeting therapy would be highly selective for tumour vasculature and 
therefore absent from normal blood vessels, as well as dispensable for all physiological 




are very difficult to find and hard to validate, but a very promising avenue of research 
has emerged which may eventually lead to truly selective tumour vasculature targeting. 
 
1.5.2 Tumour endothelial markers 
Advances in bioinformatics and gene expression analysis have led to important 
discoveries of molecular targets differentially expressed on tumour compared to 
normal endothelium. For example, roundabout-4 (ROBO4) was identified as a smaller, 
endothelial-specific member of the roundabout receptor family, which is normally 
localised to neuronal tissue224. ROBO4 showed strong expression during 
embryogenesis but was virtually absent from all adult human tissues except for those 
undergoing active angiogenesis such as tumours213,224. The C-type lectin CLEC14A 
has also been identified as highly expressed on the vasculature of various solid 
tumours, in contrast to its low or undetectable expression on normal blood vessels225. 
In another study, serial analysis of gene expression was applied to human endothelial 
isolates from both healthy colon and colorectal tumour samples to identify 46 
transcripts elevated at least 10-fold in tumour-associated compared to normal 
endothelium226. Nine of these tumour endothelial markers (TEMs), TEM1-TEM9, were 
validated further, and seven of them shown to be characteristic of both primary and 
metastatic CRC endothelium as well as found in liver metastases and in primary lung 
and brain tumours among others, confirming their general tumour-associated 
endothelial distribution226. With the exception of TEM8, all the TEMs were also found 
to be upregulated in physiological angiogenesis required for corpus luteum 





Four TEMs were subsequently characterised as cell-surface proteins and therefore 
deemed most relevant for therapeutic targeting211. In order to establish their 
significance in animal models, mouse counterparts of each of the four were identified, 
and three of them – designated mTEM1, mTEM5 and mTEM8 – found to be highly 
expressed on mouse tumour vasculature and the vasculature of developing embryos, 
but almost undetectable on normal vessels of adult mice227. Of all the TEMs 
investigated, TEM8 was the most intriguing for two reasons. It exhibited the highest 
interspecies conservation among the cell-surface markers with 96% amino acid identity 
between mouse and man227, thus warranting the applicability of future mouse studies 
to humans. Its expression pattern was also the most favourable, as it was the only 
human TEM undetectable in physiological angiogenesis, including the vessels of the 
ovaries at either mRNA or protein level211,212. Its potential for highly specific association 
with tumour vasculature led to further studies of its distribution and function, with a view 
to designing highly tumour-selective targeting strategies in the future. 
 
1.5.3 TEM8 
TEM8 is a single-pass membrane protein consisting of 564 amino acid residues, with 
a von Willebrand factor type A (vWA) domain in its extracellular region212. Shortly after 
it was first identified, TEM8 was found to be an anthrax toxin receptor, mediating 
anthrax toxin cell entry via binding of the toxin’s protective antigen subunit to the vWA 
extracellular domain of TEM8228. Its subsequently identified closest homologue of 40% 
shared amino acid identity, capillary morphogenesis gene-2 (CMG2), was discovered 
to bind anthrax toxin using the same mechanism229, leading to the alternative naming 




ANTXR2)212. Unlike TEM8 and its apparent restricted expression to human tumour 
endothelium, CMG2 is widely expressed in many human tissues229 and exhibits 11-
fold higher affinity for anthrax toxin compared to TEM8, two factors that contribute to 
CMG2 being the main mediator of anthrax lethality in vivo230. Apart from its minor 
pathological function in this disease, and its newly reported role as the receptor of the 
oncolytic Seneca Valley virus231, the physiological role of TEM8 is not yet fully 
understood. Consistent with its previously identified role in angiogenesis, it has been 
shown to bind to the a3 subunit of collagen type VI, which is also overexpressed on 
tumour endothelium232, as well as to collagen type I, thus promoting endothelial cell 
migration233 and acting as an adhesion molecule234. It has recently been proposed that 
TEM8 is also required for arteriogenesis following arterial ligation in mice235. Even 
though one study suggested that TEM8 was in fact widely expressed on normal mouse 
and human epithelial cells lining the lungs, small intestine and skin – the three main 
entry sites of the anthrax toxin-producing bacterium, Bacillus anthracis236 – these 
findings were later not reproducible212. 
 
A number of studies in mice and humans were able to demonstrate the tumour-
promoting characteristics of TEM8 and the antitumour effects produced by its targeting. 
Its downregulation has been linked to a substantial reduction in tumour growth in 
mouse models of osteosarcoma237 and HCC238, and significant TEM8 overexpression 
was observed in the tumour stroma of patients with triple-negative breast cancer 
(TNBC)239 and on the tumour endothelium of gallbladder carcinoma patients240. A 
soluble TEM8-Fc fusion protein successfully suppressed the growth and metastases 




diverting and trapping the M2 isoenzyme of pyruvate kinase which is important in 
tumour development241. Vaccinating mice against TEM8 induced potent TEM8-specific 
CTL responses, suppressed tumour angiogenesis and resulted in protection of the 
mice from lethal tumour challenges, including that of HCC, with no obvious side 
effects242,243. An anti-TEM8/truncated tissue factor fusion protein administered to mice 
bearing CRC xenografts resulted in approximately 50% reduction in both tumour 
volume and tumour growth rate compared to untreated mice; the fusion protein 
selectively targeted tumour vasculature, decreased its density and promoted targeted 
rather than non-specific thrombosis244. The same NCI group which initially identified 
TEM8 was able to show that TEM8-/- mice challenged with melanoma exhibited 
delayed tumour growth and, importantly, showed no developmental defects or faults in 
physiological angiogenesis245. The only physiological difference between wild-type and 
TEM8-/- mice was the presence of extracellular matrix (ECM) accumulation in the latter 
which manifested as dental dysplasia, an effect possibly due to the absence of TEM8 
interaction with collagen245. 
 
More recently, the same group generated monoclonal anti-TEM8 antibodies which 
displayed inhibition of tumour angiogenesis and potent antitumour activity against, 
among others, syngeneic or human xenogenic melanoma, colon and lung cancers in 
mice without affecting physiological processes such as wound healing246. In fact, wild-
type mice treated with anti-TEM8 antibodies exhibited similar delays in tumour growth 
to that observed in TEM8-/- mice. While anti-TEM8 antibodies did not lead to tumour 
regression or complete growth inhibition on their own, they considerably augmented 




chemotherapy agents, with anti-TEM8 antibody/irinotecan combination leading to 
complete cures in 5 of 11 mice treated246. Importantly, antibody treatment did not result 
in any observable toxicity in mice, even after 6 weeks of follow-up246. 
 
Overall, the most important aim of cancer immunotherapy is the achievement of truly 
selective tumour targeting. With the discovery of tumour endothelial markers and 
specifically TEM8, which has so far been detected as overexpressed only on tumour 
vasculature, this aim may be within reach. Further studies of TEM8 distribution, 
function and targeting strategies are needed before human clinical trials can be 
considered. CAR T-cells have emerged as a very promising immunotherapeutic 
modality in recent years, already showing potential for successful tumour vasculature 
targeting in various in vivo studies directed against PSMA208, VEGFR-2172 and even in 
combination therapies targeting both tumour vasculature and the tumour itself in 
mouse melanoma247. Thus, anti-TEM8 CARs, which unlike anti-TEM8 mAbs would be 
capable of eliciting the full spectrum of T-cell effector and immune-mobilising functions 
in the tumour vasculature, may provide an even more potent tumour-targeted approach 
and are therefore well worth exploring. 
 
 
1.6 Liver inflammation 
The power of the immune system has been harnessed to treat various forms of cancer 
with some remarkable recent successes with engineered T-cells. This has prompted 
interest in using similar approaches to treat other diseases. Inflammatory and 




towards the host’s own tissues, could be amenable to immunotherapies that aim to 
suppress rather than boost the immune response – for example, by using 
immunosuppressive elements such as Tregs instead of immunostimulatory T-cell 
effectors. One such example includes inflammatory conditions of the liver, where the 
progressive damage to the organ invariably results in the requirement for liver 
transplantation in order to ensure the patient’s survival. Therefore, identification of a 
selective marker of liver inflammation, and how it can be targeted using therapeutic 
Tregs, is another important focus of this thesis. 
  
1.6.1 Physiology of the human liver 
The liver is the largest organ in the human body. It carries out a multitude of crucial 
functions which include nutrient metabolism, elimination of toxins, synthesis of 
important proteins and immune surveillance248. In fact, it is specifically designed as the 
primary immune surveillance organ of the body, being densely populated by both 
innate and adaptive immune cells which normally reside in its vasculature, including 
the largest single population of macrophages – called Kupffer cells in the liver – and 
NK cells. Receiving both arterial and venous blood, the liver is constantly exposed to 
a flow of blood-borne exogenous matter, including non-harmful food particles but also 
potentially harmful pathogens; its ability to differentiate between these and activate 
immune defences when needed, or retain immune tolerance when not, is crucial for its 
proper functioning248. The importance of a healthy liver has been demonstrated in 
many in vivo studies – for example, depletion of Kupffer cells from the livers of mice 
infected with a normally sublethal dose of Listeria monocytogenes resulted in deaths 




The liver is supplied by the portal vein, which absorbs nutrients and other substances 
from the gut and delivers them to the liver, and the hepatic artery, which provides the 
liver with oxygenated blood from the systemic circulation. The deoxygenated blood 
resulting from liver metabolism is then carried away by the hepatic vein back into the 
circulation250. Between these three main vessels, within the organ itself, lies the 
complex network of capillary-like vessels called sinusoids (Figure 1.7). Liver sinusoidal 
endothelial cells (LSECs), which line the sinusoids, do not form a continuous layer but 
instead contain gaps (fenestrae), which allow the blood to pass through easily and 
reach the liver epithelial cells – hepatocytes. This fenestrated endothelium therefore 
allows the efficient exchange of nutrients and waste products between the blood and 
liver epithelium underneath250. Sinusoids also serve to significantly slow down the flow 
of blood through the liver – blood pressure in the organ is up to 50 times lower than in 
the systemic circulation – allowing enough time for the pathogens and other foreign 
substances passing through to be recognised by resident immune cells248. In fact, 
LSECs, hepatocytes and Kupffer cells, among others, are all specialised APCs, 
capable of successfully presenting antigen to resident T-lymphocytes and priming 
them for response248,250 (Figure 1.7). 
 
The immune environment of the liver is quite different to the one found in the rest of 
the body. T-cells comprise almost 50% of the entire lymphocyte population in the liver 
and demonstrate enrichment for CD8 and memory T-cell subsets as well as activated 
T-cells251. Furthermore, unlike antigen presentation in secondary lymphoid organs 
which includes co-stimulation and results in full T-cell activation, the same process in 




cells. Such T-cells proliferate but do not produce IFNg or induce specific cytotoxicity252, 
indicating the presence of a tolerogenic environment. However, in the case of 
inflammation or infection, upregulation of MHC class I and induction of MHC class II 
receptors on the surface of liver cells, together with increased co-stimulatory and 
reduced inhibitory molecule expression, all lead to CD4 T-cell activation and CD8 T-
cell licensing into effectors248. One of the most important functions of the liver, 
therefore, is successful maintenance of the balance between immune tolerance under 
physiological conditions and immune response under pathological ones; the 






Figure 1.7 – The structural and immune components of the liver 
Diagram of a liver sinusoid in cross-section (centre) showing the liver cells and immune 
cells resident in the hepatic vasculature, with images of mouse livers obtained by 
intravital microscopy surrounding it. Top left, autofluorescent green hepatocytes 
surround the sinusoids, with fluorescent red Kupffer cells (KC) lining the interior 
sinusoidal walls; top right, hepatic stellate cells (HSC, bright green) are found in the 
space of Disse, between the hepatocytes and the liver sinusoidal endothelial cells 
(LSEC, red); bottom right, bright green natural killer T (NKT) lymphocytes patrol the 
sinusoids between rows of dim green hepatocytes. Scale bars, 50µm. Reprinted by 
permission from Springer Nature: NATURE IMMUNOLOGY (Jenne CN, Kubes P. 




1.6.2 Primary sclerosing cholangitis 
An important function of the liver is the synthesis of bile acids from cholesterol253. Bile 
acids serve as metabolic regulators that facilitate nutrient absorption in the small 
intestine and, once synthesised by the liver, are stored in the gallbladder as bile. They 
are transported through conduits known as bile ducts into the intestine after every meal 
to aid digestion, following which they are recirculated back into the liver253. As it travels 
through the biliary network, bile is modified by the physiological action of the epithelial 
cells lining the bile ducts – cholangiocytes254. Damage to cholangiocytes and bile ducts 
can lead to bile flow obstruction (cholestasis), resulting in the build-up of toxic 
metabolites in the liver with simultaneous absence of bile from the intestine253. 
 
Primary sclerosing cholangitis (PSC) is a chronic, progressive inflammation of the liver 
characterised by bile duct destruction and frequently culminating in end-stage liver 
disease255. The inflammation is immune-mediated, as evidenced by immune cell 
infiltrates (including lymphocytes) predominantly around bile ducts, and eventually 
leads to inflammation and disorganised proliferation of cholangiocytes; this in turn 
results in bile duct loss, cholestatis and cirrhosis. As a result, more than half of the 
patients need a liver transplant 10-15 years after their PSC diagnosis255. A systematic 
review of worldwide PSC incidence and prevalence rates found that these vary widely 
with geographical region, but can reach 1.3 per 100,000 inhabitants (incidence) and 
16.2 per 100,000 inhabitants (prevalence) in Northern European countries256. The 
majority of patients – 60% on average – are men, with a peak incidence age of about 
40256, and approximately 60-80% of PSC patients also report inflammatory bowel 




loci linked with PSC and those associated with HLA, as well as with a number of 
autoimmune conditions such as type 1 diabetes (T1D), rheumatoid arthritis and 
psoriasis257. In fact, up to 25% of PSC patients are also affected by an autoimmune 
condition outside the liver and colon258. 
 
Sclerosing cholangitis is diagnosed as primary only when there is no identifiable 
precipitating factor; thus, secondary causes such as autoimmune hepatitis (AIH), 
infection or hereditary disorders need to be excluded in order to treat PSC 
appropriately255,259. However, there is still no cure or even a universally agreed medical 
treatment for the condition. Anti-inflammatory and immunosuppressive drugs, such as 
corticosteroids and transplant rejection treatments, have been trialled with little 
success or withdrawn due to prohibitive adverse events; treatment with 
ursodeoxycholic acid, usually given for cholestatic disease, is controversial and 
generally not recommended260. Patients who reach end-stage liver disease require 
liver transplantation; however, rates of post-transplantation PSC recurrence are high, 
with the results of a large multicentre study suggesting that this happens in 
approximately 20% of patients after less than 5 years261. This, along with PSC carrying 
an increased risk of cholangiocarcinoma, gallbladder cancer, HCC and CRC262, 
demonstrates the increasing importance of identifying new and successful therapeutic 
approaches for this debilitating disease. 
 
1.6.3 Mouse models of PSC 
In order to study the aetiology and pathology of PSC as well as new treatment 




be immunologically and genetically predisposed to develop bile duct fibrosis and 
destruction, showcase all the hallmarks of sclerosing cholangitis (such as immuno-
inflammatory infiltrates concentrating around bile ducts, duct strictures and dilatations, 
and cholangiocyte atrophy), and develop concurrent IBD, more specifically colitis. The 
disease would also ideally progress to cholangiocarcinoma and, as in humans, 
predominantly affect males263. Unfortunately, such an all-encompassing model does 
not yet exist, even though many murine models of PSC have been developed and 
allowed the study of one or more aspects of the disease. It may be that, due to the 
complex nature of PSC, no single model will ever be truly representative, and the study 
of various combinations of models will have to suffice instead263. 
 
Currently available mouse models fall into several categories. Those relying on 
chemical induction of cholangitis are hampered by the lack of complete PSC 
phenotype or high mortality rates, while those induced by infectious agents are 
generally too complex for manageable study. On the other hand, antigen-driven or 
direct biliary injury in mice leads to the development of a relatively mild PSC phenotype, 
while models of colitis do not develop liver fibrosis at all263. Several knockout mouse 
models have also been generated which, while not ideal, provide an opportunity for 
longitudinal study of PSC and its treatment options. One such model is the multidrug 
resistance gene-2 (Mdr2) knockout (MDR2 KO) mouse, which lacks the MDR2 
phospholipid transporter normally found on the apical membrane of hepatocytes; as 
this membrane faces the bile canaliculi (small channels that transport bile and 
eventually merge into bile ducts), the lack of the transporter results in complete 




are unable to form mixed phospholipid-bile acid micelles in the bile, which normally 
function to protect cholangiocytes from bile acid-induced damage. This results in 
cholangiocyte injury, bile duct disruption and bile acid leakage, inflammatory infiltration, 
fibrosis and finally cholangiocyte death – thus, a spontaneous phenotype develops 
which is both macroscopically and microscopically similar to PSC in humans265. The 
model, which is generated on a Friend leukaemia virus B-type/N (FVB/N, or simply 
FVB) background, does not develop IBD or cholangiocarcinoma but does progress to 
HCC263, and has proven suitable for testing novel PSC therapeutic strategies in a 
number of studies already266–268. The MDR2 KO FVB mice were therefore chosen as 
an appropriate animal model of liver inflammation for the purpose of this thesis. 
 
1.6.4 CLEC14A 
The C-type lectin CLEC14A is a single-pass transmembrane protein consisting of 490 
amino acid residues, with 67% sequence homology between mice and humans225. It 
is expressed at low or undetectable levels in healthy adult tissues but can be 
overexpressed on the vasculature of multiple solid tumour types as measured by both 
immunohistochemistry and immunofluorescence – for example, it was highly 
expressed on endothelial cells in HCC but absent from adjacent healthy liver tissue 
(Figure 1.8)225. A similar pattern was observed in samples from human prostate, 
breast, kidney and bladder tumours among others, identifying CLEC14A as a novel 
TEM225. Similar to TEM8, it has been found to promote endothelial cell migration and 
tube formation, with polyclonal antiserum to CLEC14A impairing both of these. 
Interestingly, it was also upregulated on endothelial cell surface under conditions of 




vasculature; this further confirmed its pro-angiogenic role and highlighted it as a 
promising target of vascular targeting therapy225. More recently, it was confirmed to 
mediate sprouting angiogenesis both in vitro and in vivo, and genetic disruption or 
antibody blockade of CLEC14A in tumour-bearing mice resulted in disruption of both 
tumour growth and vascularity269. 
 
Based on the above, as well as early immunofluorescence staining carried out in our 
lab, we hypothesised that CLEC14A is also upregulated on the vasculature of inflamed 
liver. Due to the chronic biliary injury which eventually leads to end-stage liver disease, 
cirrhosis and even cancer in patients with PSC, it is reasonable to expect a degree of 
disturbance in normal hepatic blood flow, potentially leading to low shear stress 
conditions required for CLEC14A upregulation. Its expression on liver vasculature in 
PSC, if present, would provide a promising target which could be tackled using 






Figure 1.8 – Expression of CLEC14A in human hepatocellular carcinoma and 
healthy liver tissue 
Immunohistochemical staining of human hepatocellular carcinoma (HCC) and 
adjacent healthy liver tissue using polyclonal CLEC14A antiserum (red) and 
haematoxylin  counterstain (purple). (i), white arrows show invasion of HCC into normal 
tissue. Scale bar, 200µm. (ii) and (iii), higher magnification shows CLEC14A staining 
in tumour but not in normal tissue. Scale bars, 25µm. Reprinted by permission from 
Springer Nature: ONCOGENE (Mura M, Swain RK, Zhuang X, Vorschmitt H, Reynolds 
GM, Durant S, et al. Identification and angiogenic role of the novel tumor endothelial 





1.7 Regulatory T-cell therapy 
There is evidence of significant T-cell infiltration in the liver of PSC patients, with the 
inflammation and biliary injury being heavily T-cell mediated270. Such damaging action 
of T-cells directed against host’s own tissues would normally be supressed by Tregs, 
whose main function is to prevent overactive immune responses. However, it has been 
found that the proportion of Tregs in both peripheral blood and liver of PSC patients is 
substantially lower than expected, and that the suppressive capacity of Tregs isolated 
from these patients is also impaired271. Treg-based immunotherapy would therefore 
represent a potentially effective treatment approach in PSC, especially if it can be 
specifically targeted to the liver, and as such merits further investigation. 
 
1.7.1 Tregs and autoimmunity 
Tregs are generally defined as CD4+ CD25high CD127low T-cells which also express the 
intracellular transcriptional activator Foxp3, the master regulator of their function and 
development272,273. Representing a small part of the CD4 T-cell population – 5-10% – 
they develop in the thymus and constitutively express IL-2 receptor a chain (CD25) 
and CTLA-4 among other surface molecules, as well as produce immunosuppressive 
cytokines such as TGFb and IL-10272. A proportion of Tregs also arises in the periphery 
upon Foxp3 induction resulting from antigen exposure, and in view of this there has 
been a recent move towards differentiating between thymic (tTregs) and peripheral 
Tregs (pTregs)274. Consistent with the importance of Tregs in maintaining peripheral 
tolerance and suppressing self-reactive T-cells, mutations in the Foxp3 gene have 
been found to cause profound immune dysregulation in both mice and humans275–277, 




diseases in mice278. Evidence from animal studies also suggests that both tTregs279 
and pTregs280 are essential for effective immune self-tolerance. 
 
In humans, Tregs are implicated in many autoimmune diseases. They are deficient 
both in numbers and function in AIH281 and exhibit impaired suppressive capacity in 
polyglandular syndrome type II282, while effector T-cells are less responsive than 
normal to Treg control in T1D283 and systemic lupus erythematosus284. Significant 
functional impairments in Tregs have also been documented in patients with multiple 
sclerosis (MS)285, myasthenia gravis286 and rheumatoid arthritis287. Therefore, in a wide 
range of autoimmune conditions including those of the liver, it could be therapeutically 
beneficial to restore Treg functionality. One way to achieve this in the liver would be to 
selectively enrich hepatic Tregs by redirecting functional, in vitro- or ex vivo-expanded 
regulatory T-cells to the inflamed organ273. 
 
1.7.2 Adoptive Treg transfer 
Targeting autoimmune conditions by adoptive transfer of therapeutic Tregs is not a 
new concept. It has already been successfully demonstrated, for example, in mouse 
models of autoimmune gastritis where Tregs targeted the autoantigen H+/K+ 
ATPase288, and mouse models of MS where the Tregs were directed against a major 
protein component of the myelin sheath289. As with conventional T-cells, TCR gene 
transfer can also be carried out in Tregs to redirect them to an antigen of choice, as 
has already been demonstrated in a murine model of arthritis where joint inflammation 
and bone destruction were both significantly reduced by TCR-engineered Tregs290. In 




specific) Tregs in T1D patients showed that these cells are safe, remain phenotypically 
stable and persist in the circulation long-term, warranting further phase II studies291. 
Methods are also being developed for Treg expansion that would lead to their 
increased long-term phenotypic stability in autoimmune conditions where this is 
particularly important, such as Crohn’s disease292. Overall, there are a variety of 
approaches to adoptive Treg therapy, using polyclonal or antigen-specific cells; even 
though both have shown promise, there is evidence to suggest that antigen-specific 
Tregs are superior in controlling disease compared to their non-specific 
counterparts289,293,294. 
 
For autoimmune conditions of the liver, the goal of ACT would be to target a purified 
and expanded Treg population specifically to the organ, thus enriching hepatic Tregs 
and tipping the balance in favour of immune control. Peripheral tolerance and disease 
remission have already been achieved in a mouse model of AIH treated with adoptively 
transferred autologous Tregs which were successfully directed to the inflamed liver295. 
Even though the liver-homing chemokine receptor CXCR3 is highly expressed on 
some Tregs in both mice and humans, and its corresponding ligands are upregulated 
on inflamed liver sinusoids273, the best way to achieve specific hepatic targeting in 
patients would be to render the therapeutic Tregs antigen-specific. Unfortunately, the 
paucity of disease markers in autoimmune liver conditions makes this strategy difficult, 
although in some cases – such as in a subset of AIH which exhibits T-cell reactivity to 
the liver metabolic enzyme CYP2D6 – there is an autoantigen to which Tregs can be 
redirected296. In other cases, polyclonal Treg infusion is the best available option for 




such as PSC, however, where CLEC14A serves as a potential marker of liver 
inflammation, there is also the possibility of engineering autologous Tregs to express 
high specificity receptors such as CARs targeting this endothelial marker, and thus the 
liver, in a selective way. 
 
1.7.3 Engineering Tregs to express CARs 
Since the success of conventional CAR T-cells in haematological malignancies, and 
their increasing promise in solid tumour treatment, the same genetic engineering 
approach has become of great interest in Treg immunotherapy of autoimmune 
diseases. A number of studies of both murine and human CAR Tregs have been 
carried out, all using the 2nd generation CD28 CAR construct and achieving 
transduction by retroviral or lentiviral gene transfer. The first CAR Treg study used a 
transgenic mouse model to show that 2,4,6-trinitrophenol-specific CAR Tregs 
suppressed effector T-cell responses in vitro in an antigen-dependent manner, as well 
as induced resistance to experimental colitis in vivo297. A follow-up study of the same 
antigen-specific CAR showed that it could be retrovirally engineered into mouse Tregs, 
and that their adoptive transfer into mice resulted in improvement of colitis which was 
superior to that induced by their unmodified counterparts298. Similarly promising 
findings in mouse colitis were seen with CEA-targeted CAR Tregs299, while in a mouse 
model of MS, intranasally- and intraperitoneally-administered myelin-targeted CAR 






Human Tregs have also been successfully engineered with CARs and targeted to an 
antigen of choice; however, few if any of these studies are in the context of 
autoimmunity. Nevertheless, CEA-redirected CAR Tregs have been shown to 
suppress the effector functions of autologous antigen-specific T-cells in a CEA+ tumour 
in vivo, leading to substantial tumour outgrowth301. More recently, a HLA-A2-specific 
CAR was generated which, when transduced into Tregs and injected into mice, 
prevented graft-versus-host disease (GvHD) caused by HLA-A2+ cells much more 
efficiently than Tregs expressing an irrelevant CAR302. Similarly, factor VIII-specific 
CAR Tregs were able to suppress effector T-cell responses that commonly arise in 
haemophilia A patients treated with this essential replacement therapy, thus inducing 
therapeutic immune tolerance303. Taken together, these studies provide the proof of 
principle needed to push CAR Tregs further towards the clinic, including for the 
treatment of autoimmune conditions. 
 
As of February 2018, 49 clinical trials of Treg infusions are registered on 
clinicaltrials.gov, most of which are for the treatment of GvHD, transplant rejection or 
malignancies. Only a small proportion are being carried out in autoimmune conditions, 
none of which are in the liver. None of the Treg populations currently being trialled are 
genetically engineered to induce antigen specificity. 
 
1.8 Hypotheses and aims 
This thesis consists of two projects. The first project examines the hypothesis that 
TEM8-specific CARs can be successfully transduced into primary human T-cells, with 




mouse and human tumour vasculature. If successful, the findings would potentially 
pave the way for future clinical studies of this therapeutic modality. To that end, the 
aims of the project are: 
1) To generate TEM8-specific CAR T-cells and extensively test their target 
responses, functionality and specificity in vitro; 
2) To study the safety of TEM8 CARs in healthy mice; 
3) To examine the anti-tumour potential and responses of TEM8 CARs in tumour-
bearing mouse models. 
 
The second project begins to explore the potential for CAR Treg therapy in 
autoimmune liver inflammation with a focus on PSC, and hypothesises that CLEC14A 
is a promising CAR target for Tregs in this condition. The project aims are: 
1) To examine the expression of CLEC14A in both human inflamed liver tissue and 
a PSC mouse model; 
2) To generate CLEC14A CAR Tregs and test their suppressive capacity in vitro; 





2 MATERIALS AND METHODS 
 
2.1 Tissue culture 
 
2.1.1 Maintenance of adherent cell lines 
All the adherent cell lines used in this thesis and their appropriate media are listed in 
Table 2.1. All cell media were supplemented with 10% foetal bovine serum (FBS), 100 
IU/mL penicillin, 100µg/mL streptomycin, and 2mM L-glutamine (all Gibco, Paisley, 
UK). Phoenix A (amphotropic) and Phoenix E (ecotropic) retroviral packaging cells304 
and human embryonic kidney (HEK) 293T cells were transferred to antibiotic-free 
Dulbecco’s Modified Eagle Medium (DMEM) prior to transfection with relevant DNA 
(see sections 2.4.1 and 2.4.3). The only exception to the supplementation described 
above were the human umbilical vein endothelial cells (HUVEC), which were cultured 
in Human Large Vessel Endothelial Cell Basal Medium supplemented with growth 
factors and amphotericin B/gentamycin according to manufacturer’s instructions 
(Cellworks, Buckingham, UK). All adherent cells were passaged by dissociation from 
plastic with trypsin-ethylenediaminetetraacetic acid (0.5% Trypsin-EDTA [10X], Gibco; 
diluted to 1X in phosphate-buffered saline [PBS]), neutralisation with excess medium, 
washing and resuspension in fresh medium every 2-5 days (cell-dependent), and were 





Table 2.1 – Adherent cells used as T-cell targets in this thesis 
Cell line Description Source Cell medium 
CHO-TEM8 Chinese hamster ovary (CHO) 
cells stably expressing human 
TEM8 
Brad St Croix, National 
Cancer Institute, National 
Institutes of Health (NIH), 
Frederick, MD  
F-12 Nutrient 
Mixture (Ham), 
Gibco, Paisley, UK 
CHO-CMG2 CHO cells stably expressing 
human CMG2 
Brad St Croix, NIH F-12 Nutrient 
Mixture (Ham) 
CHO-PR230 CHO control cells for CHO-
TEM8 and CHO-CMG2 
Brad St Croix, NIH F-12 Nutrient 
Mixture (Ham) 
DLD-1 Human colorectal 
adenocarcinoma cell line 
Brad St Croix, NIH  DMEM, Sigma-
Aldrich, Poole, UK 
HEK293T Human embryonic kidney 293 
(HEK293) cells containing the 
SV40 T-antigen 





HEK293 cells stably 
expressing human TEM8 
Brad St Croix, NIH DMEM 
HEK293-
mTEM8 
HEK293 cells stably 
expressing mouse TEM8 
Brad St Croix, NIH DMEM 
HUVEC Human umbilical vein 
endothelial cells 
Gibco See section 2.1.1 
LS174T Human colorectal 
adenocarcinoma cell line 
American Type Culture 
Collection (ATCC) 
DMEM 
MDA-MB-231 Human breast 
adenocarcinoma cell line 
Fedor Berditchevski, 
University of Birmingham 
DMEM 
Phoenix A HEK293T cells containing 
amphotropic viral packaging 
proteins 
Indiana University 
National Gene Vector 
Biorepository (NGVB) 
DMEM 
Phoenix E HEK293T cells containing 








2.1.2 Isolation and maintenance of human PBMCs and T-cells 
Whole blood from healthy consenting donors was collected into apheresis cones and 
subjected to density centrifugation to isolate the PBMCs. Donor blood samples were 
first diluted with an equal volume of Roswell Park Memorial Institute (RPMI) medium 
(Sigma-Aldrich), layered onto Lymphocyte Separation Medium (LSM 1077; GE 
Healthcare, Buckinghamshire, UK) and centrifuged at 800g for 30 minutes with the 
brake off. The PBMCs were aspirated from the resulting buffy layer at the interface of 
separated plasma and LSM and washed with RPMI by centrifugation at 600g for 10 
minutes, followed by another wash at 400g for 5 minutes. The cells were then 
resuspended in RPMI with 10% FBS and the contaminating platelets removed by 
centrifugation at 250g for 5 minutes. Finally, the resulting PBMCs were counted and 
either cryopreserved at 1x108 cells/vial for future use (see section 2.1.4) or activated 
for transduction straight away (see section 2.4.1). T-cells obtained from these PBMCs 
after transduction were cultured in RPMI supplemented as described in section 2.1.1, 
with the addition of 1% pooled human serum (TCS Biosciences, Buckingham, UK) to 
give T-cell medium (TCM). IL-2 (Proleukin®, Novartis, Basel, Switzerland) was also 
added to TCM at 100 IU/mL for the duration of the culture period to maintain the T-
cells. 
 
2.1.3 Isolation and maintenance of human Tregs 
Human Tregs were purified from fresh or frozen PBMCs using the 
CD4+CD25+CD127dim/- Regulatory T Cell Isolation Kit II, human (Miltenyi Biotec, Bisley, 
UK) according to manufacturer’s instructions. The resulting Tregs were cultured at 




(Gibco) at 1:1 bead:cell ratio, 1,000 IU/mL IL-2 and 100nM rapamycin (Sigma-Aldrich) 
to prevent conventional T-cell outgrowth305. 
 
2.1.4 Cryopreservation and revival of cells 
Prior to freezing, cells were harvested from their culture flasks and chilled at 4°C for 
15-20 minutes to reduce cellular metabolic rate. They were subsequently centrifuged 
at 400g for 5 minutes, the supernatant discarded and the cells resuspended at the 
desired concentration in freezing medium, which consisted of 50% FBS, 40% RPMI 
and 10% dimethyl sulfoxide (DMSO). The cells were then immediately transferred into 
sterile 1.8mL CryoTube vials (Thermo Fisher Scientific [Nunc], Roskilde, Denmark) 
and frozen at -80°C inside an isopropanol-filled freezing container designed to reduce 
the temperature of the vials by 1°C/minute. After a minimum of 4h at -80°C, the cells 
were deposited into long-term storage in liquid nitrogen. 
 
To revive previously frozen cells, the desired cryovials were removed from liquid 
nitrogen and placed in a pre-heated 37°C water bath until the cell suspension within 
was fully thawed. The cells were immediately transferred into sterile centrifuge tubes 
and relevant culture medium added to them gradually (dropwise at first). Once the cells 
were diluted in an excess of culture medium, they were centrifuged at 400g for 5 






2.1.5 Mycoplasma testing 
Periodic testing was carried out on the cell lines in use to check for contamination with 
the mycoplasma bacterium. Culture supernatant was centrifuged at 600g for 5 minutes 
and 15µL of it mixed with 15µL of MycoAlert reagent (Cambrex, East Rutherford, NJ) 
in an OptiPlate-96 (Perkin Elmer, Coventry, UK). The plate was counted using the 
TopCount NXT microplate scintillation and luminescence counter (Perkin Elmer) and 
the counts recorded, before 15µL of MycoAlert substrate (Cambrex) was added to the 
culture supernatant and the plate counted again. If the second count was higher than 
the first for a given culture, it was considered mycoplasma-positive and was discarded. 
If the ratio of first to second count was 0.7-1, the relevant culture was quarantined in a 
separate incubator and re-tested a few days later. A mycoplasma-infected culture 
supernatant was used as a positive control in all assays. All cell lines tested were 
negative for mycoplasma. 
 
 
2.2 Molecular techniques 
 
2.2.1 Cloning of TEM8-targeting CAR constructs into MP71 retroviral vector 
The second-generation TEM8 CAR construct used throughout this thesis is shown in 
Figure 2.1. To obtain it, pUC57 plasmid constructs encoding the scFv for one of five 
TEM8-specific mAbs – L1, L2, L3, L5 or 1D2 (antibody sequences: gift from Brad St 
Croix, NIH) were synthesised by GenScript (Piscataway, NJ). ClaI/NotI restriction 
enzyme digestion (both enzymes from Roche, Basel, Switzerland) was used to cleave 




CD28 co-stimulatory and CD3ζ signalling domains (original MP71 vector including the 
truncated CD34 marker and the subsequent CAR expression construct were kind gifts 
from Christopher Baum306 and David Gilham307 respectively). Following digestion, the 
five scFv inserts and the CAR expression vector were run on a 0.8% agarose gel 
(SeaKem GTG agarose, Lonza, Basel, Switzerland), the appropriate bands excised 
and the DNA extracted using the QIAquick Gel Extraction Kit (Qiagen, Hilden, 
Germany). Each insert was ligated to the vector using the Rapid DNA Ligation Kit 
(Roche) and supercompetent E.coli DH5a bacteria were transformed with the resulting 
constructs. DNA was isolated from bacterial colonies that grew overnight on ampicillin 
selection plates using the QIAprep Spin Miniprep Kit (Qiagen) according to 
manufacturer’s instructions. Following confirmation of the correct DNA sequence of all 
CAR constructs (see section 2.2.3), the EndoFree Plasmid Maxi Kit (Qiagen) was used 
to obtain larger quantities of the purified plasmids for the purpose of T-cell transduction. 
 
2.2.2 Cloning of mouse TEM8 gBlock fragment into pWPI lentiviral vector 
The mouse TEM8 (mTEM8) gBlock was synthesised by Integrated DNA Technologies 
(IDT, Coralville, IA) using the mTEM8 sequence (gift from Brad St Croix) flanked by 
sequences that anneal to the pWPI lentiviral vector. The vector, previously obtained 
from Roy Bicknell (University of Birmingham) and containing an unrelated insert, was 
digested using PacI and PmeI restriction enzymes (both from New England BioLabs 
[NEB], Ipswich, MA), run on a 0.6% agarose gel and the vector DNA band excised and 
purified using the Monarch DNA Gel Extraction Kit (NEB). The mTEM8 gBlock insert 
and pWPI lentiviral vector were then ligated at a 2:1 insert:vector ratio and competent 




Assembly Cloning Kit (NEB) according to manufacturer’s instructions. DNA from 
bacterial colonies that grew overnight on ampicillin selection plates was purified using 
the EndoFree Plasmid Maxi Kit, the DNA sequence confirmed as correct (see section 
2.2.3), and the resulting construct used to transfect LS174T target cells for use in T-
cell assays (see section 2.4.3). 
 
2.2.3 DNA sequencing 
DNA was sequenced either by the Functional Genomics and Proteomics Facility 
(University of Birmingham) or by Source BioScience (Nottingham, UK) using primers 
custom-made by Sigma-Aldrich. 
 
2.2.4 Human TEM8 quantitative polymerase chain reaction (qPCR) 
qPCR to detect human TEM8 (hTEM8) mRNA in specified target cells was performed 
using qScript cDNA SuperMix (Quantabio, Beverly, MA) and TaqMan Gene 
Expression Assay no. Hs00216777_m1 (Life Technologies, Paisley, UK) according to 







Figure 2.1 – Schematic representation of the 2nd generation TEM8 CAR construct 
used in this thesis 
The CAR sequence consists of a region encoding the single chain variable fragment 
(scFv) derived from one of five anti-TEM8 monoclonal antibodies (L1, L2, L3, L5 or 
1D2), followed by genes for the human CD28 co-stimulatory and human CD3ζ 
signalling domains. The self-cleaving 2A peptide linker derived from porcine 
teschovirus-1 ensures equimolar expression of the CAR with a truncated human CD34 
(tCD34) molecule, which acts as a non-functional marker of transduced T-cells 





2.3 TEM8 protein production 
The NEBuilder HiFi DNA Assembly Cloning Kit was used to transform competent 
bacteria with hTEM8-Fc/pFUSE-mIgG2A or mTEM8-Fc/pFUSE-mIgG2A plasmid 
vectors, both containing Zeocin resistance genes (plasmids: gift from Brad St Croix 
containing original pFUSE-mIgG2A-Fc1 vector from InvivoGen, San Diego, CA). 
Bacterial colonies that grew overnight on Fast-Media Zeo Agar plates were further 
grown in large-scale liquid cultures using Fast-Media Zeo Terrific Broth (both from 
InvivoGen). hTEM8-Fc and mTEM8-Fc DNA was purified from the resulting bacterial 
cultures using the Plasmid Maxi Kit (Qiagen). 
 
Recombinant hTEM8-Fc and mTEM8-Fc proteins were produced with kind help from 
Jamie Webster at the Protein Expression Facility (PEF, University of Birmingham). 2L 
roller bottles were coated with 1% w/v solution of poly-L-lysine (Sigma-Aldrich) in PBS 
for 2-4h at 37°C. They were then washed with PBS and HEK293T cells seeded into 
them in sufficient numbers to allow the cells to reach 80-90% confluence in 48-72h 
(250mL DMEM supplemented as described in section 2.1.1 in each bottle). The roller 
bottles were incubated at 37°C in a rotating incubator (1rpm) during this time. When 
the desired cell confluence was reached, a mix of 435µg hTEM8-Fc or mTEM8-Fc 
DNA and 2.7mL linear polyethylenimine (PEI 25000; Polysciences, Warrington, PA) in 
27mL Opti-MEM Reduced Serum Medium (Gibco) was prepared for each bottle, and 
the media in the bottles changed to 250mL Opti-MEM before adding the correct 
transfection mix to each. The roller bottles were incubated at 37°C in the rotating 
incubator for 7 days, after which the supernatants were harvested and the proteins 




to manufacturer’s instructions. The eluted hTEM8-Fc and mTEM8-Fc protein fractions 
were pooled and concentrated using the Amicon Ultra-15 Centrifugal Filter Units with 
Ultracel-30 Membrane, followed by further concentration with the Amicon Ultra-0.5 
Centrifugal Filter Units (both from Merck Millipore, Watford, UK). When run on a 10% 
SDS-PAGE gel (Mini-PROTEAN Electrophoresis System, Bio-Rad, Watford, UK), the 
resulting recombinant hTEM8-Fc and mTEM8-Fc proteins gave bands of 
approximately 70kDa in size (confirmed as correct with Brad St Croix, personal 
communication 12/10/2016), and the final concentrations of both were determined 
using the PHERAstar FS microplate reader (BMG LABTECH, Offenburg, Germany). 
 
 
2.4 Transduction protocols 
 
2.4.1 Retroviral transduction of human T-cells and Tregs with CARs 
The following quantities are given for Phoenix A cells growing in T75 flasks; if the 
process was scaled up to T150 flasks, the quantities of reagents were doubled 
accordingly. Phoenix A retroviral packaging cells in 4.5mL antibiotic-free DMEM were 
transfected with 1.8mL Opti-MEM containing 6µg L1, L2, L3, L5 or 1D2 TEM8 CAR or 
CRT3.2 CLEC14A CAR plasmid construct, 6µg pCL-Ampho retroviral packaging 
vector (NGVB) and either 72µg PEI (Sigma-Aldrich) or 60µL FuGENE 6 Transfection 
Reagent (Promega, Southampton, UK). The 2nd generation CRT3.2 CAR construct 
was the same as the one shown in Figure 2.1, with the scFv region derived from the 
CRT3 mAb specific for human and mouse CLEC14A obtained as described 




the Phoenix A cells. Both CAR DNA- and mock-transfected cells were incubated at 
37°C/5% CO2 for 48h, with the media changed to 10.5mL fresh antibiotic-free DMEM 
after the first 24h. Previously isolated PBMCs (section 2.1.2) adjusted to a 
concentration of 1x106 cells/mL TCM were activated by the addition of 30ng/mL anti-
CD3 antibody (OKT3; eBioscience, San Diego, CA), 30ng/mL anti-CD28 antibody 
(R&D Systems, Abingdon, UK) and 300 IU/mL IL-2, followed by incubation at 37°C/5% 
CO2 for 48h before transduction. On the day of transduction, non-tissue culture-treated 
6-well plates were coated with 30µg/mL RetroNectin (recombinant human fibronectin 
fragment; Takara Bio, Japan) for at least 3h, blocked with 2% w/v solution of bovine 
serum albumin (BSA; Sigma-Aldrich) in PBS for 30min, and washed once with PBS to 
prepare them for administration of retrovirus-containing and mock supernatants. The 
supernatants were then harvested from transfected Phoenix A cells, centrifuged at 
400g for 5 minutes to remove any cells, and placed in the RetroNectin-coated plates 
(2mL/well). The plates were centrifuged at 2000g for 2h at 32°C, the supernatant was 
removed, the wells washed once with PBS and activated T-cells seeded into them at 
2-2.5x106/well (1x106/mL). The plates were centrifuged again at 400g for 5 minutes 
and incubated at 37°C/5% CO2. The next day additional TCM + IL-2 (100 IU/mL) was 
added to the T-cells to allow them to expand, and the cells were transferred into tissue 
culture-treated 6-well plates 4-5 days later. They were maintained in culture as 
described in section 2.1.2. 
 
For retroviral transduction of Tregs isolated as described in section 2.1.3, the Tregs 
were activated using Human T-Activator CD3/CD28 Dynabeads according to the 




The transduction process was carried out using the CRT3.2 CLEC14A CAR construct  
and in non-tissue culture-treated 24-well plates, but was otherwise identical to the one 
described above. 
 
2.4.2 Retroviral transduction of mouse T-cells with TEM8 CARs 
Phoenix E cells were transfected with each of the five TEM8-specific CARs in the same 
way as Phoenix A cells (section 2.4.1), using pCL-Eco (NGVB) as the retroviral 
packaging vector instead of pCL-Ampho. Spleens were harvested from healthy 6-8 
week old BoyJ mice and mashed through a 70µm cell strainer (Greiner Bio-One, 
Stonehouse, UK) into a sterile Petri dish containing mouse TCM (RPMI supplemented 
with 10% FBS, 100 IU/mL penicillin, 100µg/mL streptomycin, and 2mM L-glutamine). 
The resulting suspension of mouse splenocytes was washed with RPMI by centrifuging 
at 700g for 5 minutes, the supernatant was discarded and the pellet resuspended in 
1X solution of BD Pharm Lyse lysis buffer (BD Biosciences, Oxford, UK) in sterile 
distilled water in order to lyse the red blood cells. After incubation at 37°C for 4 minutes, 
the splenocytes were washed with mouse TCM (mTCM) by another centrifugation at 
700g for 5 minutes and counted. Their concentration was adjusted to 3x106 cells/mL 
mTCM, they were activated with 2µg/mL concanavalin A and 1ng/mL IL-7 (both Sigma-
Aldrich) and incubated at 37°C/5% CO2 for 48h, after which the transduction was 
carried out as for human T-cells (section 2.4.1). 
 
2.4.3 Lentiviral transduction of LS174T cells with mTEM8 
HEK293T cells growing in 10cm dishes and placed in 4.5mL antibiotic-free DMEM 




construct (section 2.2.2), the psPAX2 lentiviral packaging vector (Didier Trono lab, 
Addgene plasmid #12260) and the pMD2.G envelope expression plasmid (Trono lab, 
Addgene plasmid #12259), together with 60µL FuGENE 6. The cells were incubated 
at 37°C/5% CO2 for 48h, with the media changed to fresh 10.5mL antibiotic-free DMEM 
after the first 24h. When the incubation was finished, lentiviral supernatant was 
harvested, centrifuged at 300g for 5 minutes to remove any cells, and 8µg/mL 
Polybrene Infection/Transfection Reagent (hexadimethrine bromide; Merck Millipore) 
added to it. The supernatant was passed through a Minisart 0.45µm syringe filter 
(Sartorius, Goettingen, Germany) and applied in place of regular DMEM to LS174T 
target cells seeded the previous day into 6cm dishes (3mL/dish). After 2-3 days, the 
newly generated LS174T-mTEM8 cells were analysed by flow cytometry – the 
presence of a green fluorescent protein (GFP) marker in the pWPI lentiviral vector 
allowed for the detection of successfully transduced target cells in the fluorescein 




2.5 Phenotypic and functional analysis of transduced T-cells 
 
2.5.1 Flow cytometry of T-cells and target cells 
All the antibodies used to label both human and mouse mock- and CAR-transduced T-
cells and human Tregs are specified in Table 2.2. When labelling, the cells were first 
washed with PBS by centrifuging at 400g for 5 minutes and resuspended in 40µl of 




Thermo Fisher Scientific, Waltham, MA; reconstituted according to manufacturer’s 
instructions). They were incubated in the dark at room temperature for 20 minutes 
before being washed with MACS buffer by another centrifugation at 400g for 5 minutes. 
The cells were then labelled with appropriate dilutions of antibodies specific for relevant 
T-cell surface markers (Table 2.2) and incubated in the dark on ice for 30 minutes, 
followed by another wash with MACS buffer as before and final resuspension in 200µl 
MACS buffer. When labelling human Tregs, the last wash was followed by fixation, 
permeabilisation and staining for Foxp3 using the Anti-Human Foxp3 Staining Set 
Alexa Fluor 488 (eBioscience) according to manufacturer’s instructions before the final 
resuspension. The T-cells were then analysed for transduction efficiency and 
phenotype using the BD LSRII Flow Cytometer (BD Biosciences) and FlowJo software 
(FlowJo LLC, Ashland, OR). Successful CAR transduction was identified by positive 
staining for the CD34 marker, which is included in its truncated form in the CAR gene 
construct and is co-expressed in equimolar quantities to the CAR (Figure 2.1). Mock-
transduced T-cells, or in specified instances staining with a concentration- and isotype-
matched control antibody (Table 2.2), was used for negative control CD34 staining. 
 
When stated, staining was also performed on relevant target cells to confirm their 
surface expression of the TEM8 protein. The above staining process was employed 





Table 2.2 – Antibodies used to stain T-cells for transduction 
efficiency/phenotype and target cells for TEM8 expression 
Antibody Clone Conjugated dye Manufacturer Dilution/amount* 
Staining of human T-cells 
Mouse anti-human 
CD4 
RPA-T4 FITC BD Biosciences 1/40 
Mouse anti-human 
CD8a 
RPA-T8 PE eBioscience 1/40 
Mouse anti-human 
CD34 
561 APC BioLegend, San 
Diego, CA 
1/20 
Staining of mouse T-cells 
Rat anti-mouse CD4 H129.19 PE BD Biosciences 1/40 
Rat anti-mouse CD8a 53-6.7 FITC BD Biosciences 1/40 
Mouse anti-human 
CD34 
561 APC BioLegend 1/20 
Staining of human Tregs 
Mouse anti-human 
CD3 
UCHT1 Alexa Fluor 700 BioLegend 1/20 
Mouse anti-human 
CD4 
RPA-T4 PE BD Biosciences 1/40 
Mouse anti-human 
CD127 
eBioRDR5 PE-Cy7 eBioscience 1/20 
Mouse anti-human 
CD34 
561 APC BioLegend 1/20 




APC BioLegend 1/40 
Rat anti-human 
Foxp3 
PCH101 Alexa Fluor 488 eBioscience 5µL 
Rat IgG2a, k isotype 
control 
eBR2a Alexa Fluor 488 eBioscience 5µL 
Staining of target cells 
L2 anti-TEM8 mAb 
2mg/mL (primary) 
N/A Unconjugated Gift from Brad St 
Croix 
2µL 
Mouse IgG2a, k 
isotype control 
1mg/mL (primary) 
ZX4 Unconjugated Thermo Fisher 
Scientific 
4µL 
Goat anti-mouse IgG 
(secondary) 
Polyclonal PE Bio-Rad 1/20 




2.5.2 IFNγ enzyme-linked immunosorbent assay (IFNγ ELISA) 
Specified target cells were seeded into 96-well flat-bottom plates, left to adhere for 3-
4h, and mock or TEM8 CAR-transduced T-cells added to them (seeding densities are 
stated in the relevant figure legends). CAR T-cells were equalised for transduction 
efficiency by adding autologous mock T-cells to each, such that all five CAR T-cell lines 
had equal proportions of transduced cells. Target cells and T-cells seeded alone were 
included as controls. Alternatively, decreasing concentrations of recombinant hTEM8-
Fc and mTEM8-Fc proteins, generated as described in section 2.3, were left to adhere 
to 96-well MaxiSorp Nunc-Immuno Plates (Thermo Fisher Scientific) for 3-4h before 
the plates were washed with PBS and the T-cells added to them as above. T-cells 
seeded alone and with the recombinant mouse IgG2a Fc fragment (R&D Systems) 
were included as controls. The T-cell/target cell or T-cell/protein co-cultures were then 
incubated overnight at 37°C/5% CO2 in 200µL/well ELISA medium (RPMI 
supplemented with 10% FBS, 100 IU/mL penicillin, 100µg/mL streptomycin, 2mM L-
glutamine and 25 IU/mL IL-2), and the supernatants were assayed for IFNγ release 
the following day according to the Thermo Fisher Scientific IFNγ ELISA protocol. The 
exact reagents used in the assay are listed in Table 2.3. The absorbance of the plates 
was read at 450nm and 655nm using the iMark Microplate Absorbance Reader (Bio-
Rad) and the readings used to generate a standard curve and calculate IFNγ 





Table 2.3 – Reagents used to develop IFNγ ELISA reactions 
Type of 
















Na2HPO4 adjusted to 









1% w/v BSA + 0.05% 
v/v Tween 20 + 0.1% 
w/v NaN3 in PBS 
Sigma-Aldrich See under 
‘Reagent’ 
200 
Wash buffer Tween 20 in PBS Fisher 
Scientific 
0.05% v/v 250 
Standard Human recombinant 
IFNγ 



















aqueous solution)  











Stop solution Phosphoric or 
sulphuric acid 
Sigma-Aldrich 1M 50 





2.5.3 Intracellular cytokine staining 
Mock or TEM8 CAR-transduced T-cells equalised for transduction efficiency were co-
cultured with specified target cells, previously left to adhere for 3-4h, in 48-well plates. 
All the cells were seeded at 5x105 cells/well in 1mL/well TCM, and T-cells cultured 
alone or in the presence of 200ng/mL Staphylococcal enterotoxin B (SEB) as positive 
control were included. After 90 minutes, 10µg/mL brefeldin A (Sigma-Aldrich) was 
added to all the wells and the plate incubated overnight at 37°C/5% CO2. The following 
day the T-cells were harvested, washed with MACS buffer by centrifugation at 400g 
for 5 minutes and labelled for surface markers using the antibodies specified in Table 
2.4. They were incubated in the dark on ice for 30 minutes, washed again and fixed 
using 4% paraformaldehyde (Fisher Scientific). After another incubation in the dark at 
room temperature for 15 minutes, the cells were washed once more and resuspended 
in 0.5% saponin (Fisher Scientific) for 5 minutes before the addition of intracellular 
staining antibodies (Table 2.4). The T-cells were then incubated in the dark at room 
temperature for 30 minutes, washed as before and finally resuspended in 200µl MACS 
buffer containing 1% paraformaldehyde. They were analysed by flow cytometry, with 
fluorescence minus one controls used to determine levels of background staining for 
IFNγ, IL-2 and TNFa. 
 
2.5.4 Proliferation assay 
Mock and transduction-equalised TEM8 CAR T-cells were labelled with 5µM 
carboxyfluorescein diacetate succinimidyl ester (CFSE) intracellular dye (CFSE Cell 
Division Tracker Kit, BioLegend) according to manufacturer’s instructions. After two 




were resuspended in TCM containing 15 IU/mL IL-2 and co-cultured with specified 
target cells previously left to adhere for 3-4h in 96-well flat-bottom plates (T-cells: 3x105 
cells/well, target cells: 2x104 cells/well, 250µL total medium/well). T-cells alone in TCM 
containing 600 IU/mL IL-2 were included as a positive control, and the plate incubated 
at 37°C/5% CO2 for four days. On day 4, the T-cells were removed and labelled as 
specified in Table 2.2 (‘Staining of human T-cells’), with the anti-CD4 FITC antibody 
substituted with the anti-CD4 PE-Texas Red one (Beckman Coulter) in order to avoid 
a clash with CFSE dye detection in the FITC channel. T-cell proliferation was then 
analysed by flow cytometry. 
 
2.5.5 Chromium release assay 
All radioactive work was carried out in accordance with University policies and 
protocols after appropriate training and authorisation had been given. Indicated target 
cells were centrifuged at 400g for 5 minutes and the resulting cell pellets labelled with 
50-100µCi chromium-51 (51Cr) radionuclide (Perkin Elmer). The cells were 
resuspended in the chromium-containing supernatant and incubated at 37°C/5% CO2 
for 2h with occasional agitation. They were subsequently given two washes with TCM 
by centrifugation at 400g for 3 minutes and seeded into 96-well conical bottom 
MicroWell plates (Nunc) at 2.5x103 cells/well. Mock or transduction-equalised TEM8 
CAR T-cells were added to each of the target cells at decreasing effector:target (E:T) 
ratios, with target cells alone in TCM or in 1% sodium dodecyl sulphate (SDS) included 
as spontaneous and maximum lysis controls respectively (200µL total TCM/well). The 
plates were then centrifuged at 400g for 3 minutes and incubated at 37°C/5% CO2 for 




test tubes (Sterilin, Newport, UK) and analysed for released chromium as a direct 
measure of target cell lysis using the Cobra II Auto-Gamma Counter (Packard). 
Specific lysis for each target cell line was calculated using the following formula (cpm 
= counts per minute, a measure of ionising radiation as reported by the Cobra 
Counter): 
% specific lysis	= sample cpm	– spontaneous cpm
maximum cpm	–	spontaneous cpm  x 100 
 
2.5.6 Treg suppression assay 
96-well MaxiSorp Nunc-Immuno Plates were coated with 10µg/mL recombinant human 
full-length CLEC14A-Fc (PEF) or purified human IgG-Fc fragment control (Bethyl, 
Montgomery, TX) for 3-4h. CRT3.2 CLEC14A-specific CAR-transduced T-cells 
(generated as described in section 2.4.1) were labelled with CFSE as specified in 
section 2.5.4 and added to protein-containing wells either alone or in co-culture with 
autologous CRT3.2 CLEC14A-specific CAR-transduced or mock Tregs at increasing 
T-cell:Treg ratios (200-300µL total medium/well, TCM with 10 IU/mL IL-2 used 
throughout). The plates were incubated at 37°C/5% CO2 for 3-4 days, after which the 
T-cells were harvested, labelled with viability dye, anti-human CD3 Alexa Fluor 700, 
anti-human CD8a PE and anti-human CD34 APC (see section 2.5.1 for the labelling 





Table 2.4 – Antibodies used for intracellular cytokine staining of T-cells 
Antibody Clone Conjugated dye Manufacturer Dilution/amount* 

















581 PE-Cy5 BD 
Biosciences 
1/40 
Intracellular stain antibodies 
Mouse anti-
human IFNγ  










MAb11 PE-Cy7 eBioscience 1/80 





2.6 In vivo studies 
All animal experiments were conducted at the University of Birmingham Biomedical 
Services Unit (BMSU) in accordance with the Animals (Scientific Procedures) Act 1986 
and under the United Kingdom Home Office-approved project licence P32634CE8 
(held by Dr Steven P. Lee) and personal licence. The mice used in all experiments 
were either the highly immunodeficient NOD scid gamma (NSG) mice (bred in-house) 
or the immunocompetent C57 black 6 (C57BL/6) mice (purchased from Charles River, 
Wilmington, MA). T-cells for transduction and injection into C57BL/6 mice were isolated 
from the spleens of BoyJ mice (bred in-house) – this congenic C57BL/6 strain has a 
distinct pan-leukocyte marker, CD45.1, which allows the tracking of CD45.1+ T-cells 
when injected into wild-type (WT) C57BL/6 mice (whose congenic marker is CD45.2). 
Unless otherwise specified, all experimental animals were 6-12 week old females with 
free access to food and water between experiments and, if ordered externally, were 
allowed to rest for at least 4 days after arriving at the facility before any procedures 
were carried out. 
 
2.6.1 Mouse breeding and genotyping 
All in-house breeding was performed by qualified BMSU staff under project licence 
70/8198 (held by BMSU director Caroline Chadwick). For experiments involving TEM8 
KO mice, male TEM8+/- mice (gift from Brad St Croix) were re-derived locally and bred 
as described before245 to generate homozygous TEM8 KO progeny on a C57BL/6 
background. During re-derivation and subsequent breeding, ear clips were collected 




using custom-made TEM8 probes. The genotype information was then used to inform 
further breeding. 
 
2.6.2 Toxicity studies in C57BL/6 WT and TEM8 KO mice 
One day after TEM8 CAR transduction as described in section 2.4.2, mock or specified 
CAR-transduced mouse splenocytes were layered onto Histopaque-1083 (Sigma-
Aldrich) and centrifuged at 400g for 30 minutes at the lowest brake setting. The 
lymphocytes were aspirated from the resulting buffy layer and washed with RPMI by 
centrifugation at 400g for 10 minutes, then once again with mTCM at 250g for 10 
minutes. The purified lymphocytes were then resuspended in Hank’s Balanced Salt 
Solution (HBSS; Lonza), counted and, unless otherwise specified, 10-20x106 T-
cells/mouse centrifuged once more at 700g for 5 minutes. The cells were resuspended 
in up to 200µL HBSS/mouse (for a mouse weighing ≥20g – scaled down accordingly if 
weights were <20g), transported on ice to the BMSU and injected intravenously into 
the tail of healthy, sublethally irradiated (4-5 grays [Gy]) C57BL/6 WT or, if present in 
the study, TEM8 KO mice. 
 
2.6.3 Multiple infusion toxicity study in NSG mice 
Mock or specified TEM8 CAR-transduced human T-cells were pooled one day after 
transduction (which is described in section 2.4.1) and washed twice with PBS by 
centrifugation at 400g for 5 minutes. After the second wash the T-cells were counted 
and 20x106 T-cells/mouse centrifuged once more at 400g for 5 minutes, resuspended 
in HBSS and injected into healthy NSG mice as described in section 2.6.2. This 




days 5 and 9 of the study (the day of first injection was counted as day 0). In this study, 
therefore, the mice were injected with three separate doses of 20x106 T-cells each. 
 
2.6.4 Tumour protection study in NSG mice 
DLD-1 human colorectal carcinoma cells, previously shown to generate TEM8-positive 
vasculature in vivo246, were dissociated from their culture flasks, counted and 
centrifuged at 400g for 5 minutes before being resuspended in HBSS at 2.5x106 
cells/mouse. They were transported on ice to the BMSU and injected subcutaneously 
into the flank of healthy NSG mice. 3 days later, 1D2 TEM8 CAR or ‘no scFv’ CAR T-
cells (‘no scFv’ - control CAR which does not contain a scFv region) were prepared as 
described in section 2.6.3 and injected into the tail vein of the tumour-bearing NSG 
mice. Tumour size was monitored by regular calliper measurements and not allowed 
to go above 1250mm3, specified in the project licence as the maximum tumour volume 
before culling would need to take place. 
 
2.6.5 Mouse monitoring, tail bleed staining and ending the experiments 
In all the studies described above, mice were closely monitored throughout and 
weighed at regular intervals. Weekly tail bleeds were also performed to track the fate 
of the injected T-cells. The blood was collected into pre-weighed microcentrifuge tubes 
containing 20µL heparin sodium (Wockhardt UK, Wrexham; stock: 1,000 IU/mL, diluted 
in PBS to 50 IU/mL), the tubes weighed again to calculate the exact volume of blood 
in each one (assuming 1mg = 1µL) and 100µL of 50 IU/mL heparin in PBS added to 
each. The tubes were centrifuged at 600g for 3 minutes to separate the plasma from 




subsequent multiplex cytokine analysis (see section 2.6.6). Another 100µL of 50 IU/mL 
heparin in PBS was then added to the remaining cell pellets in each microcentrifuge 
tube and all the tail bleed samples transferred into a 96-well conical bottom MicroWell 
plate, which was centrifuged at 600g for 3 minutes. The samples were resuspended in 
200µL/well BD Pharm Lyse lysis buffer, incubated at 37°C for 4 minutes and 
centrifuged as before – this was repeated once in order to lyse the majority of red blood 
cells. The samples were then stained as described in section 2.5.1, with the addition 
of 20µL Flow-Count Fluorospheres (Beckman Coulter) to each sample after the last 
wash to determine absolute T-cell counts during flow cytometric analysis; these, 
together with blood volumes calculated as explained above, were subsequently used 
to determine T-cell numbers and proportions/mL mouse blood. The antibodies used to 
stain the samples are listed in Table 2.2 (‘Staining of human T-cells’ and ‘Staining of 
mouse T-cells’), with mouse T-cells also being labelled with the mouse anti-mouse 
CD45.1 (clone A20) conjugated to PE-Cy7 (BD Biosciences) to differentiate between 
infused and host T-lymphocytes. 
 
If major health issues or toxicity were observed in the mice during any of the above 
studies, the mice in question were culled immediately using a Schedule 1 method 
approved by the Animals (Scientific Procedures) Act 1986. Otherwise, all mice were 
euthanised by Schedule 1 at the end of the experiment. Where specified, major mouse 
organs were harvested and fixed in neutral buffered formalin solution 10% (Sigma-
Aldrich) for subsequent sectioning, haematoxylin and eosin (H&E) staining and 
histopathological analysis. Sectioning and H&E staining were performed by the Human 




kindly imaged by Katharine Whitworth (Lee lab) using the Zeiss Axioskop 40 brightfield 
microscope (air objective at 10X magnification), after which they were examined for 
histopathology. 
 
2.6.6 Mouse plasma multiplex cytokine analysis  
Stored plasma samples from specified mouse experiments were thawed, processed 
and analysed for a panel of 26 cytokines using the Mouse Magnetic Luminex Assay 
(LXSAMSM; R&D Systems) according to manufacturer’s instructions. The mouse 
samples and cytokines analysed are stated when discussing relevant experiments in 
chapter 4. During processing, the samples were further diluted 2-fold as recommended 
in the provided Luminex protocol and subsequently run on the Bio-Rad Bio-Plex 
analyser. The original plasma volumes for each sample, as calculated in section 2.6.5, 
were used to determine the actual dilution factor of the samples before analysis; these 
were then used in conjunction with the results generated by the Bio-Plex analyser to 
calculate the exact amount of each cytokine in pg/mL. 
 
 
2.7 CLEC14A and CD31 staining in liver tissue 
All human inflamed liver samples from patients with PSC and alcoholic liver disease 
(ALD), as well as samples from liver donors whose organs were not accepted for 
transplantation (donor livers), were obtained from Gary Reynolds at the Centre for 
Liver Research (CLR, University of Birmingham) with all ethical approval in place. The 
liver disease tissue array LVD481 and normal human tissue array MNO1021 were 




tissue sections and stained alongside fixed placenta samples (Human Biomaterials 
Resource Centre) as a positive control for the immunohistochemistry procedure. This 
staining was performed with kind help from Katharine Whitworth (Lee lab). 
 
All mouse inflamed liver samples were obtained as frozen sections from male MDR2 
KO FVB mice (mouse model of PSC), and were kind gifts from Vasanthy Vigneswara 
at the CLR. Frozen liver sections from male WT and MDR2 KO C57BL/6 mice (Ditte 
Hedegaard, CLR) and frozen C57BL/6 placenta samples (Andrea White, University of 
Birmingham) were stained alongside as controls. 
 
2.7.1 Immunohistochemistry of fixed human liver tissue 
Sample and control slides were first baked at 60°C for 30 minutes. They were then 
dewaxed and rehydrated in a fume hood by submerging in xylene for 3 x 2 minutes, 
isopropanol (propan-2-ol) for 3 x 2 minutes (both reagents from Fisher Scientific), and 
finally in deionised water (dH2O) for 2 x 2 minutes. Chilled 30% hydrogen peroxide 
(Sigma-Aldrich) was diluted 1/10 in chilled methanol (AnalaR NORMAPUR, VWR, 
Lutterworth, UK) and the slides submerged in the resulting 3% hydrogen peroxide for 
5 minutes. They were transferred to a suitable container and washed with a 0.1% 
solution of Tween 20 (Sigma-Aldrich) in PBS for 3 x 5 minutes using a stirrer. The 
slides were then removed from the fume hood and antigen retrieval performed by 
placing them in an unmasking solution, which was made by diluting the tris-based 
antigen unmasking solution (Vector Laboratories, Peterborough, UK) to 1% in 1L dH2O 
and heating it in a microwave at 850W for 5 minutes. Once in the solution, the slides 




minutes before excess dH2O was added to them to bring the solution to room 
temperature. Each slide was then fitted onto a Shandon glass coverplate and placed 
into a Sequenza slide holder (both from Fisher Scientific), after which each one was 
washed 3 times with 0.1% PBS-Tween (2mL/wash). Normal horse serum blocking 
solution (Vector Laboratories) was diluted to 10% in PBS and 100µL added to each 
section, followed by incubation at room temperature for 30 minutes. The slides were 
then labelled as follows: 
- Polyclonal human CLEC14A antibody or normal sheep IgG control (both from 
R&D Systems) were diluted to 1.7µg/mL in PBS containing 2.5% v/v horse 
serum and 200µL added to the appropriate slides, followed by incubation at 
room temperature for 1h; 
OR 
Mouse anti-human CD31 antibody (clone JC70A, Dako/Agilent Technologies, 
Stockport, UK) was diluted 1/40 in PBS containing 2.5% v/v horse serum and 
200µL added to the appropriate slides, followed by incubation at 4°C for 18h 
(performed overnight); 
- Polyclonal donkey anti-sheep IgG (R&D Systems; secondary antibody for the 
CLEC14A antibody and the sheep IgG control) conjugated to horseradish 
peroxidase (HRP) was diluted 1/100 in PBS containing 2.5% v/v horse serum 
and 200µL added to the appropriate slides, followed by incubation at room 
temperature for 30 minutes; 
OR 
ImmPRESS HRP anti-mouse IgG (Vector Laboratories; secondary antibody for 




v/v horse serum and 200µL added to the appropriate slides, followed by 
incubation at 4°C for 3h. 
3 x 2mL wash steps with 0.1% PBS-Tween were performed on all slides after each 
incubation. After the last set of washes, the ImmPACT NovaRED HRP substrate 
(Vector Laboratories) was made up according to manufacturer’s instructions and 
300µL added to each section, followed by incubation at room temperature for 3 minutes 
(CLEC14A) or 5 minutes (CD31). The slides were then removed from the slide rack 
and coverplates, transferred to a container and washed with dH2O for 5 minutes using 
a stirrer. They were subsequently immersed in filtered Mayer’s haematoxylin (pfm 
medical, Poynton, UK) for 30 seconds, dH2O for 5 seconds, and in 1/10 dilution of 
Scott’s tap water substitute (Sigma-Aldrich) in dH2O for 1 minute. Finally, they were 
washed once more with dH2O for 5 minutes using a stirrer and dehydrated in the fume 
hood by immersion in isopropanol for 2 x 2 minutes and xylene for 3 x 2 minutes. Each 
slide was then pressed down onto an appropriately sized coverslip containing a drop 
of DPX Mounting Medium (CellPath, Powys, UK), left to dry for at least 24h at room 
temperature and imaged using the Zeiss Axioskop 40 brightfield microscope (air 
objective at 10X magnification). 
 
2.7.2 Immunofluorescence of frozen mouse liver tissue 
Sample and control slides were first fixed by immersion in -20°C acetone (Fisher 
Scientific) in a covered glass slide holder for 10 minutes, then transferred to a suitable 
container and washed with PBS for 3 x 5 minutes using a stirrer. Each slide was fitted 
onto a Shandon glass coverplate and placed into a Sequenza slide holder, after which 




added to each and left to incubate at room temperature for 30 minutes. All slides were 
then taken through the following four steps of the labelling procedure: 
- Polyclonal CLEC14A antibody (section 2.7.1; cross-reactive with mouse 
CLEC14A) or normal sheep IgG control  were diluted to 10µg/mL in PBS and 
100µL added to the appropriate slides, followed by incubation at 37°C for 1h; 
- Rabbit anti-sheep IgG cross-adsorbed secondary antibody, DyLight 550 (Life 
Technologies) was diluted to 10µg/mL in PBS and 100µL added to each slide, 
followed by incubation at room temperature in the dark for 1h; 
- Purified rat anti-mouse CD31 antibody (clone MEC13.3; BioLegend) was diluted 
to 10µg/mL in PBS and 100µL added to each slide, followed by incubation at 
room temperature in the dark for 1h; 
- Chicken anti-rat IgG cross-adsorbed secondary antibody, Alexa Fluor 488 (Life 
Technologies) was diluted to 10µg/mL in PBS and 100µL added to each slide, 
followed by incubation at room temperature in the dark for 1h. 
The slides were washed 3 times with PBS (2mL/wash) after each of the above 
incubations, followed by a single wash with 2mL dH2O per slide at the end of the 
staining procedure. They were removed from the slide rack and coverplates and 
partially dried off, pressed down onto appropriately sized coverslips each containing a 
drop of ProLong Gold Antifade Mountant (Invitrogen) and left to dry at room 
temperature for at least 30 minutes. They were stored in the dark at -20°C and imaged 







2.8 Statistical analysis 
Where indicated, statistical analysis was performed using GraphPad Prism 7 software, 
with statistical significance assumed if P values were less than 0.05. The exact tests 





3 GENERATION AND IN VITRO TESTING OF TEM8 CAR-ENGINEERED T-
CELLS 
 
As discussed extensively in section 1.5 of the Introduction, targeting the tumour 
vasculature – and in particular a selectively expressed tumour endothelial marker such 
as TEM8 – seems a very promising avenue of further research. In view of the reported 
success of CAR T-cells, and the encouraging data obtained with TEM8 antibody 
targeting, the therapeutic potential of CARs redirected towards TEM8 warrants in-
depth exploration. The results described in this and next chapter therefore provide 
insight into the in vitro functionality and in vivo therapeutic capacity of TEM8-targeted 
CAR T-cells and can be used to inform decisions about their further testing, both in the 
lab and, potentially, in the clinic. 
 
3.1 Human T-cells are successfully transduced with five distinct TEM8 CARs 
To construct TEM8 CARs, the sequences of five anti-TEM8 mAbs were first obtained 
as a kind gift from our collaborator Brad St Croix at the NIH, whose lab had previously 
described making and using them in mouse anti-tumour studies246. The antibodies, 
termed L1, L2, L3, L5 and 1D2, are all cross-reactive with both hTEM8 and mTEM8 at 
varying affinities in their Fab form, with 1D2 of notably lower affinity for both versions 
of the protein246 (Table 3.1). The five antibody sequences were used to generate five 
anti-TEM8 scFvs, which were successfully cloned into a retroviral vector and stably 
transduced into primary human T-cells as described in detail in sections 2.2.1 and 
2.4.1. The construct used for each of the five CARs is shown in Figure 2.1. CD34 




transduction and, due to the nature of the construct, as a direct measure of CAR levels 
on the T-cell surface. The full gating strategy routinely used to detect CAR T-cells is 
shown in Figure 3.1. 
 
Bulk populations of primary human T-cells were consistently successfully transduced 
with all five CARs, as shown in Figure 3.2A. For each transduction carried out, a mock 
T-cell population was also generated as described in section 2.4.1 which served as a 
CAR-negative control for both flow cytometry and in all subsequent functional assays. 
CD8 and CD4 T-cell subsets within a given T-cell population were both successfully 
transduced throughout, although CD4 T-cells consistently exhibited a somewhat higher 
level of CAR surface expression compared to the CD8 subset (Figure 3.2B). Once 
transduced, the generated CAR T-cells grew well in culture for at least 2-3 weeks, 
sometimes exhibiting a gradual loss of CAR surface expression over time of up to 10%. 
They were therefore used in functional assays within the first two weeks of their 
transduction whenever possible, or cryopreserved early and revived when needed – 










Figure 3.1 – T-cell gating strategy to identify CAR transduction levels of bulk T-cell populations and their CD8 and CD4 
subsets 
L1, L2, L3, L5 and 1D2 CAR T-cells and mock T-cell controls were labelled with viability dye, anti-CD8, anti-CD4 and anti-CD34 
antibodies and analysed on the flow cytometer, with CD34 acting as a surface marker of CAR expression. After gating on the T-
cell population, singlets (to exclude cell clumps) and live cells (viability dye-negative) sequentially, mock T-cells were used to 
determine the position of the CD34-negative population and thus allow correct positioning of the CD34 gate. In the CAR T-cell 
populations, the bulk T-cells within this gate were considered CAR-positive. Live T-cells were also further analysed for CD8 and 






Figure 3.2 – Representative CAR transduction levels in bulk T-cell populations 
and their CD8 and CD4 subsets 
L1, L2, L3, L5 and 1D2 CAR T-cells and mock T-cell controls were labelled with viability 
dye, anti-CD8, anti-CD4 and anti-CD34 antibodies and analysed on the flow cytometer, 
with CD34 acting as a surface marker of CAR expression. (A) Histograms showing 
representative CAR transduction levels for each of the five CARs (blue line), gated 




different donor to the one in A, showing a representative breakdown of CD8 and CD4 
populations and their respective CAR transduction levels. The overall CAR 
transduction of the bulk T-cell population was 22.7%. Data in A and B are 





Table 3.1 – The half maximum concentrations (EC50) of five anti-TEM8 Fabs 
needed to bind recombinant human or mouse TEM8 extracellular domain (ED) 
 
Reprinted from Cancer Cell, 21(2), Chaudhary A, Hilton MB, Seaman S, Haines DC, 
Stevenson S, Lemotte PK, et al, TEM8/ANTXR1 blockade inhibits pathological 
angiogenesis and potentiates tumoricidal responses against multiple cancer types, 





3.2 TEM8 CAR T-cells produce multiple cytokines in response to target cells 
Upon successful transduction, TEM8 CAR T-cells and their mock T-cell controls were 
tested for response to various targets through a series of functional assays. In a 
preliminary ELISA, mock, L1 and L2 CAR T-cells were analysed for their IFNg release 
in the presence of CHO cells stably overexpressing human TEM8 on their surface 
(CHO-TEM8), and CHO-PR230, a spontaneous TEM8-deficient mutant of CHO 
cells309 that served as the TEM8-negative control. While a strong response to CHO-
TEM8 was observed for both CARs, an unexpectedly high T-cell response was also 
seen in the presence of CHO-PR230 (Figure 3.3A). To ascertain whether this 
occurrence was limited to CHO cells, the experiment was repeated with the 
introduction of two further unrelated targets – Phoenix A304 (derived from HEK293T 
cells) and HUVEC. Once again, both L1 and L2 CAR T-cells responded strongly to all 
target cells, with the highest IFNg release still observed in the presence of CHO-TEM8 
(Figure 3.3B). The fact that mock T-cells released little or no IFNg throughout 
suggested that this unexpected cross-reactivity was a feature of CAR T-cells alone. 
 
Next, all five CAR T-cells were tested for IFNg release in response to a range of 
different target cells once more. The response pattern consistently observed in all the 
repeats of this IFNg ELISA is shown in a representative graph in Figure 3.4A. All CARs 
showed specific responses to CHO-TEM8 compared to those seen to CHO-PR230. 
Nevertheless, L1 and L2 CAR T-cells, as before, responded to all targets (including 
CHO-PR230), with especially high IFNg levels released in the presence of HUVEC. L3 
and L5 CAR T-cells did not exhibit background responses to CHO-PR230 but still 




to HUVEC compared to L5. The only CAR to respond solely to its intended TEM8-
positive target, CHO-TEM8, was 1D2. It repeatedly released IFNg in significant 
amounts only in the presence of this hTEM8-overexpressing cell line, with its 
responses to the other targets comparable to the low-level background response seen 
in mock T-cells. Consistent with the lower TEM8 affinity of the 1D2 antibody this CAR 
is derived from246, however, it was also the least strong responder to CHO-TEM8 of all 
the CARs tested. In an attempt to find the cause of the cross-reactivity in the remaining 
four CARs, the T-cells were also tested for response to CHO cells stably 
overexpressing human CMG2 – the closest TEM8 homologue which has a much wider 
tissue distribution229 – on their surface. However, none of the CAR T-cells released 
any significant amounts of IFNg when exposed to this cell line, showing that the 
responses to the other targets were not due to cross-reactivity with CMG2 (Figure 
3.4B). 
 
As the most selective TEM8 CAR, 1D2 warranted further investigation of its responses 
to other target cells. It was therefore tested in another IFNg ELISA together with the 
least cross-reactive of the other CARs, L5. In addition to the target cells tested before, 
two more were included – MDA-MB-231, a breast adenocarcinoma cell line previously 
shown to express low levels of TEM8 in vitro246, and the colorectal carcinoma cell line 
LS174T which was TEM8-negative246. In accordance with this, neither L5 nor 1D2 CAR 
T-cells responded to LS174T, but interestingly, only L5 CAR T-cells exhibited IFNg 
release in the presence of MDA-MB-231 (Figure 3.5). In the case of the 1D2 CAR, 




only recognise and respond to overexpressed TEM8 rather than lower levels of the 
protein that may be present on the surface of the other targets. 
 
To examine the release of other pro-inflammatory cytokines by TEM8 CAR T-cells 
when exposed to target cells, an intracellular cytokine release assay was performed to 
test for the proportions of each T-cell population that secreted TNFa, IFNg and/or IL-2. 
A sample of the obtained flow data is shown in Figure 3.6 and the cumulative data for 
all CAR T-cells are presented in Figure 3.7. The pattern observed in the IFNg ELISA 
was repeated here – L1 and L2 CAR T-cells were the highest responders and secreted 
one, two or all three cytokines in the presence of all targets apart from the TEM8-
negative LS174T. Particularly high responses were once again observed in the 
presence of HUVEC. A similar pattern was seen in L3 and L5 CAR T-cells but with 
reduced T-cell proportions secreting each cytokine or cytokine combination, reflecting 
their lower reactivity compared to the first two CARs. Once again, 1D2 CAR T-cells 
were the lowest responders to CHO-TEM8, but responded nonetheless; the 
proportions of these T-cells that exhibited cytokine release when exposed to other 
targets was low or undetectable. The most commonly secreted cytokine by all activated 
CAR T-cells was TNFa alone followed by the TNFa/IFNg combination, although cells 
secreting all three cytokines were also observed, particularly among the high 
responders. As before, mock T-cells were not activated by any of the targets, and T-
cells alone, whether mock or CAR, mostly secreted single cytokines in very small 
proportions, confirming that the responses seen were dependent on the presence of 
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Figure 3.3 – IFNg release of L1 and L2 CAR T-cells at decreasing input numbers in response to target cells 
Mock, L1 or L2 CAR-transduced T-cells at the indicated input numbers/well were incubated overnight with (A) CHO-PR230 or 
CHO-TEM8 (5x104 cells/well) or (B) CHO-PR230, CHO-TEM8, Phoenix A or HUVEC at high (5x104 cells/well) or low (2x104 
cells/well) target cell concentration in a 96-well plate. T-cells alone were included as a control. Supernatants were assayed by 
IFNg ELISA the following day and the resulting T-cell IFNg production expressed in pg/mL. Data in A are representative of two 






Figure 3.4 – TEM8 CAR T-cell IFNg release in response to target cells 
(A) Mock or TEM8 CAR-transduced T-cells (5x104 cells/well) were incubated alone or 
with indicated target cells (2x104 cells/well) in a 96-well plate overnight. Supernatants 
were assayed by IFNg ELISA the following day and the resulting T-cell IFNg production 
expressed in pg/mL. Data are representative of 14 independent experiments using T-
cells derived from 10 different donors. All data points are measured in triplicate and 
expressed as mean + SD. (B) Mock or TEM8 CAR-transduced T-cells (2x105 cells/well; 
different donor to the one in A) were incubated alone or with CHO-CMG2 (2x104 
cells/well) in a 96-well plate overnight and assayed as in A. All data points were 
measured in triplicate and expressed as mean + SD.  









































Figure 3.5 – Mock, L5 and 1D2 CAR T-cell IFNg release in response to target cells 
Mock, L5 or 1D2 CAR-transduced T-cells (2x105 cells/well) were incubated alone or 
with indicated target cells (2x104 cells/well) in a 96-well plate overnight. Supernatants 
were assayed by IFNg ELISA the following day and the resulting T-cell IFNg production 
expressed in pg/mL. All data points were measured in triplicate and expressed as 

























Figure 3.6 – Sample intracellular cytokine release flow data from mock and two TEM8 CAR T-cell products 
Mock or TEM8 CAR-transduced T-cells were incubated alone or with indicated target cells (all at 5x105 cells/well) in a 48-well 




a positive control. The next day the T-cells were harvested, stained with anti-CD34 surface antibody and anti-TNFa, anti-IFNg 
and anti-IL-2 intracellular antibodies and analysed on the flow cytometer. Gate thresholds were set using unstimulated T-cells 
and fluorescence minus one controls. Data show sample TNFa vs IFNg flow plots of mock, L1 and 1D2 CAR T-cells pre-gated 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.7 – Multiple cytokine release by TEM8 CAR T-cells in response to target 
cells 
Mock or TEM8 CAR-transduced T-cells were incubated alone or with indicated target 
cells (all at 5x105 cells/well) in a 48-well plate overnight. T-cells stimulated non-
specifically with the superantigen Staphylococcal enterotoxin B (SEB) were included 
as a positive control. The next day the T-cells were harvested, stained with anti-CD34 
surface antibody and anti-TNFa, anti-IFNg and anti-IL-2 intracellular antibodies and 
analysed on the flow cytometer. Gate thresholds were set using unstimulated T-cells 
and fluorescence minus one controls. Data are represented as the proportion of mock 
or CD34+ T-cells secreting one, two or all three cytokines for (A) mock, L1 and L2 and 
(B) L3, L5 and 1D2 CAR T-cells. Data are cumulative from two independent 





3.3 TEM8 CAR T-cells proliferate in response to target cells 
To test antigen-specific proliferation of TEM8 CAR T-cells, they were labelled with 
CFSE dye and incubated with their targets for four days after which CFSE expression 
was assayed by flow cytometry. Sequential dilution of the dye induced by cell division 
allowed the shift of the signal from bright to dim to serve as a direct measure of cell 
proliferation, and CAR-positive (CD34+) and non-transduced (CD34-) subsets of each 
T-cell population were analysed separately to gain a better understanding of CAR-
specific antigen-dependent responses. The proliferation patterns of two distinct 
batches of TEM8 CAR T-cells and their mock controls are shown in Figure 3.8 and 
Figure 3.9, segregated due to the difference in target cells tested and the presence of 
significant background T-cell proliferation in one of them. The overall pattern of CAR 
T-cell responses, however, was very similar to the one observed before. Mock T-cells 
alone or in the presence of targets did not proliferate, or else showed background 
proliferation consistent with all CAR T-cells produced in that batch. L1 and L2 CARs 
were yet again the most cross-reactive ones, exhibiting high responses to CHO-TEM8 
as well as to HUVEC, MDA-MB-231 and the control cell line CHO-PR230, but not to 
the TEM8-negative LS174T cells. The responses of L3 and L5 CAR T-cells were 
mostly equivalent to those of mock T-cells in the presence of CHO-PR230, but 
significantly higher to all other target cells except LS174T. 1D2 CAR T-cells were once 
more the only ones to exhibit selectivity, with CHO-TEM8 being the sole target to elicit 
consistently high proliferation in this T-cell population. 
 
The response pattern described above was mostly confined to the CD34+ fraction of 




level proliferation regardless of the target they were exposed to. Certain responses 
were higher than expected in CD34+ T-cells, however, such as the low but noticeable 
proliferation to CHO-PR230 in L3, L5 and 1D2 CARs, and to MDA-MB-231 and HUVEC 
in 1D2 CAR T-cells (Figure 3.8). Additionally, some of the CD34- T-cells exhibited what 
looked like the usual target-specific response patterns even though they did not 
express the TEM8 CARs on their surface (Figure 3.8 and Figure 3.9). On closer 
inspection, however, these unexpected observations were all confined to the CD8 T-
cell compartment, which appeared both much more reactive in general than its CD4 
counterpart, and accounted for most of the high background proliferation seen in one 
of the CAR T-cell batches. It is possible that the production of cytokines by CD34+ T-
cells in response to antigen led to a bystander effect in CD34- cells, causing them to 
proliferate as well; this effect seemed to be much more pronounced in the highly 
reactive CD8 T-cell subset. The complete absence of antigen-specific responses in the 
CD4 CD34- T-cells, and their clear presence in the CD34+ ones, suggest that TEM8 
CAR T-cells do indeed respond to their target in a manner dependent on both CAR 






Figure 3.8 – Antigen-specific proliferation of one batch of TEM8 CAR T-cells in 
response to target cells 
Mock or TEM8 CAR-transduced T-cells (3x105 cells/well) were labelled with CFSE 
intracellular dye and incubated alone or with indicated target cells (2x104 cells/well) in 
a 96-well plate for four days. On day 4 the T-cells were harvested, labelled with anti-
CD8, anti-CD4 and anti-CD34 antibodies and analysed by flow cytometry. CFSE-bright 
mock T-cells were used to correctly position the CFSE-dim proliferation gate – 
sequential dilution of the dye induced by cell division allowed the shift of the signal from 
bright to dim to serve as a direct measure of T-cell proliferation. The proportion of T-
cells shifting into the CFSE-dim gate was considered to be the proportion of the total 
CD34+ or CD34- T-cell population that had proliferated. The bulk, CD8 and CD4 CAR 





Figure 3.9 – Antigen-specific proliferation of a second batch of TEM8 CAR T-
cells in response to target cells 
Mock or TEM8 CAR-transduced T-cells (3x105 cells/well) were labelled with CFSE 
intracellular dye and incubated alone or with indicated target cells (2x104 cells/well) in 
a 96-well plate for four days. On day 4 the T-cells were harvested, labelled with anti-
CD8, anti-CD4 and anti-CD34 antibodies and analysed by flow cytometry. The bulk, 
CD8 and CD4 CAR T-cell subsets were each analysed for CD34 expression and CFSE 
expression/proliferation separately, as described in Figure 3.8. L5 CAR T-cells did not 
transduce successfully in this T-cell batch and were therefore not analysed. Data are 





3.4 TEM8 CAR T-cells show specific cytotoxicity in response to target cells 
As a final in vitro examination of TEM8 CAR T-cell responses to their targets, the target 
cells were labelled with 51Cr radionuclide and co-cultured with the T-cells; the amount 
of chromium released from the lysed target cells into the supernatant was a direct 
measure of T-cell-mediated killing. The pattern observed in all the previous functional 
assays was once more recapitulated here, and is shown in Figure 3.10. All TEM8 CAR 
T-cells specifically lysed CHO-TEM8, with L1 and L2 also exhibiting significant killing 
of CHO-PR230; all but 1D2 CAR T-cells also lysed HUVEC. In contrast, there was no 
specific T-cell cytotoxicity in response to LS174T, as evidenced by the lysis of this cell 
line being comparable in the presence of both mock and CAR T-cells. This response 
pattern was consistently observed in repeated chromium release assays. Taken 
together with the data from previous functional experiments, it confirmed the marked 
TEM8-specific responses and significant cross-reactivity of L1 and L2 CARs, slightly 
lower cross-reactivity of L3 and L5 CARs, and the specificity of 1D2 CAR T-cells for 






Figure 3.10 – Specific cytotoxicity of TEM8 CAR T-cells in response to target 
cells 
Mock or TEM8 CAR-transduced T-cells were incubated at decreasing effector:target 
(E:T) ratios with indicated chromium-labelled target cells (2.5x103 target cells/well of a 





























































































12 hours. % specific lysis for each target was calculated from spontaneous (targets 
alone) and maximum lysis values (targets incubated with 1% sodium dodecyl-
sulphate). Note: in this particular experiment there were enough HUVEC cells to test 
only the highest E:T ratio for each of the T-cells, except L2 CAR T-cells where all ratios 
were assessed. Data are representative of four independent experiments using T-cells 
derived from three different donors. All data points were measured in triplicate and 





3.5 TEM8 expression on target cells and CAR T-cell cross-reactivity 
The persistent in vitro cross-reactivity of four of the five TEM8 CAR constructs to cell 
lines other than their intended target, CHO-TEM8, warranted further investigation of 
such CAR T-cell behaviour. All the target cell lines tested were therefore examined for 
human TEM8 mRNA expression by qPCR (Figure 3.11). As expected, hTEM8 mRNA 
was clearly overexpressed in CHO-TEM8, but none was detectable in CHO-PR230 or 
CHO-CMG2. Interestingly, however, HEK293T, HUVEC and MDA-MB-231 cells all 
expressed very small, but detectable levels of hTEM8 mRNA, suggesting that TEM8 
protein expression could also be present on the surface of these targets. LS174T cells 
did not exhibit any TEM8 mRNA expression, which correlated with their previously 
observed inability to elicit specific CAR T-cell responses. 
 
To supplement the obtained data and verify expression of the TEM8 protein on the 
target cell surface, the cells were stained using the same L2 mAb which had been used 
to make the L2 CAR (the staining procedure is described in section 2.5.1). The results 
of L2 staining are shown in Figure 3.12. Consistent with the qPCR data, TEM8 was 
highly expressed on the surface of CHO-TEM8, and present at extremely low levels or 
completely undetectable on CHO-PR230 and LS174T cells. HEK293T and MDA-MB-
231 cells did stain with the L2 antibody, despite the very low hTEM8 mRNA levels 
present in these targets, possibly indicating that their surface expression of the protein 
was very stable. Curiously, however, the surface levels of TEM8 on HUVEC detected 





Taken together, these results could at least partly explain the T-cell cross-reactivity 
consistently observed in vitro, such as the responses seen to HEK293T and MDA-MB-
231 and the lack of response to LS174T. However, they still failed to clarify the very 
high reactivity of L1 and L2 CAR T-cells to CHO-PR230, a cell line that appeared to be 
completely TEM8-negative, as well as the potent responses of all but 1D2 CAR T-cells 
to HUVEC, which did not express TEM8 on their surface to any appreciable degree. 
These responses would therefore need to be discussed in more depth in order to 






Figure 3.11 – Relative hTEM8 mRNA expression of target cells used in T-cell 
functional assays 
Cell lysates from indicated target cells were examined by qPCR for their expression of 
hTEM8 mRNA. The mRNA expression levels are shown relative to those obtained for 
CHO-TEM8, which were assigned the value of 1. All data points were measured in 




























































Figure 3.12 – TEM8 protein expression on the surface of target cells used in T-
cell functional assays 
Indicated target cells were labelled with the primary L2 anti-TEM8 mAb (chimeric 
antibody with mouse IgG2a constant domain and human variable regions; blue line), 
or with the primary mouse IgG2a isotype control (red line), before being labelled further 
with the secondary fluorophore-conjugated anti-mouse IgG. TEM8 expression on the 
cells was then assayed by flow cytometry. Data are representative of three 





This chapter describes the generation of five TEM8-targeted CARs and the successful 
transduction of human T-cells with each one, resulting in potent TEM8-redirected CAR 
T-cells which release multiple cytokines, proliferate and exhibit specific lysis in 
response to TEM8-expressing target cells. However, four of the five CARs – derived 
from the L1, L2, L3 and L5 anti-TEM8 mAbs – also exhibit significant levels of reactivity 
to control cell lines, some of which do not express detectable levels of the target protein 
on their surface. The only CAR that consistently responds solely to the CHO cells that 
were engineered to overexpress TEM8 is 1D2. This is consistent with the fact that this 
CAR, when expressed in T-cells, showed the lowest avidity for TEM8, which is in turn 
consistent with the antibody upon which the CAR was based having the lowest affinity 
for the protein. The reactivity and response patterns of the five TEM8-targeted CARs 
will be discussed later, but initially the discussion will focus on the methods available 
for generating CAR expressing T-cells. 
 
3.6.1 CAR T-cell generation methods 
Retroviral transduction is a well-established method of T-cell genetic engineering. The 
MP71 retroviral vector, which forms the basis of all CAR expression constructs in this 
thesis, has previously proven superior to alternative vectors in producing highly stable 
gene expression in both murine and human T-lymphocytes310. Initially, there were 
concerns over the use of such viral vectors due to reports of retroviral gene transfer in 
the treatment of patients with X-linked severe combined immunodeficiency (SCID) that 
resulted in insertional oncogenesis and development of T-cell leukaemia311. However, 




cell leukaemia/lymphoma development, it was subsequently shown in mice that mature 
T-cells are much less susceptible to insertional mutagenesis, with mice subjected to 
engineered T-cell transplants showing no signs of resultant cancer312. In fact, a 
decade-long follow-up study of human immunodeficiency virus (HIV) patients treated 
with retrovirally-engineered CAR T-cells demonstrated that the T-cells were safe and 
exhibited no signs of oncogenesis or immortalisation over time313. Even though newer 
methods of T-cell transduction have been developed in recent years, such as RNA 
electroporation for transient CAR expression or the Sleeping Beauty 
transposon/transposase system for efficient and cost-effective DNA integration174, 
retroviruses remain one of the mainstays of stable T-cell genetic engineering. It has 
been suggested that lentiviruses are safer than retroviruses and may achieve higher 
CAR expression levels, but are currently more expensive to produce. The relatively 
low cost and proven safety of retroviral vectors has resulted in their routine use for T-
cell transduction in this thesis instead. 
 
There is an ongoing debate over the superiority of CD28 or 4-1BB as the co-stimulatory 
domain of choice in 2nd generation CARs. Greater persistence in the circulation has 
been reported for 4-1BB/CD3z CAR T-cells compared to their CD28-containing 
counterparts in several clinical trials of CD19 CARs, which could be explained by CD28 
co-stimulation leading to increased T-cell exhaustion while 4-1BB ameliorates it 
instead314. It has also been found that the two co-stimulatory domains lead to different 
T-cell metabolic profiles, with the presence of 4-1BB resulting in increased oxidative 
respiration and a CD8 central memory phenotype while CD28 led to glycolysis and the 




1BB 2nd generation CARs are still in use in equal measure by the labs which study this 
therapeutic modality177, and it is likely that the optimal construct will depend on the 
clinical situation in which it is being employed. The TEM8-targeted CARs described in 
this thesis include a CD28/CD3z domain, which has previously been used successfully 
by our lab for CARs specific for another TEM, CLEC14A, to mediate safe anti-tumour 
responses in several mouse models. Due to the established protocol working well, and 
the finding that CD28/CD3z CAR T-cells may possess more potent anti-tumour 
function and therefore eliminate tumours more quickly than 4-1BB/CD3z CARs166, the 
former was decided upon as the construct of choice. 
 
Another well-established protocol used herein is the CD3/CD28 stimulation of T-cells 
prior to transduction, which has been employed in several patient studies to generate 
large numbers of T-cells with extensive proliferative potential, the ability to persist in 
vivo and potent anti-tumour effects186,187,316,317. Furthermore, using bulk populations 
containing both CD4 and CD8 T-cells for transduction, rather than selecting for a 
particular T-cell subtype, has been shown to lead to a more potent response to 
antigen132,186,187. The more contentious issue is the subsequent in vitro maintenance 
of CAR-transduced T-cells in the presence of a reasonably high dose of IL-2 (100 
IU/mL). Even though this concentration of the cytokine is conducive to higher cell yields 
and optimal T-cell responses in functional assays, it also drives differentiation into 
effectors and results in a reduced memory T-cell population, which in turn promotes in 
vitro exhaustion and possibly poorer in vivo persistence318. The rapid expansion and 
high functional responses but eventual exhaustion of the generated TEM8 CAR T-cells 




vitro reactivity in the first 2-3 weeks post-transduction. To improve this, and promote 
the development of a memory rather than effector T-cell phenotype in culture, it might 
be beneficial to reduce maintenance IL-2 concentration in future studies. The 
suggested dose of IL-2 that gives reasonable cell expansion rates while maintaining 
T-cell memory is 20-30 IU/mL318. Alternatively, expansion of T-cells using cytokines 
other than IL-2, such as IL-7 or IL-21, has been found to generate a preferred 
phenotype for their increased persistence319. 
 
Overall, the molecular cloning and transduction methods employed here were 
established, safe and predominantly supported by the available literature, ensuring that 
the final CAR T-cell product was suitable for the studies conducted. If TEM8 CARs 
were to reach the clinic, however, the methods could be adjusted depending on the 
clinical situation in question. For example, lentiviral instead of retroviral vectors can be 
employed for CAR transduction to achieve higher CAR expression levels on T-cell 
surface, potentially resulting in greater therapeutic efficacy. If toxicity is anticipated, 
however, RNA electroporation could provide a safer alternative to stable genetic 
integration as it results only in transient CAR surface expression, ensuring timely 
disappearance of the CAR T-cell product from the circulation if toxicity does occur. If 
tumour relapse is a big concern, 4-1BB/CD3z CARs may be more desirable due to 
their superior persistence; conversely, if the tumour has responded poorly after the first 
CAR T-cell infusion, better responses may be achieved with the CD28/CD3z construct 





3.6.2 The affinities and cross-reactivity of TEM8 CARs 
Although there are various ways in which CAR T-cells can be generated for clinical 
use, before progressing to clinical studies the likely toxicity of any CAR must first be 
considered. In this regard, the observed responses of four out of five TEM8-specific 
CARs generated in this project to various cell lines that were not expected to express 
high levels of TEM8 is a cause for concern. Elucidating the reason for the observed T-
cell reactivity, and its physiological importance going forward, is difficult in part because 
low-level TEM8 expression has been detected in cell lines in culture but not necessarily 
reflected in the same tissues in vivo. For example, certain human colon cancer cell 
lines express detectable levels of surface TEM8 in vitro, possibly as a method of 
adapting to growth on plastic, but human colon cancer tumour cells have never shown 
TEM8 expression in an in vivo setting (Brad St Croix, personal communication). It is 
therefore challenging to predict how any in vitro TEM8 CAR cross-reactivity may 
translate to the clinic, but it is nevertheless an important issue to examine with a view 
to preventing any potential toxicity if patients are treated with this therapy. 
 
In the first instance, it was suspected that engineering the five antibodies into CARs 
may have inadvertently modified their TEM8 specificity and resulted in recognition of 
CMG2, the closest TEM8 homologue, even though there was no evidence of CMG2 
recognition in the original mAbs246. The ubiquitous expression profile of this anthrax 
toxin receptor229, unlike the apparently restricted one of TEM8, made it possible that 
CMG2 was expressed on the surface of the target cell lines used in this thesis, thus 
triggering CAR T-cell reactivity in their presence. However, when the five TEM8 CARs 




significant responses were observed (Figure 3.4B and Figure 3.5), rendering it unlikely 
that the recognition of this protein was accountable for the prominent CAR T-cell 
reactivity to control cell lines. 
 
Another explanation may be that the more reactive CARs were able to recognise low-
level TEM8 expression on target cells. CAR T-cells require lower expression 
thresholds of their target antigen than the antibodies from which they are derived and 
are more potent in mediating immune effects, leading to instances of serious adverse 
events in patients treated with CARs engineered from previously clinically approved 
antibodies132,202. It is possible, therefore, that the four original high-affinity anti-TEM8 
mAbs – L1, L2, L3 and L5 – were converted to very potent CARs responsive to 
exceedingly low levels of surface TEM8 expression. On the other hand, the 1D2 
antibody, the affinity of which for human TEM8 was 20-40 times lower in its Fab form 
than that of the other four antibodies246 (Table 3.1), gave a CAR which was only 
capable of recognising overexpression of the target protein such as the one found on 
CHO-TEM8. In fact, a similar observation was recently made by another group, which 
found that the different affinities of two anti-EGFR antibodies, cetuximab and 
nimotuzumab, resulted in very different specificities for the target antigen when the 
antibodies were converted to 2nd generation CD28/CD3z CARs320. While both CARs 
triggered efficient T-cell activation in the presence of cell lines expressing high 
densities of EGFR on their surface, the nimotuzumab-CAR, derived from the antibody 
with much lower affinity for EGFR than cetuximab, resulted in significantly lower or 
non-existent T-cell responses to targets with reduced expression of the protein. The 




regardless of EGFR density on target cell surface320, much like the responses 
observed for the four TEM8 CARs derived from high-affinity anti-TEM8 mAbs. 
 
The above observations support the recently introduced approach of CAR ‘affinity 
tuning’ – adjusting the affinity of the scFv domain so as to allow the CAR T-cells to 
efficiently recognise high levels of target expression on tumour tissue while sparing 
normal cells, which frequently express low levels of the target, from deleterious T-cell-
mediated toxicity. As suggested by the study described above320, the low affinity of the 
deriving antibody may in fact be the strength of the resultant CAR, which is 
subsequently much less likely to mediate on-target, off-tumour toxicity. Affinity tuning 
based on target antigen density has also been proposed elsewhere, supported by 
findings that high-affinity CAR T-cells recognise any level of expression of their target, 
including that which is undetectable by flow cytometry; low-affinity CARs, however, 
cause robust T-cell responses to high target antigen levels while sparing cells with 
physiological-level expression321,322. A tool for modelling T-cell antigen recognition has 
also been described which has found that low-affinity receptors perform better than 
high-affinity ones at high doses of target antigen323 – all of which suggests that the 1D2 
CAR is the most promising TEM8 CAR going forward, and that affinity tuning is an 
essential consideration for future CAR T-cell therapy. 
 
3.6.3 TEM8 expression on the surface of target cells 
CAR T-cell affinities notwithstanding, it is challenging to explain some of the highest 
cross-reactivity observed in the more potent TEM8 CARs, L1 and L2 CARs in 




CARs triggered very high T-cell responses to CHO-PR230 – a cell line which does not 
contain any human TEM8 mRNA (Figure 3.11) or express any appreciable levels of 
the corresponding protein by flow cytometry (Figure 3.12), and which has also 
previously proven to be TEM8-negative when tested by Western blotting246. Despite all 
this, CHO-PR230 has been shown to maintain low expression of full-length TEM8 by 
Northern blotting309, suggesting that the gene is expressed and therefore may be 
responsible for the recognition of this cell line by the most high-affinity CARs, L1 and 
L2. Another possibility is the expression of endogenous hamster TEM8 by CHO-PR230 
cells in vitro which, if similar enough to mouse TEM8 which L1 and L2 mAbs are both 
cross-reactive with, could also trigger responses in these CAR T-cells. Finally, it has 
previously been reported that human microvascular endothelial cells (HMEC) 
upregulate their in vitro TEM8 expression in response to serum deprivation212,246. It is 
possible that reaching confluence while growing in culture temporarily deprived CHO-
PR230 of optimal amounts of growth factors and induced cell stress, which in turn 
caused them to express endogenous TEM8. However, the fact that this has not been 
observed before for this cell line (Brad St Croix, personal communication), and that L1 
and L2 CARs consistently responded to CHO-PR230 to a high degree regardless of 
the confluency of the target cells or the level of exhaustion of their media, renders this 
unlikely. 
 
The CAR T-cell responses observed to other cell lines are mostly consistent with what 
is known about TEM8 expression on these target cells. HEK293T and MDA-MB-231 
both express low but detectable levels of human TEM8 protein, as observed both here 




explaining the responses of L1, L2, L3 and L5 CAR T-cells to them – and the absence 
of 1D2 CAR T-cell responses due to low target density. LS174T cells have been 
consistently identified as TEM8-negative (ref. 246 and Figure 3.12) and accordingly 
none of the CAR T-cells responded to this cell line, demonstrating that even high-
affinity CARs are not activated when their target is truly absent. The particularly high 
responses to HUVEC by four of the CARs, however, are still difficult to explain. Despite 
low-level TEM8 mRNA expression (Figure 3.11), corresponding protein expression is 
not detectable on these cells by flow cytometry (Figure 3.12). Even though serum 
starvation may induce in vitro TEM8 expression on HUVEC, especially since they are 
closely related to HMEC in which this has already been demonstrated212,246, it is 
unlikely that this would be the case as the cells were regularly passaged and fed to 
avoid exhaustion of the media. An interesting possibility, however, is that TEM8 is able 
to exist on the cell surface in different forms, depending on its interaction with 
components of the actin cytoskeleton – this can result in the protein being shielded 
from recognition by detection antibodies324. It is therefore possible that the L2 antibody 
used here for flow cytometric detection is only able to bind to a particular configuration 
of TEM8 which may not be the predominant one on the surface of HUVEC. In fact, the 
same study which reported the above finding also found TEM8 expression by reverse 
transcription PCR (RT-PCR) in HUVEC324, confirming the data described in this thesis 
and increasing the possibility of the TEM8 protein being present on these cells, even 
if it has not yet been detected. 
 
Interestingly, as this thesis was being written, a group working on a similar project to 




derived TEM8 CARs, focusing on the potential use of the CARs in triple-negative 
breast cancer (TNBC)325. Even though the range of target cells tested was not the 
same as the one presented here, there were some similarities allowing for comparisons 
to be drawn. For example, in the in vitro T-cell functional assays, both 2nd generation 
(CD28/CD3z) and 3rd generation (CD28/4-1BB/CD3z) L2 CARs secreted cytokines, 
proliferated and exhibited cytotoxicity in response to a range of TEM8-positive tumour 
endothelial and TNBC cell lines, including MDA-MB-231. This study reported that 
MDA-MB-231 was positive for TEM8 expression by flow cytometry, confirming our own 
data (Figure 3.12). They also demonstrated that endothelial cell lines including HUVEC 
were TEM8-negative by flow cytometry, but did not report whether their L2 CAR T-cells 
responded to HUVEC325. It was interesting to note, however, that the paper also 
showed that both 2nd and 3rd generation L2 CAR T-cells responded to b.END3, a 
murine brain tumour endothelial cell line which expressed very low or undetectable 
levels of TEM8 according to their flow cytometric analysis325. Another point of interest 
in the paper is that both CARs proliferated in response to low and high concentrations 
of recombinant TEM8 protein alike, with the 2nd generation CAR exhibiting almost 
equal proliferation at both concentrations. In fact, the 2nd generation L2 CAR exhibited 
stronger responses than its 3rd generation counterpart in all functional studies, which 
was suggested to be due to its lower activation threshold325. Taken together, and 
coupled to the data presented so far in this thesis, the findings strongly suggest that 
high-affinity CARs are able to detect and respond to exceedingly low levels of their 
target antigen, even when its expression is undetectable by flow cytometry, and that 





4 EXPLORATION OF IN VIVO TOXICITY AND ANTI-TUMOUR RESPONSE OF 
TEM8 CAR-ENGINEERED T-CELLS 
 
Having performed the in vitro studies and determined that TEM8 CAR T-cells 
successfully and strongly responded to TEM8 on a range of target cells, with the 1D2 
CAR especially selective for overexpression of the protein, it was necessary to 
examine their toxicity and anti-tumour effects in vivo. 1D2 was considered particularly 
promising of the five CARs precisely due to its consistently demonstrated specificity 
for high levels of surface-expressed TEM8, such as the ones that might be found on 
tumour vasculature. Cross-reactivity remained a concern with the other four CARs, 
however, rendering toxicity studies in healthy mice essential before any tumour 
challenge was also introduced. Even though pre-existing evidence argued against 
TEM8 expression on healthy mouse tissue, or indeed anywhere except on murine 
embryonic and tumour vasculature227,246, the data presented in the previous chapter 
meant that in vivo safety studies became the first priority. 
 
Depending on the mouse strain in the experiments described in this chapter – C57BL/6 
or NSG – murine or human CAR T-cells were used respectively. Murine T-cells were 
transduced with the CARs in a similar way to human T-cells (as described in section 
2.4.2) but often exhibited much higher levels of resultant CAR expression than their 
human counterparts, commonly being over 60% CD34+. If C57BL/6 mice were used, 
they were irradiated prior to CAR T-cell infusion to aid T-cell engraftment. The infused 




marker CD45.1, and could therefore be tracked in the circulation of C57BL/6 mice 
which express CD45.2 instead. 
 
4.1 Early in vivo study shows potential toxicity of L2 and L3 CARs 
In a pilot toxicity study in healthy C57BL/6 mice, mock, L1, L2, L3, L5 and 1D2 CAR T-
cells were injected into the tail vein of one mouse each with the intention of tracking 
their fate in the circulation by regular tail bleeds, and of monitoring the health of the 
mice over time by observation and weighing at regular intervals. The detailed 
preparation and injection procedure was described in section 2.6.2. Within the first hour 
of the T-cell injection, the mice were closely observed for post-infusion reactions but 
did not show any ill effects. Within the first 24h, however, L2 and L3 CAR-injected mice 
developed signs of toxicity, including general lethargy to a sufficiently high extent that 
the experienced animal technicians in the BMSU required the mice to be culled. All the 
other mice appeared healthy, but on the day of the first tail bleed the 1D2 CAR-injected 
mouse died suddenly during the bleeding procedure. This occurrence, though 
uncommon, had been documented previously in unrelated animal experiments and 
was not therefore considered to be caused by the CAR T-cell treatment. The remaining 
three mice were monitored over the following weeks but remained healthy and active, 
with their weight steadily growing over time after the initial drop commonly seen in mice 
following irradiation (Figure 4.1). 
 
The tail bleed data obtained from the three mice revealed that the total numbers of 
infused T-cells steadily rose over a period of four weeks, showing that they were 




population gradually dropped over time, however, which was in accordance with the 
host immune system being repopulated following the irradiation (Figure 4.2). This 
pattern was more pronounced in CD8 T-cells, which were present in higher numbers 
than their CD4 counterparts in the infused T-cell product. Interestingly, mock T-cells 
were much more numerous in the blood of the relevant mouse than L1 and L5 CAR T-
cells were in their respective mice. This could point towards the tendency of the host 
immune system to eliminate significant numbers of infused T-cells carrying TEM8 
CARs, or else show that many CAR T-cells had left the circulation early on. In fact, 
when only CD34+ T-cell numbers and proportions were examined in each CAR T-cell-
injected mouse over time, there seemed to be a selective deletion of this subset from 
the peripheral circulation (Figure 4.3). As noted before for human T-cells, mouse CD4 
T-cells transduced better than the CD8 subset, as evidenced by higher CD34 
expression within the infused CD4 T-cell population. However, for both L1 and L5 CAR 
T-cells, whether CD4 or CD8, CD34+ cells were virtually undetectable in the peripheral 
circulation of the mice by day 28. 
 
From the single tail bleed performed on the 1D2 CAR-injected mouse, it was very 
interesting to observe that the number of CD34+ T-cells in this population, as well as 
their proportion within infused T-cells, were both much higher than those recorded for 
L1 and L5 CAR T-cells in the same tail bleed (Figure 4.3). The data, however limited, 
pointed to 1D2 CAR T-cells being more able to persist at least in the circulation, and 
the lack of toxicity such as that observed in L2 and L3 CARs was very encouraging. 





Figure 4.1 – Mouse body weights over time in pilot CAR T-cell toxicity study in 
C57BL/6 mice 
Healthy, sublethally irradiated (4Gy) C57BL/6 mice were injected with 20x106 mock or 
CAR T-cells which were 55.0% (L1), 64.3% (L2), 39.9% (L3), 54.6% (L5) and 59.4% 
(1D2) CD34+ (one mouse per condition). L2 and L3 CAR-injected mice exhibited toxicity 
and were culled within the first 24h, and the 1D2 CAR-injected mouse died during the first 
tail bleed, leaving three mice in the experiment. These were weighed at regular intervals 
for 38 days after T-cell injection. 
  

























Figure 4.2 – Numbers of infused (CD45.1+) T-cells in mouse peripheral blood and 
their proportion of the total T-cell population over time in pilot CAR T-cell toxicity 
study in C57BL/6 mice 
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Healthy, sublethally irradiated (4Gy) C57BL/6 mice were injected with 20x106 mock or 
CAR T-cells which were 55% (L1), 64.3% (L2), 39.9% (L3), 54.6% (L5) and 59.4% (1D2) 
CD34+ (one mouse per condition). L2 and L3 CAR-injected mice exhibited toxicity and 
were culled within the first 24h, and the 1D2 CAR-injected mouse died during the first tail 
bleed, leaving three mice in the experiment. On days 3, 7 and 28 after T-cell injection, tail 
bleed samples were collected and stained with anti-CD45.1, anti-CD8, anti-CD4 and anti-
CD34 antibodies. Flow-count beads were included in the samples to calculate absolute T-
cell counts during flow cytometric analysis. The analysis was performed by gating on T-
cells, singlets, live cells and CD8/CD4 subsets sequentially, followed by CD45.1+ gating 
on each subset individually and on the two together. The data are presented as numbers 
of infused (CD45.1+) T-cells/mL blood, calculated using flow-count beads and 
corresponding tail bleed volumes, over time (left) or as % CD45.1+ T-cells in the CD8, CD4 






Figure 4.3 – Numbers of transduced (CD34+) CAR T-cells in mouse peripheral blood and their proportion of the infused 
T-cell population over time in pilot CAR T-cell toxicity study in C57BL/6 mice 
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Healthy, sublethally irradiated (4Gy) C57BL/6 mice were injected with 20x106 mock or CAR T-cells which were 55% (L1), 64.3% 
(L2), 39.9% (L3), 54.6% (L5) and 59.4% (1D2) CD34+ (one mouse per condition). L2 and L3 CAR-injected mice exhibited toxicity and 
were culled within the first 24h, and the 1D2 CAR-injected mouse died during the first tail bleed, leaving three mice in the experiment. 
On days 3, 7 and 28 after T-cell injection, tail bleed samples were collected and stained with anti-CD45.1, anti-CD8, anti-CD4 and 
anti-CD34 antibodies. Flow-count beads were included in the samples to calculate absolute T-cell counts during flow cytometric 
analysis. The analysis was performed by gating on T-cells, singlets, live cells and CD8/CD4 subsets sequentially, followed by CD45.1+ 
gating on each subset individually and on the two together. Each CD45.1+ gate was then examined further by gating on CD34+ T-
cells. The data are presented as numbers of transduced (CD34+) T-cells/mL blood, calculated using flow-count beads and 
corresponding tail bleed volumes, over time (top) or as % CD34+ T-cells in the infused (CD45.1+) fraction of CD8, CD4 or both CD8 
and CD4 T-cell subsets together over time (bottom). In the bottom graphs, % CD34+ values on day 0 correspond to the CAR 
transduction levels of mouse T-cells immediately prior to T-cell infusion. Tail bleed data obtained from the 1D2 CAR-injected mouse 





4.2 1D2 CAR T-cells persist in the peripheral circulation of healthy mice while 
other CARs are selectively removed from it 
The toxicity study that followed the pilot one focused on repeating the same 
experimental setup as before in a larger group of mice while being careful to account 
for the possibility of repeated toxicity. An additional control was also introduced – a ‘no 
scFv’ CAR – where the T-cells were transduced with a CAR that lacked the scFv 
domain, and was therefore not specific for any given antigen. This was used to assess 
whether any effects seen were dependent on the specific TEM8-binding domain of the 
CAR construct. 
 
In the study, healthy male C57BL/6 mice were injected with mock, ‘no scFv’ CAR- or 
one of five TEM8 CAR-transduced T-cells as before. Two mice were injected with each 
CAR T-cell treatment apart from L2 and L3 CARs, which were given only to one mouse 
each due to previously observed toxicity. This time, however, none of the mice 
developed overt toxicity reactions within the first 24h or for the entire duration of the 
experiment. Except for the usual drop in weight in the first few days following 
irradiation, the mice were active and healthy and for the most part steadily gained 
weight over time (Figure 4.4). The smaller of the two ‘no scFv’ CAR-injected mice 
never fully gained its initial weight back and was transiently unwell several days into 
the experiment, however it recovered quickly and exhibited no further symptoms of 
distress. The staff in charge of animal welfare observed that this occasionally 
happened in the animals regardless of their treatment and did not consider it a cause 





Tail bleeds were performed on all mice at regular intervals and, as before, it was noted 
that CD8 T-cells were present in higher numbers and proportions in all the infused T-
cell populations (Figure 4.5). The number of infused mock T-cells rose over time while 
the CAR T-cell numbers remained relatively steady, but their proportion of the total T-
cell population gradually dropped in all the treated mice as the host immune systems 
recovered once again. Even though this indicated that the injected T-cells persisted 
well in the peripheral circulation, focusing on the CAR-expressing (CD34+) subset of 
each T-cell population yielded a very interesting pattern once more. The proportions of 
CD34+ T-cells within the infused cell populations showed that all but ‘no scFv’, 1D2 
and, interestingly, L2 CAR T-cells were almost completely undetectable at day 21 
(Figure 4.6). As consistently observed before, the CD34+ % was higher in the CD4 
than the CD8 T-cell subset for all CARs examined, and in the case of L2 CAR T-cells, 
their persistence at day 21 was only apparent in the CD4 compartment; the CD8 CD34+ 
% was comparatively very low. This was in contrast to the persistence of 1D2 and ‘no 
scFv’ CAR T-cells, which was clearly present in both T-cell subsets. 
 
Taken together, the data indicated that 1D2 CAR T-cells persisted in the peripheral 
circulation when all the other TEM8 CARs were selectively removed from it. The 
presence of L2 CAR-expressing CD4 T-cells was also of note, although previously 
observed toxicity and the clear elimination of the cytotoxic CD8 T-cell compartment in 
the L2 CD34+ T-cell population suggested that these T-cells were also susceptible to 
deletion from the periphery. The persistence of the non-antigen-specific CAR 




that this effect was dependent on the scFv moiety present and, possibly, to its affinity 
for the target antigen. 
 
The fact that no mice in the study succumbed to toxicity, and that tail bleeds were 
therefore carried out on all of them, afforded the opportunity to explore the cytokines 
secreted by the injected T-cells. The rapidity of onset of the toxicity reaction in the 
previous experiment bore the hallmarks of CRS, and although the mice in this study 
showed no macroscopic signs of it, the first two tail bleeds (taken on days 4 and 9 post 
T-cell injection) were analysed for the presence of cytokines to explore the possibility 
of occult T-cell responses. Mouse plasma samples were assayed for a panel of 26 
cytokines as described in section 2.6.6, and the results obtained for the ones most 
relevant to mouse CRS307,326–328 are shown in Figure 4.7. On day 4, the plasma 
samples from the mice injected with L2 and L3 CARs both showed detectable levels 
of IFNg, IL-5 and to a lesser extent IL-6, although these all dropped or were completely 
undetectable by day 9. Even though TNFa and IL-2 were not recorded in any of the 
samples, the presence of IFNg and IL-6 (both of which have been strongly correlated 
with CRS in other studies) in the two CAR T-cell treatments which previously showed 







Figure 4.4 – Mouse body weights over time in second CAR T-cell toxicity study 
in C57BL/6 mice 
Healthy, sublethally irradiated (5Gy) C57BL/6 mice were injected with 18-25x106 mock 
or CAR T-cells which were 76.9% (no scFv), 80.7% (L1), 85.1% (L2), 80.0% (L3), 70.1% 
(L5) and 83.5% (1D2) CD34+ (two mice per condition, except for mock, L2 CAR and L3 
CAR T-cells – one mouse per condition). The mice were weighed at regular intervals for 
21 days after T-cell injection. 
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Figure 4.5 – Numbers of infused (CD45.1+) T-cells in mouse peripheral blood and their proportion of the total T-cell 
population over time in second CAR T-cell toxicity study in C57BL/6 mice 
Healthy, sublethally irradiated (5Gy) C57BL/6 mice were injected with 18-25x106 mock or CAR T-cells which were 76.9% (no 
scFv), 80.7% (L1), 85.1% (L2), 80.0% (L3), 70.1% (L5) and 83.5% (1D2) CD34+ (two mice per condition, except for mock, L2 CAR 
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and L3 CAR T-cells – one mouse per condition). On days 4, 9, 15 and 21 after T-cell injection, tail bleed samples were collected and 
stained with anti-CD45.1, anti-CD8, anti-CD4 and anti-CD34 antibodies. Flow-count beads were included in the samples to calculate 
absolute T-cell counts during flow cytometric analysis. The analysis was performed by gating on T-cells, singlets, live cells and 
CD8/CD4 subsets sequentially, followed by CD45.1+ gating on each subset individually and on the two together. The data are 
presented as numbers of infused (CD45.1+) T-cells/mL blood, calculated using flow-count beads and corresponding tail bleed 
volumes, over time (top) or as % CD45.1+ T-cells in the CD8, CD4 or both CD8 and CD4 T-cell subsets together over time (bottom). 






Figure 4.6 – Numbers of transduced (CD34+) CAR T-cells in mouse peripheral blood and their proportion of the infused 
T-cell population over time in second CAR T-cell toxicity study in C57BL/6 mice 
Healthy, sublethally irradiated (5Gy) C57BL/6 mice were injected with 18-25x106 mock or CAR T-cells which were 76.9% (no 
scFv), 80.7% (L1), 85.1% (L2), 80.0% (L3), 70.1% (L5) and 83.5% (1D2) CD34+ (two mice per condition, except for mock, L2 CAR 
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and L3 CAR T-cells – one mouse per condition). On days 4, 9, 15 and 21 after T-cell injection, tail bleed samples were collected and 
stained with anti-CD45.1, anti-CD8, anti-CD4 and anti-CD34 antibodies. Flow-count beads were included in the samples to calculate 
absolute T-cell counts during flow cytometric analysis. The analysis was performed by gating on T-cells, singlets, live cells and 
CD8/CD4 subsets sequentially, followed by CD45.1+ gating on each subset individually and on the two together. Each CD45.1+ gate 
was then examined further by gating on CD34+ T-cells. The data are presented as numbers of transduced (CD34+) T-cells/mL blood, 
calculated using flow-count beads and corresponding tail bleed volumes, over time (top) or as % CD34+ T-cells in the infused 
(CD45.1+) fraction of CD8, CD4 or both CD8 and CD4 T-cell subsets together over time (bottom). In the bottom graphs, % CD34+ 
values on day 0 correspond to the CAR transduction levels of mouse T-cells immediately prior to T-cell infusion. Where there were 






Figure 4.7 – Levels of selected cytokines measured in the plasma of C57BL/6 
mice on days 4 and 9 of the second CAR T-cell toxicity study 
Healthy, sublethally irradiated (5Gy) C57BL/6 mice were injected with 18-25x106 mock 
or CAR T-cells which were 76.9% (no scFv), 80.7% (L1), 85.1% (L2), 80.0% (L3), 70.1% 
(L5) and 83.5% (1D2) CD34+ (two mice per condition, except for mock, L2 CAR and L3 
CAR T-cells – one mouse per condition). On days 4, 9, 15 and 21 after T-cell injection, tail 
bleed samples were collected and the plasma from the first two stored for analysis. Day 4 
and 9 plasma samples were subsequently analysed in a mouse multiplex cytokine assay 
for a panel of 26 cytokines, nine of which were considered most strongly correlated with 
cytokine release syndrome and are shown here. Cytokine quantities were calculated in 
pg/mL of plasma. Where there were two mice per treatment group, the data points are 


















































































































































4.3 L2 CAR T-cells cause toxicity in healthy NSG mice 
The promising in vivo persistence and safety data obtained with 1D2 CAR T-cells, and 
the potential for toxicity in the most highly TEM8-responsive (but also most cross-
reactive) L2 CAR, prompted further investigation of these two CAR T-cell products in 
particular. In order to test the safety of maximising the infused CAR T-cell dose, healthy 
NSG mice were to be injected intravenously with three doses of 20x106 L2, 1D2 or ‘no 
scFv’ CAR T-cells each on days 0, 5 and 9 of the study (three mice per treatment 
group). NSG mice were chosen due to the absence of an endogenous immune system 
and the consequent possibility of injecting them with human T-cells which, unlike 
murine ones, could be expanded in vitro to large enough numbers for multiple 
infusions.  However, less than 24h after the first T-cell dose, all three L2 CAR-injected 
mice exhibited symptoms of toxicity – significantly reduced levels of activity, hunched 
posture, ruffled appearance and general lethargy. Experienced animal technicians in 
the BMSU agreed that these needed to be culled immediately. The 1D2 and ‘no scFv’ 
CAR-injected mice, however, appeared healthy and did not exhibit any adverse events 
even after the second and third dose of CAR T-cells. They remained active and steadily 
gained weight until the end of the experiment on day 16 (Figure 4.8). 
 
Even though tail bleed data could not be obtained for the mice treated with the L2 CAR, 
the data from the rest of the mice indicated that both 1D2 and ‘no scFv’ CAR T-cells 
were able to persist and increase in number in the peripheral circulation over the 
course of the experiment, although naturally some of this effect may reflect the 
repeated infusions (Figure 4.9). Focusing only on the CD34+ fraction of the infused T-




to using human T-cells, a similar pattern of 1D2 CAR T-cell persistence was observed 
once again (Figure 4.10). Even though absolute CD34+ T-cell numbers were variable 
in the ‘no scFv’ CAR-infused mouse group, CD34+ T-cell proportions of the total infused 
populations remained reasonably constant for both 1D2 and ‘no scFv’ CARs. This 
pattern was apparent in both CD8 and CD4 T-cell subsets and reinforced once again 
the in vivo persistence of the 1D2 CAR. 
 
In an attempt to examine the toxicity caused by L2 CAR T-cells more closely, major 
organs were harvested from all three treated mice immediately after their culling and 
the resulting organ sections compared to those obtained from 1D2 and ‘no scFv’ CAR-
injected mice following the end of the experiment. Despite the clearly observable 
toxicity in the L2 CAR-infused mice during the experiment, none of their organs showed 
pathology or differed in appearance to the organs of mice injected with 1D2 or ‘no scFv’ 
CARs (Figure 4.11). Subsequent analyses focused on the T-cells that had been 
prepared for infusion into the mice. The cells were tested in vitro for IFNg release to 
titrating concentrations of recombinant human TEM8, where L2 CAR T-cells showed a 
much higher avidity for the target protein compared to 1D2 CAR T-cells (Figure 4.12A). 
This once again raised the possibility that L2 CAR T-cells recognised low-level TEM8 
expressed on healthy mouse tissue leading to a toxic response whereas 1D2 CAR T-
cells were unable to detect it, even though it was not yet clear which tissue(s) this might 
be. At the same time, both L2 and 1D2 CAR T-cells were shown to respond specifically 
to cellular targets overexpressing TEM8 in vitro, but L2 CAR T-cells also showed strong 
responses to other cell lines that appeared to express relatively little or no TEM8 




mice, namely that L2 CAR T-cells were responding to a target other than TEM8 present 





Figure 4.8 – Mouse body weights over time in multiple infusion CAR T-cell 
toxicity study in NSG mice 
On day 0, healthy NSG mice were injected with 20x106 L2, 1D2 or ‘no scFv’ CAR T-cells 
which were 21.8% (no scFv), 21.3% (L2) and 24.5% (1D2) CD34+ (three mice per 
condition). All three L2 CAR-injected mice exhibited toxicity and were culled within the first 
24h. The remaining mice were injected as before with two more T-cell doses on days 5 
and 9 (represented by black arrows on the graph). The mice were weighed at regular 
intervals for 16 days after the first T-cell injection. 
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Figure 4.9 – Numbers of infused T-cells in mouse peripheral blood over time in 
multiple infusion CAR T-cell toxicity study in NSG mice 
On day 0, healthy NSG mice were injected with 20x106 L2, 1D2 or ‘no scFv’ CAR T-cells 
which were 21.8% (no scFv), 21.3% (L2) and 24.5% (1D2) CD34+ (three mice per 
condition). All three L2 CAR-injected mice exhibited toxicity and were culled within the first 
24h. The remaining mice were injected as before with two more T-cell doses on days 5 
and 9. On days 5, 9 and 13 after the first T-cell injection, tail bleeds were performed (prior 
to T-cell infusions if these were happening on the same day), and the samples stained 
with anti-CD8, anti-CD4 and anti-CD34 antibodies. Flow-count beads were included in the 
samples to calculate absolute T-cell counts during flow cytometric analysis. The analysis 
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was performed by gating on T-cells, singlets, live cells and CD8/CD4 subsets sequentially. 
The data are presented as numbers of infused T-cells/mL blood, calculated using flow-
count beads and corresponding tail bleed volumes, over time in ‘no scFv’ CAR- (top) or 






Figure 4.10 – Numbers of transduced (CD34+) CAR T-cells in mouse peripheral blood and their proportion of the total 
infused T-cell population over time in multiple infusion CAR T-cell toxicity study in NSG mice 
On day 0, healthy NSG mice were injected with 20x106 L2, 1D2 or ‘no scFv’ CAR T-cells which were 21.8% (no scFv), 21.3% (L2) 
and 24.5% (1D2) CD34+ (three mice per condition). All three L2 CAR-injected mice exhibited toxicity and were culled within the first 
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24h. The remaining mice were injected as before with two more T-cell doses on days 5 and 9. On days 5, 9 and 13 after the first T-
cell injection, tail bleeds were performed (prior to T-cell infusions if these were happening on the same day), and the samples stained 
with anti-CD8, anti-CD4 and anti-CD34 antibodies. Flow-count beads were included in the samples to calculate absolute T-cell counts 
during flow cytometric analysis. The analysis was performed by gating on T-cells, singlets, live cells and CD8/CD4 subsets 
sequentially, then examined further by gating on CD34+ T-cells in each subset separately and the two together. The data are 
presented as numbers of transduced (CD34+) T-cells/mL blood, calculated using flow-count beads and corresponding tail bleed 
volumes, over time (top) or as % CD34+ T-cells in the infused fraction of CD8, CD4 or both CD8 and CD4 T-cell subsets together 
over time (bottom). In the bottom graphs, % CD34+ values on day 0 correspond to the CAR transduction levels of human T-cells 









Figure 4.11 – Representative tissue sections from NSG mice in the multiple 
infusion CAR T-cell toxicity study 
On day 0, healthy NSG mice were injected with 20x106 L2, 1D2 or ‘no scFv’ CAR T-cells 
which were 21.8% (no scFv), 21.3% (L2) and 24.5% (1D2) CD34+ (three mice per 
condition). All three L2 CAR-injected mice exhibited toxicity and were culled within the first 
24h. The remaining mice were injected as before with two more T-cell doses on days 5 
and 9. Major mouse organs were harvested from L2 CAR-injected mice following their 
culling and from the rest of the mice at the end of the experiment, fixed in formalin and 
sectioned before being stained using haematoxylin and eosin (H&E) and examined for 
histopathology. The sections were imaged at 10X magnification on a brightfield 






Figure 4.12 – In vitro hTEM8 and target cell responses by CAR T-cells used in 
multiple infusion CAR T-cell toxicity study in NSG mice 
(A) L2, 1D2 or ‘no scFv’ CAR-transduced T-cells used in the multiple infusion CAR T-
cell toxicity study were incubated in a 96-well plate overnight at 5x104 cells/well with 
decreasing concentrations of human recombinant TEM8-extracellular domain 
(hTEM8-ED). Supernatants were assayed by IFNg ELISA the following day and the 
resulting T-cell IFNg production expressed in pg/mL. All data points were measured in 
triplicate and expressed as mean ± SD. (B) The same T-cells as in A were incubated 
alone or with indicated target cells (2x104 cells/well) in a 96-well plate overnight and 




expressed as mean + SD. The levels of response to CHO-TEM8 compared to those to 
CHO-PR230 were significantly higher for both L2 and 1D2 CAR T-cells (**, P<0.01; 
***, P<0.001), as measured by Student’s t-test and corrected for multiple comparisons 




4.4 L2 CAR T-cells potentially target low-level TEM8 expression on healthy 
mouse tissue 
To help ascertain the underlying cause of the observed toxicity in L2 CAR-injected 
mice, TEM8 KO mice on C57BL/6 background were obtained as described in section 
2.6.1. They were injected with L2, 1D2 or ‘no scFv’ CAR T-cells alongside their 
C57BL/6 WT counterparts (two mice per group), with an additional WT mouse injected 
with mock T-cells as a further control. It was reasoned that, if toxicity arose in L2 CAR-
infused WT mice, but not TEM8 KO mice, it could be concluded with reasonable 
certainty that this was due to L2 CAR T-cells responding to TEM8 expressed on healthy 
mouse tissue(s) or vasculature. If, however, the adverse reactions were to occur in 
both WT and KO mice, cross-reactivity of the L2 CAR with an unrelated protein would 
be the most likely explanation. 
 
In this experiment, unlike the previous one, no toxicity was observed in any of the 
treated mice. They all appeared active and did not exhibit signs of lethargy or acute 
illness. The only exception was one of the TEM8 KO mice injected with ‘no scFv’ CAR 
T-cells which developed a very sore and bulging left eye within 12h of the injection, 
which grew progressively worse over the next two days. The animal was considered 
to be in distress and pain and was therefore culled on the second day after the T-cell 
infusion. This adverse effect was entirely unforeseen and, although it could not be 
adequately explained, it appeared to be related to the KO phenotype – soon after the 
first mouse, two more TEM8 KO mice developed the same sore and bulging eye, one 
of which was injected with L2 and the other with 1D2 CAR T-cells. In these two mice, 




of close observation, the affected eye of each mouse returned to its normal size, but it 
had also developed a cloudy appearance resembling a cataract. Both mice seemed 
otherwise healthy and their weight, like that of the rest of the mice, either increased or 
remained stable until the experiment ended (Figure 4.13). Nevertheless, their affected 
eyes remained cloudy for the duration of the study. 
 
Tail bleeds were performed during the experiment to track the fate of the injected T-
cells in the peripheral circulation of all the mice. This revealed once more their 
proliferation and expansion over time and the decrease in their proportion of the total 
T-cell population as the host immune systems were gradually restored after irradiation 
(Figure 4.14). The absolute numbers of mock and ‘no scFv’ CAR T-cells in the 
circulation were always higher than those of 1D2 and especially L2 CAR T-cells in both 
CD8 and CD4 compartments, regardless of whether the mice were WT or TEM8 KO. 
This once again highlighted the tendency of the antigen-specific CARs to be eliminated 
early on after the T-cell injection, which was further confirmed by the CD34+ T-cell data. 
This showed the familiar pattern of mock and ‘no scFv’ CAR T-cells persisting in the 
circulation over time, 1D2 CAR T-cells still being present at similar levels in both WT 
and KO mice, and L2 CAR T-cells being virtually undetectable in WT mice by day 13 
(Figure 4.15). It was very interesting to observe, however, that unlike in WT mice, L2 
CAR T-cells persisted in TEM8 KO mice to a considerable degree. The difference in 
numbers and proportions of CD34+ T-cells between TEM8 KO mice and their WT 
counterparts was particularly striking on day 6 of the experiment, although it was still 
pronounced on day 13. This led to the conclusion that, while overt toxicity was not 




eliminated from the mouse circulation possibly due to the recognition of a target which 
was not present in TEM8 KO mice. While this result does not entirely eliminate the 
possibility of L2 CAR T-cells cross-reacting with an unrelated antigen, it does provide 
evidence that their loss from the circulation is largely a result of recognising TEM8 
expressed on healthy mouse tissue(s). 
 
Consistent with the absence of symptoms of CRS in the mice, multiplex cytokine 
analysis of mouse plasma samples from days 1 and 6 of the experiment revealed no 
upregulated cytokine levels, except IL-1b which was present in all the mice to a similar 
degree (Figure 4.16). Apart from this, and very small amounts of IL-5 detected in some 
plasma samples, there was no evidence of any significant cytokine response having 






Figure 4.13 – Mouse body weights over time in CAR T-cell toxicity study in 
C57BL/6 WT and TEM8 KO mice 
Healthy, sublethally irradiated (4Gy) C57BL/6 WT or TEM8 KO mice were injected with 
13x106 mock or CAR T-cells which were 93.4% (no scFv), 91.2% (L2) and 93.7% (1D2) 
CD34+ (two WT and two KO mice per condition, except for one WT mouse injected with 
mock T-cells). One of each of the TEM8 KO mice injected with L2, 1D2 and ‘no scFv’ CAR 
T-cells exhibited ocular toxicity, and the ‘no scFv’ CAR-injected KO mouse (mouse 2.5) 
was culled on day 2, leaving only mouse 2.3 in this treatment group. The mice were 
weighed at regular intervals for 17 days after T-cell injection. 
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Figure 4.14 – Numbers of infused (CD45.1+) T-cells in mouse peripheral blood and their proportion of the total T-cell 
population over time in CAR T-cell toxicity study in C57BL/6 WT and TEM8 KO mice 
Healthy, sublethally irradiated (4Gy) C57BL/6 WT or TEM8 KO mice were injected with 13x106 mock or CAR T-cells which were 
93.4% (no scFv), 91.2% (L2) and 93.7% (1D2) CD34+ (two WT and two KO mice per condition, except for one WT mouse injected 
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with mock T-cells). One of each of the TEM8 KO mice injected with L2, 1D2 and ‘no scFv’ CAR T-cells exhibited ocular toxicity, and 
the ‘no scFv’ CAR-injected KO mouse was culled on day 2, leaving only one mouse in this treatment group. On days 6 and 13 after 
T-cell injection, tail bleed samples were collected and stained with anti-CD45.1, anti-CD8, anti-CD4 and anti-CD34 antibodies. Flow-
count beads were included in the samples to calculate absolute T-cell counts during flow cytometric analysis. The analysis was 
performed by gating on T-cells, singlets, live cells and CD8/CD4 subsets sequentially, followed by CD45.1+ gating on each subset 
individually and on the two together. The data are presented as numbers of infused (CD45.1+) T-cells/mL blood, calculated using 
flow-count beads and corresponding tail bleed volumes, over time (top) or as % CD45.1+ T-cells in the CD8, CD4 or both CD8 and 
CD4 T-cell subsets together over time (bottom). Where there were two mice per treatment, the data points are expressed as mean 






Figure 4.15 – Numbers of transduced (CD34+) CAR T-cells in mouse peripheral blood and their proportion of the infused 
T-cell population over time in CAR T-cell toxicity study in C57BL/6 WT and TEM8 KO mice 
Healthy, sublethally irradiated (4Gy) C57BL/6 WT or TEM8 KO mice were injected with 13x106 mock or CAR T-cells which were 
93.4% (no scFv), 91.2% (L2) and 93.7% (1D2) CD34+ (two WT and two KO mice per condition, except for one WT mouse injected 
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with mock T-cells). One of each of the TEM8 KO mice injected with L2, 1D2 and ‘no scFv’ CAR T-cells exhibited ocular toxicity, and 
the ‘no scFv’ CAR-injected KO mouse was culled on day 2, leaving only one mouse in this treatment group. On days 6 and 13 after 
T-cell injection, tail bleed samples were collected and stained with anti-CD45.1, anti-CD8, anti-CD4 and anti-CD34 antibodies. Flow-
count beads were included in the samples to calculate absolute T-cell counts during flow cytometric analysis. The analysis was 
performed by gating on T-cells, singlets, live cells and CD8/CD4 subsets sequentially, followed by CD45.1+ gating on each subset 
individually and on the two together. Each CD45.1+ gate was then examined further by gating on CD34+ T-cells. The data are 
presented as numbers of transduced (CD34+) T-cells/mL blood, calculated using flow-count beads and corresponding tail bleed 
volumes, over time (top) or as % CD34+ T-cells in the infused (CD45.1+) fraction of CD8, CD4 or both CD8 and CD4 T-cell subsets 
together over time (bottom). In the bottom graphs, % CD34+ values on day 0 correspond to the CAR transduction levels of mouse T-
cells immediately prior to T-cell infusion. Where there were two mice per treatment, the data points are expressed as mean ± SD. 






Figure 4.16 – Levels of selected cytokines measured in the plasma of C57BL/6 
WT and TEM8 KO mice on days 1 and 6 of the CAR T-cell toxicity study 
Healthy, sublethally irradiated (4Gy) C57BL/6 WT or TEM8 KO mice were injected with 
13x106 mock or CAR T-cells which were 93.4% (no scFv), 91.2% (L2) and 93.7% (1D2) 
CD34+ (two WT and two KO mice per condition, except for one WT mouse injected with 
mock T-cells). One of each of the TEM8 KO mice injected with L2, 1D2 and ‘no scFv’ CAR 
T-cells exhibited ocular toxicity, and the ‘no scFv’ CAR-injected KO mouse was culled on 
day 2, leaving only one mouse in this treatment group. On days 1 and 6 after T-cell 
injection, tail bleed samples were collected and the plasma stored for analysis. The 
plasma samples were subsequently analysed in a mouse multiplex cytokine assay for a 
panel of 26 cytokines, nine of which were considered most strongly correlated with 
cytokine release syndrome and are shown here. Cytokine quantities were calculated in 
pg/mL of plasma. Where there were two mice per treatment group, the data points are 
expressed as mean ± SD. 




















































































































































































































































































































4.5 1D2 CAR T-cells are not tumour-protective in a pilot study in NSG mice 
Throughout the CAR safety studies described in preceding sections, L2 CAR T-cells 
injected into healthy WT mice showed a clear potential for toxicity or, if not toxic, mostly 
failed to persist in the peripheral circulation over time. Even though the early toxicity of 
L3 CAR T-cells observed in the pilot safety study was not seen again, the CAR-
expressing fraction of these cells also failed to persist when examined further, along 
with L1 and L5 CAR T-cells. The 1D2 CAR was the only TEM8 CAR which was 
consistently safe and detected in the circulation at the end of each experiment, making 
it the most promising candidate for mouse tumour protection studies. 1D2 CAR T-cells 
were therefore tested against a colorectal carcinoma xenograft, DLD-1, which was 
itself TEM8-negative but had been shown previously to generate a TEM8-positive 
tumour vasculature in vivo246. As all CARs were derived from antibodies which were 
fully cross-reactive with both human and mouse TEM8, it was anticipated that 1D2 
CAR T-cells could respond to mTEM8 on mouse tumour vasculature and lead to 
tumour control or regression. 
 
In a pilot anti-tumour study, six NSG mice received subcutaneous flank injections of 
DLD-1 cells as described in section 2.6.4, and three days later half of them were 
injected with 1D2 CAR T-cells while the other half received ‘no scFv’ CAR T-cell 
controls. The mice had no adverse reactions to the T-cell treatment, with their weights 
being mostly steady throughout the experiment (Figure 4.17), and the tail bleeds 
performed showed expansion of infused T-cells (Figure 4.18) as well as persistence 
of the CD34+ fraction in both CAR T-cell products over time (Figure 4.19). Despite this, 




no effect on tumour growth compared to the ‘no scFv’ CAR controls (Figure 4.20A). 
Even though the individual tumour volumes of 1D2 CAR-treated mice were somewhat 
lower than those observed in their control-treated counterparts (Figure 4.20B), the 
overall difference between the two groups was not significant. Therefore, an 







Figure 4.17 – Mouse body weights over time in DLD-1 tumour protection study 
in NSG mice 
On day 0, six healthy NSG mice were injected subcutaneously into the flank with 
2.5x106 DLD-1 colorectal carcinoma cells each. On day 3, they were each injected with 
20x106 1D2 or ‘no scFv’ CAR T-cells which were 20.0% (no scFv) and 23.2% (1D2) CD34+ 
(three mice per treatment group). The mice were weighed at regular intervals for 15 days 
after tumour cell injection. 
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Figure 4.18 – Numbers of infused T-cells in mouse peripheral blood over time in 
DLD-1 tumour protection study in NSG mice 
On day 0, six healthy NSG mice were injected subcutaneously into the flank with 
2.5x106 DLD-1 colorectal carcinoma cells each. On day 3, they were each injected with 
20x106 1D2 or ‘no scFv’ CAR T-cells which were 20.0% (no scFv) and 23.2% (1D2) CD34+ 
(three mice per treatment group). On days 5 and 12 after T-cell injection, tail bleed samples 
were collected and stained with anti-CD8, anti-CD4 and anti-CD34 antibodies. Flow-count 
beads were included in the samples to calculate absolute T-cell counts during flow 
cytometric analysis. The analysis was performed by gating on T-cells, singlets, live cells 
and CD8/CD4 subsets sequentially. The data are presented as numbers of infused T-
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cells/mL blood, calculated using flow-count beads and corresponding tail bleed volumes, 
over time in ‘no scFv’ CAR- (top) or 1D2 CAR-injected mice (bottom). The data points are 






Figure 4.19 – Numbers of transduced (CD34+) CAR T-cells in mouse peripheral blood and their proportion of the total 
infused T-cell population over time in DLD-1 tumour protection study in NSG mice 
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On day 0, six healthy NSG mice were injected subcutaneously into the flank with 2.5x106 DLD-1 colorectal carcinoma cells each. 
On day 3, they were each injected with 20x106 1D2 or ‘no scFv’ CAR T-cells which were 20.0% (no scFv) and 23.2% (1D2) CD34+ 
(three mice per treatment group). On days 5 and 12 after T-cell injection, tail bleed samples were collected and stained with anti-CD8, 
anti-CD4 and anti-CD34 antibodies. Flow-count beads were included in the samples to calculate absolute T-cell counts during flow 
cytometric analysis. The analysis was performed by gating on T-cells, singlets, live cells and CD8/CD4 subsets sequentially, then 
examined further by gating on CD34+ T-cells in each subset separately and the two together. The data are presented as numbers of 
transduced (CD34+) T-cells/mL blood, calculated using flow-count beads and corresponding tail bleed volumes, over time (top) or as 
% CD34+ T-cells in the infused fraction of CD8, CD4 or both CD8 and CD4 T-cell subsets together over time (bottom). In the bottom 
graphs, % CD34+ values on day 0 correspond to the CAR transduction levels of human T-cells immediately prior to T-cell infusion. 






Figure 4.20 – Tumour volumes measured in mice over time in DLD-1 tumour 
protection study 
On day 0, six healthy NSG mice were injected subcutaneously into the flank with 
2.5x106 DLD-1 colorectal carcinoma cells each. On day 3, they were each injected with 
20x106 1D2 or ‘no scFv’ CAR T-cells which were 20.0% (no scFv) and 23.2% (1D2) CD34+ 
(three mice per treatment group). Tumour size was monitored by regular calliper 




group, with data points expressed as mean ± SD, and as (B) individual tumour volume 
measurements in each mouse. In A, the difference in mean tumour volume between 
the two treatment groups was not significant at any time point, as measured by two-
way analysis of variance (ANOVA) with repeated measures by columns (time points) 





4.6 1D2 CAR T-cells do not respond to mouse TEM8 
Even though the five anti-TEM8 mAbs that were used to generate CARs bound to both 
human and mouse TEM8 in their original, Fab form, the affinity of 1D2 for hTEM8 was 
markedly lower than that of the other four antibodies. Furthermore, while the affinities 
of the rest of the mAbs for hTEM8 and mTEM8 were very similar, that of 1D2 for 
mTEM8 was four times lower than its affinity for the human version of the protein246. 
Because of this, and the apparent lack of tumour protective function of 1D2 CAR T-
cells, they were tested in vitro for responses to both human and mouse TEM8. 
 
In a repeat of the IFNg ELISA assay, HEK293 cells engineered to express mTEM8 or 
hTEM8 on their surface were included as targets, alongside parent HEK293 cells, 
CHO-PR230 and CHO-TEM8. The previously observed pattern of cross-reactivity of 
all but 1D2 CAR T-cells with CHO-PR230 and HEK293 was seen once again, but all 
CARs showed a specific response to human TEM8 over the control when 
overexpressed in CHO cells (Figure 4.21A). On the other hand, responses to both 
human and mouse TEM8 expressed in HEK293 cells were less clear, largely due to 
the high background response to HEK293 cells alone. 1D2 CAR T-cells did show a 
weak but clear response to human TEM8, but had no response above background to 
HEK293 cells expressing mouse TEM8. Even when they were not diluted with mock 
T-cells in order to equalise their CAR transduction levels with that of the other four, the 
levels of IFNg release to the mTEM8-expressing cell line were the same as those 
observed in the mock T-cell population (Figure 4.21B). Similar results were observed 
in a chromium release assay, where all five CARs mediated human TEM8-specific 




levels of lysis to HEK293 cells, even with mock T-cells (Figure 4.22). When tested 
against decreasing concentrations of recombinant hTEM8 or mTEM8 in another IFNg 
ELISA (Figure 4.23), all CAR T-cells responded to hTEM8, some of them even 
exhibiting saturation and decrease in IFNg release above a certain protein 
concentration. However, while all the other CARs also responded to mTEM8, 1D2 CAR 
T-cells exhibited extremely low or undetectable IFNg responses even at the highest 
concentration of the mouse protein; this was true of both 1D2 CAR T-cells equalised 






Figure 4.21 – TEM8 CAR T-cell IFNg release in response to hTEM8 and mTEM8-
expressing target cells 
Mock or TEM8 CAR-transduced T-cells (2x105 cells/well) were incubated alone or with 
indicated target cells (2x104 cells/well) in a 96-well plate overnight. In (A), all CAR T-
cells were equalised for CAR transduction efficiency by being diluted with appropriate 
amounts of mock T-cells, as normally done for all functional assays. In (B), 1D2 CAR 
T-cells undiluted with mock T-cells were also tested at the same time. Following the 
overnight incubation, supernatants were assayed by IFNg ELISA and the resulting T-
cell IFNg production expressed in pg/mL. All data points were measured in triplicate 
and expressed as mean + SD. 
  





































Figure 4.22 – Specific cytotoxicity of TEM8 CAR T-cells in response to hTEM8- 
and mTEM8-expressing target cells 
Mock or TEM8 CAR-transduced T-cells were incubated at decreasing effector:target 
(E:T) ratios with indicated chromium-labelled target cells (2.5x103 target cells/well of a 
96-well plate), and supernatants harvested and analysed for released chromium after 
12 hours. % specific lysis for each target was calculated from spontaneous (targets 
alone) and maximum lysis values (targets incubated with 1% sodium dodecyl-























































































Figure 4.23 – TEM8 CAR T-cell IFNg release in response to decreasing 
concentrations of recombinant hTEM8 and mTEM8 protein 
Mock or TEM8 CAR-transduced T-cells (2x105 cells/well) were incubated in a 96-well 
plate overnight with decreasing concentrations of recombinant hTEM8-Fc (top) or 
mTEM8-Fc (bottom). All CAR T-cells were equalised for CAR transduction efficiency 
by being diluted with appropriate amounts of mock T-cells, as normally done for all 
functional assays, but 1D2 CAR T-cells undiluted with mock T-cells (1D2’) were also 
tested at the same time. Following the overnight incubation, supernatants were 
assayed by IFNg ELISA and the resulting T-cell IFNg production expressed in pg/mL. 
All data points were measured in triplicate and expressed as mean ± SD.  
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In the assays described above which utilised cells as targets, a very high background 
T-cell response was observed to HEK293; it was therefore difficult to tell whether the 
CAR T-cells responded specifically to HEK293-mTEM8 or if the responses seen were 
due to their already high reactivity to the parent cell line. As a final test of CAR T-cell 
recognition (or lack thereof) of mTEM8 expressed on cell surface, LS174T cells were 
transduced with a GFP+ mTEM8 lentiviral construct as described in section 2.4.3. The 
transduction was successful, with the newly obtained LS174T-mTEM8 cells expressing 
high levels of GFP post-transduction and staining positive for TEM8 surface expression 
using the L2 mAb (Figure 4.24). The parent TEM8-negative LS174T cells were the 
only target to which none of the TEM8 CAR T-cells previously responded, making this 
cell line the ideal negative control. All five CAR T-cells were then tested for IFNg release 
in the presence of LS174T or LS174T-mTEM8 cells, and while none of them responded 
to the parent cell line, all but 1D2 CAR T-cells produced IFNg in response to LS174T-
mTEM8 (Figure 4.25). L1 and L2 CARs were the highest responders, as observed 
before, but L3 and L5 CAR T-cells also produced substantial amounts of the cytokine. 
On the other hand, 1D2 CAR T-cell responses to LS174T-mTEM8, whether equalised 
for transduction efficiency or not, were not significantly raised above background levels 
observed for mock T-cells. Finally, in a chromium release assay using the same T-cells 
and targets (Figure 4.26), specific cytotoxicity to the mTEM8-expressing cell line was 
exhibited by L1, L2, L3 and L5 CAR T-cells. The 1D2 CAR, however, did not induce 
specific killing of LS174T-mTEM8, confirming the inability of this CAR to elicit a T-cell 
response to the mouse version of the target protein. While disappointing, this result 




and established that the therapeutic efficacy of 1D2 CAR T-cells would have to be 






Figure 4.24 – The results of the transduction of LS174T cells with a GFP+ 
lentiviral mTEM8 gBlock construct 
LS174T cells were transduced with a green fluorescent protein (GFP)-positive mTEM8 
lentiviral construct, left to recover for 2-3 days, and both the parent LS174T and the 
newly generated LS174T-mTEM8 cells analysed for GFP and TEM8 expression. (A) 
Both cell lines were analysed for transduction efficiency by flow cytometry. The 
presence of a GFP marker in the lentiviral vector allowed for the detection of 
successfully transduced target cells in the FITC channel. (B) Both cell lines were 
labelled with the TEM8-specific L2 mAb (cross-reactive with both human and mouse 
TEM8; blue line), or with the mouse IgG2a isotype control (red line), before being 
labelled further with the secondary fluorophore-conjugated anti-mouse IgG. TEM8 






Figure 4.25 – TEM8 CAR T-cell IFNg release in response to LS174T cells with or 
without surface mTEM8 expression 
Mock or TEM8 CAR-transduced T-cells (2x105 cells/well) were incubated alone or with 
indicated target cells (2x104 cells/well) in a 96-well plate overnight. All CAR T-cells 
were equalised for CAR transduction efficiency by being diluted with appropriate 
amounts of mock T-cells, as normally done for all functional assays, but 1D2 CAR T-
cells undiluted with mock T-cells (1D2’) were also tested at the same time. Following 
the overnight incubation, supernatants were assayed by IFNg ELISA and the resulting 
T-cell IFNg production expressed in pg/mL. All data points were measured in triplicate 
and expressed as mean + SD. 
  






















Figure 4.26 – Specific cytotoxicity of TEM8 CAR T-cells in response to LS174T 
cells with or without surface mTEM8 expression 
Mock or TEM8 CAR-transduced T-cells were incubated at decreasing effector:target 
(E:T) ratios with indicated chromium-labelled target cells (2.5x103 target cells/well of a 
96-well plate), and supernatants harvested and analysed for released chromium after 
12 hours. % specific lysis for each target was calculated from spontaneous (targets 
alone) and maximum lysis values (targets incubated with 1% sodium dodecyl-





In this chapter the five TEM8 CARs were tested for their safety and persistence in the 
peripheral circulation of healthy mice, demonstrating that L2 and possibly L3 CARs 
were occasionally toxic to the treated animals; when not exhibiting toxicity, these along 
with L1 and L5 CARs were for the most part lost from the circulation within several 
days. 1D2 CAR T-cells, on the other hand, appeared safe and persisted in the blood 
for the duration of each experiment. However, when they were tested in mice following 
a tumour challenge, they failed to confer any protection from tumour progression, which 
was subsequently discovered to be a possible result of the inability of 1D2 CAR T-cells 
to recognise the mouse version of the TEM8 protein. Although this CAR is clearly 
capable of responding to human TEM8, without a TEM8 knock-in mouse available it is 
not possible to test the therapeutic potential (and to revisit the potential toxicity) of this 
agent in mouse studies. 
 
4.7.1 Toxicity of high-affinity TEM8 CARs in healthy mice 
Of all the TEM8 CARs tested, the only evidence of overt toxicity was seen for the L2 
and, in one instance, the L3 CAR. The severity of the observed symptoms in L2 CAR-
injected mice, both in the single C57BL/6 mouse and the three NSG mice which 
exhibited them and had to be culled as a consequence, indicated that L2 CARs may 
not be a safe therapeutic option under any circumstance. However, not every toxicity 
study showed adverse events in L2 CAR-infused mice, much like not every treatment 
is toxic to each patient it is administered to – this made the establishment of the 




or indeed any TEM8 CAR, could be safely administered in human clinical trials in the 
future. 
 
The rapid onset of toxic symptoms in the affected mice suggested a possible cytokine 
storm. The reduced mobility, hunched posture and ruffled fur observed in all of the 
affected animals were in agreement with previous studies which reported similar 
symptoms when antibody or CAR T-cell injections given to mice resulted in CRS307,329–
331. It was unfortunate that, due to the need for immediate culling, plasma samples for 
cytokine analysis could not be obtained from the four mice experiencing L2 CAR-
induced toxicity. Nevertheless, the samples taken from other mice for comparison were 
tested as described in the preceding sections for the presence of cytokines most 
commonly associated with mouse CRS307,326–330. It was interesting to note that, even 
when mice did not exhibit overt toxic effects, L2, L3 and to some extent L1 CAR T-cells 
were still producing increased levels of IFNg, IL-5 and IL-6 in their circulation on day 4 
after T-cell injection (Figure 4.7). These cytokines were all upregulated in the studies 
of mice developing cytokine storms in response to anti-CD3, anti-CD28 or CAR T-cell 
treatment307,329,330, with the levels reported in the CAR T-cell study307 very similar to 
those observed in this thesis; IFNg was highlighted as a particularly important mediator 
of CRS effects. TNFa is another cytokine observed almost universally to be raised in 
CRS, however it peaks early and is not normally present beyond the first few hours 
post-treatment329; this could be the reason why it is also not observed in the plasma 
samples analysed herein. Even though the mice that the samples came from did not 




L1 CAR-treated animals points to the possibility of occult responses by high-affinity 
TEM8 CARs even when overt toxicity is absent. 
 
In the study of 2nd generation CD19 CAR T-cells in mice with B-cell lymphoma referred 
to above307, 75% of mice receiving high CAR T-cell doses developed the previously 
described CRS symptoms and were culled within 2-4 days; those receiving lower 
doses of the CAR (<5x106 CAR-positive T-cells) developed the same symptoms in a 
milder form and eventually recovered. Similarly, the mice which exhibited toxicity in 
response to TEM8 CAR treatment in this thesis all received close to or well above 
5x106 CAR-expressing T-cells within the T-cell populations infused into them (sections 
4.1 and 4.3) and developed signs of CRS within the first 24h. However, the highest 
numbers of L2 or L3 CAR T-cells given to mice did not mediate toxicity (sections 4.2 
and 4.4). 
 
Contrary to the findings in this thesis, a study of natural killer group 2D (NKG2D) CARs 
in various mouse models concluded that the presence of the host immune system was 
necessary for CRS-like symptoms to develop, reporting that NSG mice injected with 
20x106 NKG2D CAR T-cells remained healthy while the less immunocompromised 
mice developed cytokine storms331. This brings into question the toxicity observed in 
NSG mice in the experiment described here (section 4.3) suggesting that it may not 
have been CRS, or alternatively that the mechanisms involved may be more complex 
and may differ depending on the CAR and mouse model used. From the rapidity of 
symptom onset, appearance and behaviour of the mice and limited evidence of 




the most likely explanation for the toxic effects observed in the animal experiments 
described in this chapter. This is supported by the finding that there was no observable 
pathology in the organs of the treated mice which exhibited adverse effects compared 
to those that did not (Figure 4.11) – something that has also been reported by the study 
referred to above331. 
 
Curiously, no toxicity was reported in the recently published study of 2nd and 3rd 
generation L2 CAR T-cells for the treatment of TNBC in mice325. It should be noted 
that, while both CARs were tested in several anti-tumour experiments with no adverse 
effects, only 3rd generation L2 CARs were injected into healthy immunocompromised 
mice and tracked as part of a toxicity study. It had already been stated that the 3rd 
generation L2 CARs had a higher activation threshold than their 2nd generation 
counterparts, requiring higher levels of antigen for response325. This could perhaps 
explain the reason why no adverse events were observed, as TEM8 expression in 
healthy mice, if present, is expected to be low246. Nonetheless, these reported findings 
were surprising in light of our own experience with the L2 CAR. In addition, we have 
heard from another group using the L2 anti-TEM8 antibody for immunotherapy studies 
in mice who also found toxicity, although these data are yet to be published. 
 
4.7.2 TEM8 expression on healthy mouse tissue 
Apart from CRS-like symptoms in some mice treated with L2 and L3 CARs, another 
consistently observed effect in the in vivo studies described in this thesis was the rapid 
selective depletion of CAR-expressing (CD34+) T-cells from mouse peripheral 




lost from the blood over time to a greater or lesser extent, 1D2 CAR T-cells were the 
only ones to persist at the end of each experiment, with the notable exception of the 
CD4 subset of L2 CAR T-cells in one mouse in the study described in section 4.2. The 
high in vitro responses of all but the 1D2 CAR to cells expressing very low levels of 
TEM8, coupled with their rapid loss from murine circulation, suggests that the TEM8 
CAR T-cells were recognising low-level expression of their target on healthy mouse 
tissue and being retained in these tissue sites. In fact, it is possible that both the 
cytokine storms and the loss of CAR T-cells from peripheral blood were a result of 
TEM8 recognition by the high-affinity CARs. The possibility of TEM8 CAR T-cells 
responding to a target unrelated to TEM8 cannot be fully discounted – nevertheless, 
the persistence of the high-affinity L2 CAR T-cells in TEM8 KO mice, and their 
concurrent elimination from the circulation of WT animals, points to TEM8 expression 
in healthy tissues being at least one of the major reasons for the loss of CAR T-cells 
from the circulation. 
 
Despite early studies reporting that TEM8 is solely detectable on tumour-associated 
vasculature, mounting evidence suggests that its expression is in fact much more 
widespread, even if it is comparatively low in normal tissue. TEM8 transcripts have 
been detected by RT-PCR on normal endothelial and smooth muscle cells324, in 
various digestive tissues and on a range of vital organs including heart, lungs and brain 
of both humans332 and mice333, as well as on stem cells334 and circulating endothelial 
cells335. It has been suggested, however, that inter-individual variability of TEM8 
expression is high, and that its levels are likely to be different in various normal tissues 




low-level expression of the TEM8 protein on healthy murine cells which cannot be 
detected by staining techniques such as immunofluorescence246. As discussed already 
in the previous chapter, TEM8 CAR T-cells other than the low-affinity 1D2 CAR may 
be highly sensitive even to very low levels of target antigen undetectable by antibody 
staining. Therefore, the toxicity as well as the selective loss of TEM8 CAR-expressing 
T-cells observed in the experiments described herein are most likely a direct result of 
T-cell recognition of their intended target on an as yet unidentified healthy tissue. 
 
4.7.3 Eye toxicity in TEM8 KO mice 
Quite apart from the toxicity observed in WT mice, an adverse effect specific to the 
C57BL/6 TEM8 KO strain was the development of a swollen and sore left eye, which 
gradually reduced in size over time but became cloudy in appearance, resembling a 
cataract. This effect only became apparent after CAR T-cell injection but did not seem 
to be related to any one treatment, as mice injected with both TEM8 CARs and the 
non-specific CAR control developed the same reaction. It was also acknowledged on 
closer inspection that, in general, healthy TEM8 KO mice had a less elongated head 
and slightly more protruding eyes than their WT littermates, which became very 
pronounced in those that developed the eye anomaly following CAR T-cell injection. 
While entirely unexpected, this adverse effect can perhaps be explained by the 
similarities between TEM8 KO mice and patients with a rare autosomal recessive 
condition known as GAPO syndrome. 
 
GAPO is the acronym derived from four principal manifestations of the condition – 




atrophy – all of which arise due to mutations in human TEM8336. The tissues of patients 
with GAPO syndrome demonstrate abnormal extracellular matrix (ECM) depositions 
and extensive involvement of connective tissue in disease pathology336, which is in 
keeping with the identified role of TEM8 in collagen binding and cell migration. In 
addition, ECM accumulation and dental abnormalities in GAPO patients are 
recapitulated in TEM8 KO mice245 and, even though the phenotype in mice is less 
severe than that in humans337, it is entirely possible that the animals can also develop 
the progressive optic atrophy exhibited by patients with the TEM8 mutation. In fact, a 
study of TEM8 KO mice has already shown that these homozygous mutants can 
display growth retardation, a shortened skull with a protruding forehead, and midfacial 
hypoplasia which is characterised by large and bulging eyes338. In this study the 
affected eyes of TEM8 KO mice also appeared cloudy338, further confirming that optical 
anomalies are a very possible scenario. 
 
The appearance of the affected TEM8 KO mice described in this thesis bore the most 
resemblance to a patient with GAPO syndrome with left-sided optic atrophy who was 
reported to have developed cerebral arterial atherosclerosis339 as well as, curiously, to 
a patient with Apert syndrome who, among other things, exhibited midfacial hypoplasia 
and corneal opacity in the left eye340. The resemblance to the latter was particularly 
striking. Apert syndrome is caused by a mutation in the fibroblast growth factor 
receptor-2 (FGFR2) gene, which causes prolonged signalling of the protein and leads 
to the described malformations341. Furthermore, it has been shown that TEM8 
knockout mediates complex crosstalk mechanisms in primary fibroblasts and 




impossible to say with certainty how, or indeed if, CAR T-cell injection triggered the 
ocular defects in some of the TEM8 KO mice, the described evidence points to the 
heavy involvement of the KO phenotype and the complex interactions of signalling 
molecules and growth factors brought about by the TEM8 genetic mutation. 
 
4.7.4 Tumour protection by TEM8 CARs 
Despite successful recognition of TEM8 overexpression in vitro by the 1D2 CAR, and 
the promising safety and in vivo persistence profile of 1D2 CAR T-cells, they failed to 
provide protection from tumour challenge in mice due to their subsequently discovered 
inability to recognise mouse TEM8. This had not been anticipated before, as human 
and mouse TEM8 share 99% amino acid sequence homology in the extracellular 
binding region (Brad St Croix, personal communication) and all five originating anti-
TEM8 antibodies were fully cross-reactive with both. Nevertheless, the affinity of the 
1D2 antibody in its Fab form, already much weaker for hTEM8 than that of the other 
four Fabs, was a further four times weaker for mTEM8 than for the human version of 
the protein246 (Table 3.1). This potentially resulted in a CAR that could not recognise 
expression of the mouse protein at all. Even though sequence homology between 
hTEM8 and mTEM8 is very high, an antibody has been developed which recognises 
only human and not mouse TEM8 by binding a different epitope to that bound by cross-
reactive antibodies324. This suggests that the 1D2 antibody also binds to a region that 
is only partially shared between human and mouse TEM8, resulting in its very low 
affinity for mTEM8 and the observed selectivity for hTEM8 of the derived CAR. While 
this prevents the 1D2 CAR from being studied in a standard mouse model, where any 




than human proteins, generating a human TEM8 knock-in mouse model could be a 
promising way forward for exploring the anti-tumour efficacy (and potential toxicity) of 
this CAR in pre-clinical studies. Should it prove successful, its low-affinity hTEM8-
targeting scFv moiety may be a significant advantage, allowing it to respond only to 
tissues overexpressing TEM8 – such as tumour vasculature – and spare any low-level 
TEM8 expressed on normal cells. 
 
In contrast to previously reported findings, a study has recently shown that the slower 
tumour growth in TEM8 KO mice is related to their malnutrition resulting from 
misaligned incisors; when soft food was provided as rescue, these mice regained both 
their weight and normal tumour growth rates exhibited in WT littermates343. Despite 
this, and the consequent assertion that TEM8 is not essential for tumour growth343, 
targeting the vasculature of various solid tumours with both anti-TEM8 antibodies246 
and TEM8 CAR T-cells325 has successfully resulted in tumour regression. TEM8 CAR 
T-cells were able to control both patient-derived TNBC xenografts and tumours formed 
from metastatic TNBC cells, however they were not curative325. Importantly, both the 
antibody and the CAR T-cells used in the studies above were derived from the L2 Fab. 
While this did not result in toxicity in its naked antibody form246, the experimental data 
presented in this thesis argue that L2 CAR T-cells can be toxic due to their potent 
effector function and heightened sensitivity to low-level TEM8 expression on normal 
tissue. Because of this, and the rapid selective loss of all high-affinity TEM8 CARs from 
peripheral circulation of the mice, it can be argued that the lower affinity 1D2 CAR may 




5 GENERATION AND SUPPRESSIVE POTENTIAL OF CAR-ENGINEERED 
TREGS TARGETING CLEC14A IN INFLAMED LIVER 
 
As discussed in detail in sections 1.6 and 1.7 of the Introduction, there is increasing 
interest in using immunotherapy to target autoimmune and inflammatory conditions, 
especially those with high unmet clinical need such as certain conditions of the liver. 
Adoptive transfer of Tregs to treat a variety of autoimmune diseases has already 
proven successful in animal studies and is being increasingly trialled in the clinic. 
Antigen-specific Tregs redirected towards a target in the inflammatory site have also 
proven superior to polyclonal Tregs in various mouse models of autoimmune 
conditions. However, the general paucity of known autoantigens or disease markers in 
inflammatory conditions renders the generation of antigen-specific Tregs difficult, with 
only the suboptimal polyclonal Treg ACT currently being tested in patients. This 
problem is present in autoimmune diseases of the liver too, where there is only one 
pilot feasibility study of autologous polyclonal Treg infusions into patients with AIH 
currently being carried out344. The aim of this part of the thesis, therefore, was to 
examine the therapeutic potential of antigen-specific Tregs in PSC, a debilitating 
inflammatory liver condition which is strongly associated with other autoimmune 
diseases and results in the need for liver transplantation in more than half of affected 
patients255. The expression of a novel TEM, CLEC14A, was hypothesised to be raised 
on the surface of liver endothelial cells in PSC due to the previously discovered 
association of this TEM with vasculature characterised by disturbed blood flow and low 
shear stress225. If expressed, this protein would provide a promising target for 




of the suppressive action of the Tregs in vitro and of their therapeutic efficacy in a PSC 
mouse model. 
 
5.1 CLEC14A is expressed in human inflamed liver 
To determine whether CLEC14A is expressed in the livers of patients with inflammatory 
hepatic diseases, and specifically PSC, fixed liver sections were obtained from patients 
with PSC, alcoholic liver disease (ALD) and from those whose donor livers were 
rejected for transplantation. The sections originated from four patients for each of the 
three conditions, with the latter two selected as additional examples of hepatic 
inflammation or distress for comparison with PSC. Normal (non-inflamed) liver sections 
from two patients were also obtained as part of tissue arrays. 
 
Following immunohistochemical staining and imaging of all samples for the endothelial 
marker CD31 and for CLEC14A, as described in section 2.7.1, it was observed that 
normal liver sections predominantly expressed low or undetectable levels of CLEC14A 
on the endothelium (Figure 5.1). On the other hand, rejected donor livers, as well as 
those originating from patients with PSC and ALD, all exhibited prominent endothelial 
CLEC14A staining (Figure 5.1 and Figure 5.2). To ensure the staining was specific, 
spare sections from each patient sample were treated at the same time with a 
concentration-matched IgG control for the anti-CLEC14A antibody – all of the control 
sections were completely free of staining (Figure 5.3). 
 
The results obtained showed that CLEC14A was not only expressed on the hepatic 




even when the underlying cause of such inflammation is not necessarily known (such 
as in the case of donor livers which had been rejected). This confirmed the value of 
CLEC14A as a potential disease marker for future targeted therapies of autoimmune 
and inflammatory liver diseases. As the focus of this project was on PSC, it next 
became necessary to examine the expression of CLEC14A in the available PSC 









Figure 5.1 – Representative normal and donor human liver sections stained for 
CD31 and CLEC14A by immunohistochemistry 
Fixed sections from non-inflamed (normal) livers and those from donor livers which 
had been rejected for transplantation were stained by immunohistochemistry for the 
endothelial marker CD31 (left) or for the C-type lectin CLEC14A (right) and examined 
by brightfield microscopy. Horseradish peroxidase (HRP) staining (brown) indicates 
the presence of endothelial cells or CLEC14A respectively. Normal liver sections 1 and 
2 originated from two patients whose samples were part of tissue arrays MNO1021 
and LVD481 (Pantomics) respectively. Rejected donor liver sections were provided by 
the Centre for Liver Research (CLR, University of Birmingham). Sections from one 










Figure 5.2 – Representative human liver sections from inflammatory liver 
conditions stained for CD31 and CLEC14A by immunohistochemistry 
Fixed liver sections from patients with alcoholic liver disease (ALD) or primary 
sclerosing cholangitis (PSC) were stained by immunohistochemistry for the endothelial 
marker CD31 (left) or for the C-type lectin CLEC14A (right) and examined by brightfield 
microscopy. HRP staining (brown) indicates the presence of endothelial cells or 
CLEC14A respectively. All ALD and PSC sections were provided by the Centre for 
Liver Research (CLR, University of Birmingham). Sections from one patient with ALD 
and two patients with PSC are shown here and are representative of samples from 










Figure 5.3 – Representative normal, donor and inflamed human liver sections 
stained with IgG control for CLEC14A by immunohistochemistry 
Fixed sections from non-inflamed (normal) liver, donor livers which had been rejected 
for transplantation, and livers with ALD or PSC were stained by immunohistochemistry 
with a concentration-matched IgG control for the anti-CLEC14A antibody alongside 
corresponding CLEC14A-stained sections shown in Figure 5.1 and Figure 5.2. Donor 





5.2 CLEC14A is expressed in the liver of MDR2 KO FVB mice 
As described in the Introduction (section 1.6.3), none of the existing mouse models of 
PSC completely replicate the complex pathology and full course of the disease. 
Nevertheless, KO mouse models, MDR2 KO chief among them, afford the opportunity 
to study the condition longitudinally and test potential therapeutic approaches. MDR2 
KO mice on FVB background develop a spontaneous PSC-like phenotype265 which 
progresses with age and eventually results in HCC263, making this model reasonably 
representative of the human condition. The availability of the animal model at the CLR 
meant that their liver samples were readily obtainable and could be tested for 
CLEC14A expression on the hepatic endothelium. 
  
Frozen sections from the livers of male MDR2 KO FVB mice of various ages were 
stained by immunofluorescence for CD31 and CLEC14A as described in section 2.7.2. 
As evidenced by confocal microscopy imaging, these 5-10 week old mice all expressed 
CLEC14A on the surface of their liver vasculature, exhibiting co-localisation of the 
target protein with the endothelial marker CD31 (Figure 5.4). The intensity of 
CLEC14A fluorescence appeared equally strong in both younger and older mice. 
Mouse sections stained with the IgG control for the anti-CLEC14A antibody only 
exhibited low levels of non-specific staining, confirming that the CLEC14A expression 
observed was genuine. In addition, immunofluorescence staining of frozen liver 
sections from 6-8 week old FVB WT mice showed only low CLEC14A expression in 
these healthy controls (Figure 5.5). It should be noted that the FVB WT sections are 
only representative of two mice, and further staining of these would need to be carried 




was similar to very low-level CLEC14A detected in human healthy liver sections (Figure 
5.1) suggests that this mouse model provides a good representation of the human 
condition. 
 
Taken together, these findings established that the relevant disease marker was 
expressed in the available PSC mouse model and could be further examined as a 






Figure 5.4 – Representative liver sections from MDR2 KO FVB mice of various 
ages stained for CD31 and CLEC14A by immunofluorescence 
Frozen liver sections from male MDR2 KO FVB mice aged 5, 8-9 or 10 weeks were 
stained by immunofluorescence for the endothelial marker CD31 (green) and 
CLEC14A or the appropriate IgG control (red) and examined by confocal microscopy. 
The merged images for each sample are shown, with areas of co-localisation in yellow. 
The sections shown are representative of one mouse (5 weeks), two mice (8-9 weeks), 





Figure 5.5 – Representative liver sections from 6-8 week old FVB WT mice 
stained for CD31 and CLEC14A by immunofluorescence 
Frozen liver sections from male FVB WT mice aged 6-8 weeks were stained by 
immunofluorescence for the endothelial marker CD31 (green) and CLEC14A or the 
appropriate IgG control (red) and examined by confocal microscopy. The merged 






5.3 Human Tregs are successfully engineered to express a CLEC14A CAR 
To generate CLEC14A-specific human regulatory T-cells, Tregs were isolated from a 
donor PBMC population and transduced with a CLEC14A CAR construct, CRT3.2, as 
described in sections 2.1.3 and 2.4.1 respectively. Following transduction, CAR Tregs 
(and, when available, mock Treg controls) were stained with a panel of antibodies to 
examine their phenotype and CAR transduction levels (the panel is detailed in Table 
2.2). The gating strategy, together with phenotypic marker and CAR expression levels 
obtained in one of the representative Treg batches, are shown in Figure 5.6. The 
consistently high proportion of CD3+CD4+ T-cells obtained after Treg isolation 
exhibited variable amounts of CD127lowFoxp3+ cells present, with the variability 
seemingly donor-dependent. Nevertheless, the Treg subset was regularly transduced 
successfully with the CRT3.2 CAR, as evidenced by CD34 expression of the 
CD3+CD4+CD127lowFoxp3+ T-cell population. 
 
As previously described in several publications305,345,346, Treg phenotype is maintained 
in culture by the inclusion of rapamycin, usually at a concentration of 100nM. When at 
first the isolated Tregs were expanded without the addition of this immunosuppressive 
drug, a substantial conventional T-cell (Tconv) outgrowth was observed, as evidenced 
by the loss of Foxp3 expression and a conversion to a predominantly CD127high T-cell 
phenotype (Figure 5.7, TREG BATCH 1). However, when rapamycin was introduced 
into a second batch of Tregs, the initial decline in Foxp3 expression which preceded 
its introduction was significantly slowed down, and the phenotype remained stable for 





Taken together, the data showed that human regulatory T-cells could be successfully 
isolated, transduced with the desired CAR, and maintained and expanded in vitro. 
Their suppressive potential, however, as well as their advantage over non-transduced 






Figure 5.6 – Gating strategy to identify purified Tregs successfully transduced with a CLEC14A CAR 
CRT3.2 CLEC14A CAR Tregs, and mock Treg controls if present, were stained with viability dye, anti-CD3, anti-CD4, anti-




antibody or its corresponding concentration-matched isotype control and analysed on the flow cytometer, with CD34 acting as 
a surface marker of CAR expression. The gates were put sequentially on the T-cell population, singlets (to exclude cell clumps), 
live cells (viability dye-negative), CD3+CD4+ and finally CD127lowFoxp3+ Tregs. Within this final subset, mock Tregs or the 
appropriate concentration-matched anti-CD34 antibody isotype control were used to determine the position of the CD34-negative 
population and thus allow correct positioning of the CD34 gate. The Tregs falling within this gate were considered CAR-positive. 






Figure 5.7 – Effect of rapamycin on the maintenance of Treg phenotype with time spent in culture 
CRT3.2 CLEC14A CAR Tregs were stained and pre-gated on the CD3+CD4+ population as described in Figure 5.6. The position 
of the Foxp3 gate was determined by staining with the appropriate concentration-matched isotype control. The Tregs were 
maintained in culture in the presence of CD3/CD28 beads, 1,000 IU/mL IL-2 and either in the absence (Treg batch 1) or presence 





5.4 Pilot studies exploring the suppressive activities of CLEC14A-specific CAR 
Tregs 
At this stage in the project, I was approaching the end of my time in the laboratory so 
could only conduct some initial experiments to explore the suppressive activity of 
CRT3.2 CLEC14A CAR-engineered Tregs. To establish whether they were able to 
suppress the proliferation of autologous T-cells, the CRT3.2 CAR Tregs were first 
incubated with CFSE-labelled CRT3.2 CAR Tconv or their mock-transduced 
counterparts in the presence of recombinant human CLEC14A-Fc or the IgG-Fc 
control. Four different Tconv:Treg ratios and Tconv alone were tested. As described 
previously for T-cell proliferation assays (section 3.3), Tconv were harvested after four 
days and their CFSE expression examined by flow cytometry, with dilution of the dye 
being a direct measure of cell proliferation. It is important to note that the CFSE-
negative Treg and the CFSE-positive Tconv populations exhibited significant overlap 
in the FITC channel instead of forming discrete peaks, possibly due to dye leakage 
from Tconv and its subsequent uptake by Tregs (Figure 5.8A). Therefore, to 
distinguish between these two populations, the gating was set only on the CD8+ Tconv 
cells as this excluded any Tregs (which were all CD4+). All the suppression data 
reported herein is therefore expressed in terms of CD8 Tconv. 
 
As shown in Figure 5.8B, CAR Tregs successfully suppressed the proliferation of 
autologous CAR Tconv in the presence of their target, CLEC14A, at all Tconv:Treg 
ratios, compared to Tconv in the absence of Tregs. This proliferation was CLEC14A-
specific since CAR Tconv proliferation in response to IgG-Fc was minimal. Mock 




and Fc, but again both of these responses were suppressed in equal measure when 
the CAR Tregs were added. This suggested that the CLEC14A CAR on the surface of 
Tregs, which was expected to lead to greater suppression of non-specific Tconv 
proliferation in the presence of CLEC14A, did not improve the activity of the Tregs. 
 
To explore further whether CLEC14A-specific CAR Tregs conferred any advantages 
over untransduced Tregs in suppressing autologous Tconv proliferation, the assay 
described above was repeated with the inclusion of a mock Treg control. The new 
assay was carried out twice – once for four days and once for a shortened period of 
three days – and analysed for CD8 Tconv proliferation as before. The results are 
shown in Figure 5.9. The four-day assay showed a very similar pattern to the one 
described above, with CAR Tregs successfully suppressing the proliferation of Tconv 
in the presence of CLEC14A; nevertheless, mock Tregs exhibited equal or greater 
suppressive capacity compared to CAR Tregs at all Tconv:Treg ratios. This was less 
pronounced in the 3-day assay due to less overall proliferation observed, but was still 
apparent. As before, CAR Tregs were also able to suppress the non-specific 
proliferation of mock Tconv, although in the 4-day assay this was only seen at higher 
Tconv:Treg ratios and was clearly not enhanced by the presence of CLEC14A. 
 
The data shown here are limited by the fact that, due to time constraints, only two Treg 
batches were tested and only one of these included a mock Treg control. Nevertheless, 
these initial results indicate that expression of the CRT3.2 CLEC14A-specific CAR in 
Tregs has not increased their suppressive activity in the presence of their target 




expressing the CAR or in the absence of CLEC14A. However, further experiments and 
analyses are required before definite conclusions can be drawn about the potential of 






Figure 5.8 – Suppression of proliferation of one batch of conventional CD8 CAR 
T-cells by their autologous CAR Tregs in the presence or absence of antigen 
Conventional T-cells (Tconv) transduced with the CRT3.2 CLEC14A CAR, or their 
mock-transduced controls, were labelled with CFSE intracellular dye and incubated 
alone or with autologous CRT3.2 CLEC14A Tregs at increasing Tconv:Treg ratios for 
four days. The cells were incubated in the presence of recombinant human CLEC14A-
Fc (CLEC14A) or a concentration-matched IgG-Fc control (Fc). On day 4 the T-cells 
were harvested, labelled with viability dye, anti-CD8, anti-CD4 and anti-CD34 
antibodies and analysed by flow cytometry. (A) Representative histograms of CFSE 
expression showing the proliferation of bulk Tconv (top) and CD8 Tconv (bottom) when 
incubated alone with IgG-Fc control protein (left) or CLEC14A (middle), or at 1:1 ratio 
with autologous Tregs in the presence of either protein (right). The overlap of Treg and 
Tconv peaks when Tregs were present in the bulk T-cell populations made data 
interpretation difficult; analysis was therefore performed using CD8 Tconv proliferation 
instead. (B) Proportion of proliferated Tconv expressed as % of the total CD8 Tconv 





Figure 5.9 – Suppression of proliferation of a second batch of conventional CD8 CAR T-cells by their autologous CAR 
or mock Tregs in the presence or absence of antigen 
Tconv transduced with the CRT3.2 CLEC14A CAR, or their mock-transduced controls, were labelled with CFSE intracellular dye 




The cells were incubated in the presence of recombinant human CLEC14A-Fc (CLEC14A) or the IgG-Fc control (Fc). On day 3 
or 4 the T-cells were harvested, labelled with viability dye, anti-CD8, anti-CD4 and anti-CD34 antibodies and analysed by flow 






This chapter presents preliminary data on CLEC14A expression on the vasculature of 
the inflamed PSC liver in both humans and mice, and shows that Tregs isolated from 
human PBMCs can be successfully transduced with a CLEC14A CAR with a view to 
targeting PSC inflammation with antigen-specific immunotherapy. The chapter also 
begins to explore the in vitro suppressive capacity of the generated Tregs and finds 
that, although successful, the CAR Tregs do not appear to suppress autologous T-cell 
proliferation any more than their mock-transduced counterparts. These, however, are 
very early data which would need to be explored in greater depth in order to give 
definitive answers about potential benefits of CLEC14A CAR Tregs. In addition, a pilot 
study of the Tregs in MDR2 KO FVB mice, although planned, was unfortunately not 
carried out due to time constraints. In vivo experiments would be the logical next step 
and would provide greater insight into the therapeutic potential of CLEC14A CAR Tregs 
in PSC, possibly paving the way for future clinical studies if successful. 
 
5.5.1 The suitability of the MDR2 KO FVB model 
As discussed already in section 1.6.3, no mouse model that completely replicates the 
complexity of PSC exists yet, with many producing suboptimal liver inflammation or 
resulting in unacceptable toxicity263. Knockout mouse models, however, provide the 
advantage of studying the disease longitudinally. For example, cystic fibrosis 
transmembrane conductance regulator (CFTR) KO mice spontaneously develop biliary 
injury resembling PSC, but this phenotype is weak unless colitis is further induced 
chemically and carries with it a high risk of intestinal obstruction263,347. Furthermore, 




treatment with a xenobiotic347, making the CFTR KO model suboptimal and difficult to 
work with. On the other hand, the MDR2 KO mouse develops progressive cholestatic 
hepatitis and biliary injury very similar to PSC without the need for any additional 
treatment, eventually progressing further to HCC263,265. The availability of this murine 
model on FVB background at the University of Birmingham meant that sections could 
easily be obtained for analysis, and its representative PSC-like phenotype suggested 
that it would lend itself well to studies of immunotherapeutic approaches that could 
later be applied to patients. 
 
It is interesting to note that sections from 6 and 12 week old male MDR2 KO C57BL/6 
(BL6) mice, which were also readily available, were stained alongside those from male 
MDR2 KO FVB mice, but did not show any evidence of CLEC14A expression despite 
also exhibiting PSC-like liver injury. Even though this at first suggests that CLEC14A 
may not be an ideal disease marker for this condition, it has been shown that MDR2 
KO mice on BL6 background develop a much less severe chronic liver inflammation 
than those on FVB background, resulting in delayed progression to HCC; this 
difference is especially prominent in males348. MDR2 KO BL6 mice develop cholangitis 
and inflammation more rapidly than their age-matched FVB counterparts only in the 
first month of life, but while this phenotype becomes more severe over time in MDR2 
KO FVB mice, it actually decreases in severity in BL6 mice by 3 months of age. In 
addition, 3 month old MDR2 KO FVB mice display increased fibrosis, liver enzyme 
disturbances, and importantly, higher levels of immune cell infiltrates – T-cells among 
them – than MDR2 KO BL6 mice of the same age348. This, therefore, correlates well 




concurrent presence in the sections from FVB mice of similar age. Importantly, the 
strong presence of a T-cell infiltrate in MDR2 KO FVB livers suggests that Treg-
mediated therapies may indeed be of benefit in this model, and in PSC in general. 
 
In order to validate CLEC14A as a marker of PSC inflammation further, it would be 
interesting to look at its expression on the liver vasculature of the more recently 
generated MDR2 KO BALB/c mouse model, which displays significantly faster rate of 
progression of both fibrosis and subsequent liver cancer compared to the FVB strain349. 
CLEC14A expression in these mice, if present, would provide yet another PSC model 
in which Treg therapy could potentially be tested in the future. 
 
5.5.2 Treg stability and in vitro culture methods 
Once isolated from PBMCs, it can be difficult for regulatory T-cells to remain stable in 
culture or in vivo due to their plasticity, which renders them very susceptible to reverting 
to other T-cell phenotypes. For example, a pro-inflammatory environment such as that 
of Crohn’s disease may cause the conversion of Tregs to inflammation-promoting Th17 
cells which can be deleterious therapeutically292. Similarly, if maintained in vitro with 
no stimulation other than through CD3 and CD28, Tregs will eventually take on the 
phenotype of conventional T-cells and lose their suppressive capacity. There are a 
number of strategies which can be employed to increase human Treg stability both in 
vitro and in vivo, the most utilised one being the addition of the mTOR inhibitor 
rapamycin to Tregs growing in culture273. Rapamycin has been shown to not only 
stabilise the regulatory phenotype and suppressive capacity of these cells, but also to 




effectors in a number of different studies305,345,346,350. In addition, IL-2 is necessary for 
Treg proliferation and overall survival and has also been routinely used in their in vitro 
culture, usually at a high dose of 1,000 IU/mL273,345,346,350. Both of these strategies were 
employed to maintain human Tregs for the purpose of this thesis, with a clear 
stabilisation in regulatory phenotype once rapamycin at the commonly used 
concentration of 100nM was introduced (Figure 5.7). 
 
Even though the isolated Tregs were successfully cultured and maintained their 
suppressive capacity in the experiments described in this chapter, their phenotype can 
be further stabilised in future studies by additional strategies reported in the literature. 
Isolating CD4+CD25+CD127low T-cells is considered a good starting point for a pure 
Treg population – as performed herein – but CD45RA has been proposed as another 
important surface marker to select for in order to increase Treg proliferative capacity 
while keeping their suppressive potential273,294. It has been suggested that expanding 
the CD4+CD25+CD127lowCD45RA+ T-cell subset results in substantial numbers of 
Tregs with high Foxp3 expression even in the absence of rapamycin351, and that this 
subset does not convert to pro-inflammatory Th17 cells in vitro292. Another strategy 
that can be used is the treatment of Tregs with all-trans retinoic acid (atRA), the active 
vitamin A derivative352. This has been shown to inhibit Treg conversion to other T-
helper phenotypes and help maintain Treg suppressive capacity in the pro-
inflammatory setting of collagen-induced arthritis in mice352, making it a potentially very 
effective approach to treating chronic inflammation characteristic of autoimmune 
disease. However, the use of rapamycin and atRA in combination rather than atRA 




use353. Other strategies to enrich for the most suppressive and phenotypically stable 
Tregs both in vitro and in vivo may include selection for Tregs expressing the co-
inhibitory receptor T-cell Ig and ITIM domain (TIGIT), which is associated with lineage 
stability354, or forced Treg overexpression of Eos, a key transcription factor which 
prevents regulatory T-cell reprogramming even in environments that could destabilise 
them355. 
 
5.5.3 CAR Treg suppression capacity 
Tregs naturally act in a targeted, antigen-specific fashion, exerting their 
immunosuppressive action where appropriate. Adoptive Treg transfer has therefore 
been extensively explored as a way to enhance both the numbers and the suppressive 
function of Tregs to treat autoimmune disease294. However, merely increasing the dose 
of adoptively transferred polyclonal Tregs often isn’t enough to generate a response. 
Even though early clinical trials have reported on their safety when infused into 
patients291, these cells have a range of antigen specificities which only contain very 
low frequencies of the disease-relevant Tregs; large numbers of polyclonal Tregs thus 
need to be administered, which is not always possible356. Furthermore, treatment with 
a wide range of regulatory T-cell specificities can also lead to non-specific 
immunosuppression, which in turn increases the risk of infection and even reactivation 
of latent virus – this has already been reported357. On the other hand, rendering Tregs 
antigen-specific not only reduces the therapeutic dose required and lowers the risk of 
non-specific suppression, but also increases Treg potency up to 100 times compared 
to a polyclonal population due to specific targeting358. In addition, it may not be 




autoimmune condition for antigen-specific Tregs to be successful. As they possess the 
capacity for local immunosuppression of autoreactive T-cells directed against a 
different antigen, it may be enough to simply redirect the Tregs towards any antigen 
selectively expressed in the inflamed tissue290. 
 
In order to generate antigen-specific regulatory T-cells, one of the most promising 
approaches is genetic engineering with a TCR or CAR targeted to an antigen of choice. 
CAR-targeted Tregs have already been successful in several murine studies of 
autoimmune conditions298–300, and were therapeutically superior to a non-specific Treg 
population in mouse models of colitis298,299, GvHD302 and haemophilia A303. Guided by 
this principle, the experiments reported in this thesis used human Tregs engineered 
with a CAR redirected towards CLEC14A, testing them for suppression in response to 
their target protein and comparing the observed responses to those of mock-
engineered (control) Tregs. However, our initial experiments have so far not 
demonstrated superiority of CLEC14A CAR Tregs over non-specific Tregs with regards 
to their suppressive capacity (Figure 5.9). Nevertheless, the data are very preliminary 
and derived only from a single CAR and mock Treg batch; drawing definitive 
conclusions from them is therefore not possible at this stage, with further studies being 
required. 
 
It was noted in the present study that, paradoxically, higher Tconv:Treg ratios resulted 
in greater suppression of Tconv proliferation (Figure 5.8 and Figure 5.9). It is possible 
that this was a result of too many cells present in the wells when the Tconv:Treg ratio 




The experiment would need to be repeated with other Treg batches to validate this 
observation, but it would be interesting to explore lower Treg titrations and whether 
they lead to a greater difference in suppression activity between CAR and mock Tregs. 
This may be especially relevant since it was also noted that conventional T-cells 
exhibited high rates of cell death during the suppression assay incubations. 
Competition between the two T-cell subsets for the limited IL-2 available, and the 
preferential use of the cytokine by the Tregs, may have led to death of some Tconv; 
therefore, it is necessary to improve effector T-cell survival in order to be able to 
interpret any future assay results correctly. It would also be beneficial to test the 
CLEC14A CAR Tregs in other functional assays, such as those examining cytokines 
released in response to antigen (e.g. the immunosuppressive cytokine IL-10) in order 
to elucidate their function and antigen specificity more fully. Finally, in vitro studies on 
cell lines expressing CLEC14A, as well as in vivo experiments in representative mouse 
models such as the MDR2 KO FVB strain, are all necessary to gauge the therapeutic 
efficacy and potency of CLEC14A-targeted regulatory T-cells in inflammatory 





6 GENERAL DISCUSSION 
 
This thesis set out to explore the promising approach of CAR T-cell engineering in the 
context of solid tumours, more specifically for targeting the tumour vasculature, by 
testing the in vitro and in vivo functionality of CAR T-cells redirected against the tumour 
endothelial marker TEM8. This TEM had previously been identified as overexpressed 
on tumour blood vessels, but present only at very low or undetectable levels on healthy 
vasculature of both mice and humans226,246. As originally hypothesised, T-cells were 
amenable to transduction with TEM8 CARs and proved very effective at responding to 
their target protein on the surface of cells; however, four of the five CARs also exhibited 
extensive in vitro reactivity to other cell lines and either resulted in in vivo toxicity or 
were selectively lost from the peripheral circulation of the treated mice. The only TEM8 
CAR to prove safe as well as persist in the blood was 1D2, but its inability to recognise 
mouse TEM8 expressed on murine tumour vasculature rendered any further tumour 
protection or toxicity studies in currently available animal models obsolete. CAR 
engineering of Tregs was also explored in the context of autoimmunity, namely as a 
potential treatment for the autoimmune liver condition primary sclerosing cholangitis. 
While CAR Tregs targeting the vasculature marker CLEC14A, which is expressed in 
the PSC liver, did not prove superior to non-specific Tregs with regards to suppressive 
capacity, the data are very preliminary and merit a more thorough examination of this 
CAR Treg approach before any definitive conclusions can be reached. 
 
The use of CAR T-cell immunotherapy for cancer is currently the focus of intense 




FDA approvals of CARs for the treatment of ALL359 and large B-cell lymphoma360. 
Research continues in both haematological and solid tumours, with the latter being 
particularly challenging to treat due to the inherently suppressive tumour 
microenvironment adversely affecting any immunotherapies aimed at it. Nevertheless, 
here as well progress is being made, not only in the CAR T-cell field but in cancer 
immunotherapies in general. The knowledge obtained from targeting tumours is also 
increasingly applied to treating other conditions such as autoimmune disorders and 
transplant rejection, where CAR Tregs are especially promising. This chapter aims to 
discuss novel immunotherapeutic strategies using CAR-engineered T-cells, and how 
these might be applied to targeting the tumour vasculature using TEM8 CARs or in the 
treatment of liver inflammation with CLEC14A-specific CAR Tregs in the future. 
 
6.1 Metabolic modulation of tumours and CAR T-cell treatment 
The absence of T-cell infiltration and defects in the antigen processing and 
presentation pathways characteristic of many solid tumours render checkpoint 
inhibition, cancer vaccines and even standard TIL therapy ineffective. In these cases, 
engineering T-cells to express CARs, which recognise native surface-expressed 
antigens independent of any processing pathways, is a very promising approach to 
treating these otherwise non-immune infiltrated “cold” tumours. Nevertheless, the 
metabolic barriers of the tumour microenvironment (TME) still need to be overcome by 
CAR T-cells in order to access the tumour in the first place, rendering metabolic 
modulation a particularly important area of CAR research174. The tumour 
microenvironment is typically starved of nutrients, hypoxic and acidic, and the low 




all act to impair normal T-cell function. To overcome nutrient starvation, for example, 
CAR T-cells could be further genetically engineered to overexpress glucose or amino 
acid transporters, thus enabling them to compete with the tumour for the limited 
resources available174. In addition, concurrent inhibition of the main transcription factor 
associated with low oxygen levels, hypoxia-inducible factor-1a (HIF-1a) by a drug such 
as tirapazamine361, could make the tumours more sensitive to CAR T-cell treatment by 
providing a more hospitable environment for their anti-tumour activity. The lack of 
arginine, the amino acid normally necessary for T-cell activation and proliferation, 
could also be counteracted by administering inhibitors of the enzyme arginase which 
is responsible for arginine depletion in the TME362. An arginase inhibitor is already 
showing promising results in a clinical trial of patients with advanced solid tumours363, 
and could provide a potent metabolic boost if administered in combination with CAR 
T-cells. 
 
Another important metabolic factor that adversely affects tumour-targeting T-
lymphocytes is the expression of the immunosuppressive enzyme IDO by the cells of 
the tumour microenvironment. IDO catalyses the degradation of the essential amino 
acid tryptophan; this depletion suppresses T-cell proliferation and leads to lack of T-
cell accumulation at the tumour site66. IDO is associated with poor prognosis in several 
solid cancers174 and has also been shown to lead to inhibition of CAR T-cells, resulting 
in their failure to control IDO-expressing tumours even when the tumour cells were 
positive for the antigen targeted by the CAR T-cells364. Therefore, co-administration of 




solid tumour indications365, could be of great benefit for tumours otherwise resistant to 
immunotherapy or standard chemotherapy. 
 
Even though tumour vasculature-targeting CAR T-cells, such as those bearing TEM8 
CARs, are not as exposed to the inhospitable TME as T-cell immunotherapies 
redirected against the tumour itself, tumour-associated blood vessels can themselves 
be a metabolic barrier and thus need to be taken into account when designing CAR T-
cell strategies. To maximise the anti-tumour potential of TEM8 CAR T-cells, one or 
more of the approaches described above could be employed – for example, 
tirapazamine could be administered following CAR T-cell treatment to eliminate the 
remaining tumour tissue that becomes hypoxic following the destruction of some of the 
vasculature. Additionally, TEM8 CAR T-cells could be given a survival advantage in 
highly glycolytic tumours by being engineered with a 4-1BB rather than a CD28 co-
stimulatory domain, which would help promote oxidative metabolism of the T-cells and 
give them enhanced respiratory capacity315. If both immediate anti-tumour activity and 
long-term T-cell persistence are required, however, the administration of both 
CD28/CD3z and 4-1BB/CD3z TEM8 CAR T-cells might be the optimal therapeutic 
approach. Finally, the reported expression of PD-L1 on tumour vasculature366, which 
can inhibit T-cell activity by binding to PD-1 on T-cell surface, can also be exploited 
and reversed to provide stimulation of TEM8 CARs instead. An engineered T-cell 
switch receptor with a PD-1 extracellular domain has been described which, upon 
binding PD-L1, causes stimulation through its CD28 intracellular moiety and results in 
efficient activation of a desired target-specific CAR also expressed on the T-cell 




PD-L1 mAbs at the tumour site, which has resulted in efficient reduction in tumour 
growth in humanised mouse models368. Whether by modifying them to locally secrete 
anti-PD-L1 blocking antibodies in the tumour vasculature, or by co-opting the normally 
inhibitory PD-L1/PD-1 binding axis using a PD-1/CD28 stimulatory construct instead, 
genetically engineering TEM8 CAR T-cells in this way would provide them with 
substantial therapeutic and survival advantages when targeting tumour blood vessels. 
 
6.2 Antigen specificity and safety of CAR T-cells 
Many alternative CAR designs are being explored with the aim of making their antigen-
binding domains more structurally diverse as well as target-specific. For example, if 
there is no antibody available for re-formatting into a CAR, designed ankyrin repeat 
proteins can be similarly effective as the tumour-targeting CAR moieties369, and if a 
functional scFv domain cannot be easily obtained, dual-chain CARs utilise the natural 
antibody configuration to bind with high affinity and selectivity to the cognate antigen370. 
The latter may be of relevance to the more highly reactive TEM8 CARs – in view of 
their increased avidity for TEM8 when the original antibodies are reformatted to CAR 
scFv domains, keeping the natural antibody configurations in the TEM8 CAR construct 
may increase the selectivity of the CARs for high-level TEM8 expression. 
 
To expand the therapeutic range of the existing CAR structure, and potentially prevent 
antigen loss as a tumour escape mechanism, tandem CARs (TanCARs) have been 
described which simultaneously bind to two tumour-restricted antigens and are 
activated by each one individually or synergistically by both371. A CD28/CD3z TanCAR 




its extracellular region has already shown superior anti-tumour efficacy compared to 
single CAR-expressing T-cells in a mouse model of glioblastoma372. This approach 
could also allow for targeting of both the tumour cells themselves and the tumour 
stroma, providing a mechanism to battle the inhospitable TME371. For example, TEM8 
CARs could be made into TanCARs incorporating a TEM8 scFv together with a scFv 
recognising the fibroblast activation protein (FAP), a serine protease expressed by 
tumour-associated stromal cells in the vast majority of epithelial cancers373. In two 
separate studies, FAP-specific CAR T-cells mediated potent anti-tumour effects in 
vivo374,375, especially in combination with CAR T-cells targeting an antigen expressed 
on the tumour cells themselves374. Therefore, a TEM8/FAP TanCAR could provide an 
effective therapeutic approach for targeting both the tumour vasculature and the 
immunosuppressive stroma in the remaining tumour after some of the vasculature is 
eliminated. 
 
A major concern with some of the CARs in the clinic, and one that was also highlighted 
for TEM8 CARs by the work described in this thesis, is their safety. As previously 
discussed in the Introduction (sections 1.4.2 and 1.4.3), toxicities have been reported 
in trials of CAR T-cell treatment for both haematological and solid tumours, most of 
them related to on-target/off-tumour recognition and cytokine storms. In order to 
improve their safety profile, a number of combinatorial CAR strategies have been 
developed, such as the previously mentioned dissociation of CD3z and co-stimulatory 
signals into two co-expressed CARs which both need to be engaged for full T-cell 
activation207,376. For example, CARs recognising TEM8 and CLEC14A could be 




tumour vasculature. An elegant approach allowing for the titration of CAR T-cell 
response levels has also been described, whereby the antigen recognition and 
signalling domains of the CAR are split and their heterodimerisation made dependent 
on the presence of a small molecule377. This ON-switch CAR is therefore only activated 
in the presence of both its cognate antigen and the otherwise inert small molecule, the 
dose of the latter determining the amount of therapeutic CAR activity. Re-engineering 
TEM8-specific CARs to the ON-switch format could therefore provide a way to 
gradually titrate their dose and monitor toxicity reactions more closely, both in 
preclinical animal models and, provided a suitable inert small molecule can be found, 
in clinical trials in patients. Another method of titrating CAR T-cell response levels is 
by using a semisynthetic “switch” molecule that combines the desired antigen-binding 
antibody fragment with the inert FITC dye and acts as a bridge between the antigen 
itself and an anti-FITC CAR378. The ability to optimise the binding interactions of this 
intermediate bridging molecule as desired, and thus modify the immunological synapse 
between the CAR T-cell and the tumour cell, has already resulted in reduced toxicity 
in vivo378 – a very important finding which could be used in future animal studies where 
toxicity is a concern, such as the ones using TEM8 CARs described in this thesis. 
 
A way to increase both the specificity and safety of CAR T-cells, as well as remodel 
the tumour microenvironment to make it more optimal for therapeutic T-cell action, has 
been recently proposed by using synthetic Notch (synNotch) receptors on the surface 
of the T-cells379. Upon activation of these receptors by their target antigen, expression 
of a CAR specific for a second tumour antigen is induced; thus only dual antigen-




providing high specificity and reduced off-tumour toxicity of the CAR. Additionally, 
synNotch receptors can customise T-cell responses within the tumour through 
transcriptional activation, inducing specific cytokine secretion or facilitating the 
localised delivery of therapeutic payloads such as antibodies380, thus directly 
combatting the immunosuppressive effects of the tumour microenvironment. To 
increase the specificity of tumour blood vessel targeting, an anti-TEM8 scFv could be 
incorporated into a synNotch receptor on the T-cell surface which, upon activation, 
would induce the expression of a CAR recognising a second tumour vasculature-
associated antigen – for example, a ligand of the NKG2D receptor. It has been shown 
that mouse tumour vasculature expresses the NKG2D ligand Rae1, and that NKG2D-
based CAR T-cells targeting the murine tumour blood vessels led to reduced cancer 
angiogenesis and growth381. In humans, up to eight different NKG2D ligands are 
expressed in various primary tumours, both on the tumour cells themselves and the 
associated vasculature; a clinical trial of NKG2D receptor-based CAR T-cells is 
currently in progress in patients with one of seven different malignancies, including 
CRC, TNBC and pancreatic cancer382. A TEM8/NKG2D synNotch receptor would 
therefore not only provide more specific targeting of cancer-associated blood vessels 
and expand the range of potential tumour indications it can be used in, but also allow 
for favourable modulation of the tumour microenvironment through NKG2D-mediated 
targeting of immunosuppressive TME components such as Tregs382. 
 
If antigen specificity and safety of TEM8 CARs can be achieved by the strategies 
outlined above, further optimisation of anti-tumour effects and toxicity mitigation 




electroporation can be used to express the desired TEM8 CAR on the T-cell surface 
only transiently, allowing the receptor to be extinguished spontaneously within days of 
the T-cell injection if toxicity arises383. If stable CAR surface expression by means of 
retro- or lentiviral transduction of the T-cells is required, however, careful dose 
escalation would be necessary, with potential addition of a suicide switch such as the 
inducible caspase 9 system to enable selective deletion of the CAR T-cell product in 
the event of toxicity384. Additional strategies to optimise the TEM8 CAR T-cells include, 
for example, gene editing to render them deficient for their endogenous ab TCR prior 
to CAR transduction, allowing for the administration of third party CAR T-cells to any 
patient that needs them without fear of GvHD385. These “off-the-shelf” CAR T-cells can 
also be rendered resistant to destruction by chemotherapeutic agents used in pre-
conditioning regimens, such that T-cell engraftment is improved while tumour 
destruction is maintained. To avoid prolonged in vitro T-cell expansion protocols prior 
to reinfusion into patients, the cells could potentially be programmed for tumour 
recognition by using nanoparticles to introduce CAR DNA into them quickly and 
efficiently in situ; such nanoparticles are stable and cost-effective to maintain, and their 
use has resulted in long-term disease remission in tumour-bearing mice386. 
Alternatively, a recent breakthrough in CAR gene editing reported that targeted CD19 
CAR gene delivery to the T-cell receptor a (TRAC) locus resulted in both greater 
potency and delayed exhaustion of the T-cells after repeated antigen exposure387, 
vastly increasing their potential for sustained therapeutic activity over prolonged 
periods. Such an approach taken with TEM8 CAR T-cells could lead to a much more 





6.3 Autoimmunity and CAR Tregs 
The potential of the CAR platform is such that its use is now being expanded into areas 
other than oncology. CAR engineering of Tregs to treat inflammatory conditions, GvHD 
and transplant rejection was already discussed in section 1.7.3 of this thesis, and 
although there are as yet no human trials of CAR-engineered Tregs for any condition, 
the promising results from the relevant in vitro and in vivo studies will certainly lead to 
their clinical testing in the near future. CAR Tregs targeting inflamed vascular 
endothelial cells, such as the ones directed against CLEC14A and described in chapter 
5 of this thesis, may also hold promise for future therapies of autoimmune diseases of 
the liver. Further in vitro data would first need to be generated before taking the cells 
forward to any pilot animal experiments, but the preliminary data and the existence of 
an appropriate mouse model are encouraging. 
 
As with TEM8 CAR T-cells, combinatorial targeting strategies could be applied to 
increase the specificity and safety of CAR Tregs as well. For example, the CLEC14A 
CAR Tregs could be engineered further to overexpress the liver-homing chemokine 
receptor CXCR3, which would help direct the cells specifically to the inflamed liver 
vasculature where the corresponding CXCR3 ligands are upregulated273. Furthermore, 
expression of the previously mentioned NKG2D ligands is also thought to be induced 
in inflamed tissues such as those found in autoimmune diseases382. Validating their 
expression in autoimmune liver conditions such as PSC and, if appropriate, 
constructing a specific way to target the inflamed liver – for example, using a 
CLEC14A/NKG2D TanCAR on the surface of Tregs – could provide a novel and potent 




weigh the predicted benefits of administering liver vasculature-targeting CAR Tregs to 
a PSC patient against the risks and toxicity issues that could arise. Compared to life-
threatening cancers, the safety concerns are much more limiting in chronic 
autoimmune conditions and require the benefits of treatment to substantially outweigh 
the risks in order for therapy to be considered viable. Nevertheless, the frequent 
culmination of PSC in end-stage liver disease and thus in the requirement for liver 
transplantation255, coupled with the increased risk of several cancers in PSC 
patients262, means that there is a high unmet need for a successful therapeutic 
approach to this debilitating condition. If CLEC14A-specific CAR Tregs can be 
rendered safe and effective in mouse models of the disease using the strategies 
suggested above, it can be argued that the benefits of testing them in patients would 
outweigh the risks that could potentially arise from their administration. 
 
6.4 Conclusions 
The main application of CARs where they have seen the most success are still 
haematological malignancies, although solid tumour targeting is being explored to a 
much greater extent than before and generating very promising data. Of particular 
relevance to this thesis is tumour vasculature targeting where, if successful, CARs 
could drastically improve rates of solid tumour destruction and help contain metastatic 
spread in patients suffering from many different cancers. Another emerging indication 
for CARs are autoimmune and inflammatory conditions, where in vivo studies using 
CAR-engineered Tregs have already shown promise; this has opened up the 
possibility of using CAR Tregs to target the inflamed vasculature in autoimmune liver 




targeting CARs reach clinical trials, it would be important to introduce safety measures 
into them due to their potential for toxicity to healthy tissue – for example, by split 
signalling, combinatorial antigen sensing or careful titration of the introduced dose 
using a small inert molecule, all of which are discussed in this chapter. If safety 
obstacles can be overcome, and an appropriate target with its expression restricted 
mostly to tumour or inflamed endothelium – such as TEM8 and CLEC14A respectively 
– be specifically targeted, the therapeutic potential of these CARs alone or in 
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